



(12) **DEMANDE DE BREVET CANADIEN**
CANADIAN PATENT APPLICATION

(13) **A1**

(86) **Date de dépôt PCT/PCT Filing Date:** 2022/10/21

(87) **Date publication PCT/PCT Publication Date:** 2023/04/27

(85) **Entrée phase nationale/National Entry:** 2024/04/11

(86) **N° demande PCT/PCT Application No.:** US 2022/047491

(87) **N° publication PCT/PCT Publication No.:** 2023/069754

(30) **Priorité/Priority:** 2021/10/22 (US63/270,813)

(51) **Cl.Int./Int.Cl.** **C12N 15/113** (2010.01),
A61K 31/7115 (2006.01), **A61K 31/712** (2006.01),
A61K 31/7125 (2006.01), **A61K 31/713** (2006.01),
A61P 1/16 (2006.01), **C12N 9/10** (2006.01)

(71) **Demandeur/Applicant:**
AMGEN INC., US

(72) **Inventeurs/Inventors:**
RULIFSON, INGRID, US;
MEADE, BRYAN, US;
LONG, JASON C., US;
MURRAY, JUSTIN K., US

(74) **Agent:** SMART & BIGGAR LP

(54) **Titre :** CONSTRUCTIONS D'ARNI POUR INHIBER L'EXPRESSION DE GPAM ET LEURS METHODES D'UTILISATION

(54) **Title:** RNAI CONSTRUCTS FOR INHIBITING GPAM EXPRESSION AND METHODS OF USE THEREOF

(57) **Abrégé/Abstract:**

The disclosure relates to RNAi constructs, such as siRNA, for reducing expression of the GPAM gene. Methods of using such RNAi constructs to treat or prevent liver disease, such as nonalcoholic fatty liver disease (NAFLD), are also described.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

27 April 2023 (27.04.2023)



(10) International Publication Number

WO 2023/069754 A3

(51) International Patent Classification:

C12N 15/113 (2010.01) A61K 31/712 (2006.01)

C12N 9/10 (2006.01) A61K 31/7125 (2006.01)

A61K 31/713 (2006.01) A61P 1/16 (2006.01)

A61K 31/7115 (2006.01)

DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/047491

(22) International Filing Date:

21 October 2022 (21.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/270,813 22 October 2021 (22.10.2021) US

(71) Applicant: **AMGEN INC.** [US/US]; One Amgen Center
Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors: **RULIFSON, Ingrid**; c/o Amgen Inc., One Amgen Center Drive, Law Department-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US). **MEADE, Bryan**; c/o Amgen Inc., One Amgen Center Drive, Law Department-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US). **LONG, Jason C.**; c/o Amgen Inc., One Amgen Center Drive, Law Department-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US). **MURRAY, Justin K.**; c/o Amgen Inc., One Amgen Center Drive, Law Department-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US).

(74) Agent: **KONG, Lawrence**; 1120 Veterans Blvd., South San Francisco, California 94080 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

25 May 2023 (25.05.2023)

(54) Title: RNAI CONSTRUCTS FOR INHIBITING GPAM EXPRESSION AND METHODS OF USE THEREOF

(57) Abstract: The disclosure relates to RNAi constructs, such as siRNA, for reducing expression of the GPAM gene. Methods of using such RNAi constructs to treat or prevent liver disease, such as nonalcoholic fatty liver disease (NAFLD), are also described.



WO 2023/069754 A3

RNAI CONSTRUCTS FOR INHIBITING GPAM EXPRESSION AND METHODS OF USE THEREOF

FIELD OF THE INVENTION

[0001] The present invention relates to compositions and methods for modulating liver expression of glycerol-3-phosphate acyltransferase, mitochondrial (GPAM). In particular, the present invention relates to nucleic acid-based therapeutics for reducing GPAM expression via RNA interference and methods of using such nucleic acid-based therapeutics to treat or prevent liver disease, such as nonalcoholic fatty liver disease (NAFLD).

BACKGROUND OF THE INVENTION

[0002] Comprising a spectrum of hepatic pathologies, nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, the prevalence of which doubled in the last 20 years and now is estimated to affect over 20% of the world's population (Sattar et al. (2014) *BMJ* 349: g4596; Loomba and Sanyal (2013) *Nature Reviews Gastroenterology & hepatology* 10(11):686-690; Kim and Kim (2017) *Clin Gastroenterol Hepatol* 15(4):474-485; Petta et al. (2016) *Dig Liver Dis* 48(3):333-342; Huang et al. (2021) *Nat Rev Gastro & Hepatology* (18):223-238). NAFLD begins with the accumulation of triglyceride in the liver and is defined by the presence of cytoplasmic lipid droplets in more than 5% of hepatocytes in an individual 1) without a history of significant alcohol consumption and 2) in which the diagnosis of other types of liver disease have been excluded (Zhu et al (2016) *World J Gastroenterol* 22(36):8226-33; Rinella (2015) *JAMA* 313(22):2263-73; Yki-Jarvinen (2016) *Diabetologia* 59(6):1104-11). In some individuals the accumulation of ectopic fat in the liver, called steatosis, triggers inflammation and hepatocellular injury leading to a more advanced stage of disease called nonalcoholic steatohepatitis (NASH) (Rinella, *supra*). As of 2015, 75-100 million Americans are predicted to have NAFLD, with NASH accounting for approximately 10-30% of NAFLD diagnoses (Rinella, *supra*; Younossi et al (2016) *Hepatology* 64(5):1577-1586).

[0003] Glycerol-3-phosphate acyltransferase, mitochondrial (GPAM, GPAT1), having a sequence as found in Genbank XM_005269998.1, is associated with non-alcoholic steatohepatitis (NASH). Missense mutations in GPAM associate with accumulation of excess liver fat and non-alcoholic fatty liver disease (NAFLD) related phenotypes (Jamialahmadi, O., et al., Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease. *Gastroenterology*, 2021. 160(5): p. 1634-1646 e7).

[0004] Currently, NAFLD symptoms are managed via weight loss and treatment of any secondary conditions, as no pharmacologic treatments have been approved. Thus, there is a need for compositions and methods that treat NAFLD in affected individuals.

SUMMARY OF THE INVENTION

[0005] The present disclosure provides an RNAi construct comprising a sense strand and an antisense strand, wherein the antisense strand comprises a region having a sequence that is complementary to a GPAM mRNA sequence, such as a GPAM mRNA sequence set forth in Table 1, and wherein the RNAi construct inhibits the expression of GPAM. In certain embodiments, the RNAi construct comprises a region having at least 15 contiguous nucleotides differing by no more than 3 nucleotides from an antisense sequence listed in Table 2. In some embodiments, the antisense strand hybridizes to a GPAM mRNA sequence listed in Table 1.

[0006] In some embodiments, the sense strand of the RNAi constructs described herein comprises a sequence that is sufficiently complementary to the sequence of the antisense strand to form a duplex region of about 15 to about 30 base pairs in length. In these and other embodiments, the sense and antisense strands each are about 15 to about 30 nucleotides in length. In some embodiments, the RNAi constructs comprise at least one blunt end. In other embodiments, the RNAi constructs comprise at least one nucleotide overhang. Such nucleotide overhangs may comprise at least 1 to 6 unpaired nucleotides and can be located at the 3' end of the sense strand, the 3' end of the antisense strand, or the 3' end of both the sense and antisense strand. In certain embodiments, the RNAi constructs comprise an overhang of two unpaired nucleotides at the 3' end of the sense strand and the 3' end of the antisense strand. In other embodiments, the RNAi constructs comprise an

overhang of two unpaired nucleotides at the 3' end of the antisense strand and a blunt end of the 3' end of the sense strand/5' end of the antisense strand.

[0007] The RNAi constructs of the invention may comprise one or more modified nucleotides, including nucleotides having modifications to the ribose ring, nucleobase, or phosphodiester backbone. In some embodiments, the RNAi constructs comprise one or more 2'-modified nucleotides. Such 2'-modified nucleotides can include 2'-fluoro modified nucleotides, 2'-O-methyl modified nucleotides, 2'-O-methoxyethyl modified nucleotides, 2'-O-allyl modified nucleotides, bicyclic nucleic acids (BNA), glycol nucleic acids (GNAs), inverted bases (e.g. inverted adenosine) or combinations thereof. In one particular embodiment, the RNAi constructs comprise one or more 2'-fluoro modified nucleotides, 2'-O-methyl modified nucleotides, or combinations thereof. In some embodiments, all of the nucleotides in the sense and antisense strand of the RNAi construct are modified nucleotides.

[0008] In some embodiments, the RNAi constructs comprise at least one backbone modification, such as a modified internucleotide or internucleoside linkage. In certain embodiments, the RNAi constructs described herein comprise at least one phosphorothioate internucleotide linkage. In particular embodiments, the phosphorothioate internucleotide linkages may be positioned at the 3' or 5' ends of the sense and/or antisense strands.

[0009] In some embodiments, the antisense strand and/or the sense strand of the RNAi constructs of the invention may comprise or consist of a sequence from the antisense and sense sequences listed in Table 2. In certain embodiments, the RNAi construct may be any one of the duplex compounds listed in Table 2.

[0010] The disclosure also provides a composition comprising the aforementioned RNAi construct and a pharmaceutically acceptable carrier, excipient, or diluent, as well as methods of reducing the expression of GPAM in a patient in need thereof comprising administering to the patient the aforementioned RNAi construct or composition.

DETAILED DESCRIPTION

[0011] The present invention is based, in part, on the design and generation of RNAi constructs that target the GPAM gene and reduce expression of GPAM in liver cells. The specific inhibition of GPAM expression is useful for treating or preventing conditions

associated with GPAM expression, including liver-related diseases, such as, for example, simple fatty liver (steatosis), nonalcoholic steatohepatitis (NASH), cirrhosis (irreversible, advanced scarring of the liver), or GPAM-related obesity.

[0012] The disclosure provides compositions and methods for regulating the expression of the glycerol-3-phosphate acyltransferase, mitochondrial (GPAM) gene. In some embodiments, the gene may be within a cell or subject, such as a mammal (e.g., a human). In some embodiments, compositions of the invention comprise RNAi constructs that target a GPAM mRNA and reduce GPAM expression in a cell or mammal. Such RNAi constructs are useful for treating or preventing various forms of liver-related diseases, such as, for example, simple fatty liver (steatosis), nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), cirrhosis (irreversible, advanced scarring of the liver), or GPAM-related obesity.

[0013] Human genetic evidence indicates that a single nucleotide polymorphism (SNP) in GPAM, rs2792751(T), is “NAFLD-promoting.” This SNP is a common, missense mutation resulting in an amino acid change in GPAM: Ile43Val. Carriers of this SNP exhibit increased magnetic resonance imaging proton density fat fraction (MRI-PDFF) and increased risk (odds ratio, OR) with fatty liver and all-cause cirrhosis. Carriers also exhibit increased serum total cholesterol, LDL, HDL, triglycerides (TG), ALT and ALP, increased neutrophil and sex hormone binding globulin levels (Haas, M.E., et al., Machine learning enables new insights into clinical significance of and genetic contributions to liver fat accumulation. 2020: medRxiv 2020.09.03.20187195; Jamialahmadi, O., et al., Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease. *Gastroenterology*, 2021. 160(5): p. 1634-1646 e7; Hammond, L.E., et al., Mitochondrial glycerol-3-phosphate acyltransferase-deficient mice have reduced weight and liver triacylglycerol content and altered glycerolipid fatty acid composition. *Mol Cell Biol*, 2002. 22(23): p. 8204-14). Thus, the human data evidence indicates a correct directionality for a GPAM siRNA-mediated therapy to treat patients with NASH.

[0014] The genetics of GPAM are consistent with what is known about its mechanism of action and biology. The functional enzymatic role of GPAM is well

characterized (Gimeno, R.E. and J. Cao, Thematic review series: glycerolipids. Mammalian glycerol-3-phosphate acyltransferases: new genes for an old activity. *J Lipid Res*, 2008. 49(10): p. 2079-88; Gonzalez-Baro, M.R., T.M. Lewin, and R.A. Coleman, Regulation of Triglyceride Metabolism. II. Function of mitochondrial GPAT1 in the regulation of triacylglycerol biosynthesis and insulin action. *Am J Physiol Gastrointest Liver Physiol*, 2007. 292(5): p. G1195-9). Expressed predominantly in lipogenic tissues, GPAM protein is localized to the outer mitochondrial membrane and transfers acyl-CoA from glycerol-3-phosphate to lysophosphatidic acid, serving as the rate-limiting step responsible for initiation of the TG synthesis pathway. GPAM-deficient mice are viable, fertile, and exhibit no gross abnormalities (Hammond et al. (2002)). On a high fat diet, GPAM-deficient mice are protected from fat pad increase, liver TG accumulation, increased serum lipids, and exhibit increased hepatocyte β -oxidation, plasma ketone levels, and decreased TG synthesis (Hammond et al. (2002); Hammond, L.E., et al., Mitochondrial glycerol-3-phosphate acyltransferase-1 is essential in liver for the metabolism of excess acyl-CoAs. *J Biol Chem*, 2005. 280(27): p. 25629-36; Kuhajda, F.P., et al., Pharmacological glycerol-3-phosphate acyltransferase inhibition decreases food intake and adiposity and increases insulin sensitivity in diet-induced obesity. *Am J Physiol Regul Integr Comp Physiol*, 2011. 301(1): p. R116-30; Wendel, A.A., et al., Glycerol-3-phosphate acyltransferase 1 deficiency in ob/ob mice diminishes hepatic steatosis but does not protect against insulin resistance or obesity. *Diabetes*, 2010. 59(6): p. 1321-9; Xu, H., et al., Hepatic knockdown of mitochondrial GPAT1 in ob/ob mice improves metabolic profile. *Biochem Biophys Res Commun*, 2006. 349(1): p. 439-48).

[0015] A role for GPAM in preclinical nonalcoholic steatohepatitis (NASH) models has been described (Liao, K., et al., Glycerol-3-phosphate Acyltransferase1 Is a Model-Agnostic Node in Nonalcoholic Fatty Liver Disease: Implications for Drug Development and Precision Medicine. *ACS Omega*, 2020. 5(29): p. 18465-18471). Using three different animal models to induce increasing degrees of NASH and fibrosis, a direct correlation between increasing GPAM mRNA and protein expression with increasing NAFLD activity score (NAS) and fibrosis was observed. GPAM-deficient mice have also been shown to be protected from hepatocellular carcinoma (HCC) (Ellis, J.M., et al., Mice deficient in

glycerol-3-phosphate acyltransferase-1 have a reduced susceptibility to liver cancer. *Toxicol Pathol*, 2012. 40(3): p. 513-21). Thus, in addition to regulating steatosis, data suggests silencing GPAM in the liver may improve severe liver outcomes (Li, X., et al., *Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features. Theranostics*, 2018. 8(6): p. 1740-1751; Ng, C.K.Y., et al., *Proteogenomic characterization of hepatocellular carcinoma*. 2021: bioRxiv 2021.03.05.434147).

[0016] RNA interference (RNAi) is the process of introducing exogenous RNA into a cell leading to specific degradation of the mRNA encoding the targeted protein with a resultant decrease in protein expression. Advances in both the RNAi technology and hepatic delivery, as well as growing positive outcomes with other RNAi-based therapies, suggest RNAi as a compelling means to therapeutically treat NAFLD by directly targeting GPAM.

[0017] As used herein, the term “RNAi construct” refers to an agent comprising an RNA molecule that is capable of downregulating expression of a target gene (e.g. GPAM) via an RNA interference mechanism when introduced into a cell. “RNA interference” is the process by which a nucleic acid molecule induces the cleavage and degradation of a target RNA molecule (e.g. messenger RNA or mRNA molecule) in a sequence-specific manner, e.g. through an RNA induced silencing complex (RISC) pathway. In some embodiments, the RNAi construct comprises a double-stranded RNA (dsRNA) molecule comprising two antiparallel strands of contiguous nucleotides that are sufficiently complementary to each other to hybridize to form a duplex region. A double-stranded RNAi construct also may be referred to as an RNAi “trigger.” The terms “hybridize” or “hybridization” refer to the pairing of complementary polynucleotides, typically via hydrogen bonding (e.g., Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding) between complementary bases in the two polynucleotides. The strand comprising a region having a sequence that is substantially complementary to a target sequence (e.g., target mRNA) is referred to as the “antisense strand.” The “sense strand” refers to the strand that includes a region that is substantially complementary to a region of the antisense strand. In some embodiments, the sense strand may comprise a region that has a sequence that is substantially identical to the target sequence.

[0018] In certain embodiments, the sense strand and antisense strand of the double-stranded RNA may be two separate molecules that hybridize to form a duplex region but are otherwise unconnected. Such double-stranded RNA molecules formed from two separate strands are referred to as “small interfering RNAs” or “short interfering RNAs” (siRNAs). siRNAs are a class of non-coding, double-stranded RNA molecules that are typically about 20-27 base pairs and are central to RNAi. Thus, in some embodiments, the RNAi constructs of the invention comprise an siRNA. In other embodiments, the RNAi construct may be a microRNA (also known as “miRNA” or “mature miRNA”). miRNAs are small (approximately 18-24 nucleotides in length), non-coding RNA molecules present in plants, animals, and some viruses. miRNAs resemble siRNA, but miRNAs originate from hairpin mRNA structures. miRNAs regulate gene expression by base-pairing to complementary regions of target mRNAs.

[0019] In some embodiments, the invention is an RNAi construct directed to GPAM. In some embodiments, the RNAi construct is an siRNA that comprises a sense strand and an antisense strand, wherein the antisense strand comprises a region that is complementary to GPAM mRNA sequence. The region of the RNAi antisense strand may be complementary to any suitable region of a GPAM mRNA sequence.

[0020] In some embodiments, the RNAi construct binds the GPAM rs2792751(T) site. The disclosed RNAi construct, however, is not required to hybridize to a particular GPAM SNP. In some embodiments, the RNAi construct is an siRNA molecule that contains any of the sequences set forth in Table 1 or 2.

[0021] A double-stranded RNAi molecule may include chemical modifications to ribonucleotides, including modifications to the ribose sugar, base, or backbone components of the ribonucleotides, such as those described herein or known in the art. Any such modifications, as used in a double-stranded RNA molecule (e.g. siRNA, shRNA, or the like), are encompassed by the term “double-stranded RNA” for the purposes of this disclosure.

[0022] As used herein, a first sequence is “complementary” to a second sequence if a polynucleotide comprising the first sequence can hybridize to a polynucleotide comprising the second sequence to form a duplex region under certain conditions, such as physiological

conditions. Other such conditions can include moderate or stringent hybridization conditions, which are known to those of skill in the art. A first sequence is considered to be fully complementary (100% complementary) to a second sequence if a polynucleotide comprising the first sequence base pairs with a polynucleotide comprising the second sequence over the entire length of one or both nucleotide sequences without any mismatches. A sequence is “substantially complementary” to a target sequence if the sequence is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% complementary to a target sequence. Percent complementarity can be calculated by dividing the number of bases in a first sequence that are complementary to bases at corresponding positions in a second or target sequence by the total length of the first sequence. A sequence may also be said to be substantially complementary to another sequence if there are no more than 5, 4, 3, 2, or 1 mismatch over a 30 base pair duplex region when the two sequences are hybridized. Generally, if any nucleotide overhangs, as defined herein, are present, the sequence of such overhangs is not considered in determining the degree of complementarity between two sequences. By way of example, a sense strand of 21 nucleotides in length and an antisense strand of 21 nucleotides in length that hybridize to form a 19 base pair duplex region with a 2 nucleotide overhang at the 3' end of each strand would be considered to be fully complementary as the term is used herein.

[0023] In some embodiments, a region of the antisense strand comprises a sequence that is fully complementary to a region of the target RNA sequence (e.g. GPAM mRNA). In such embodiments, the sense strand may comprise a sequence that is fully complementary to the sequence of the antisense strand. In other such embodiments, the sense strand may comprise a sequence that is substantially complementary to the sequence of the antisense strand, e.g., having 1, 2, 3, 4, or 5 mismatches in the duplex region formed by the sense and antisense strands. In certain embodiments, it is preferred that any mismatches occur within the terminal regions (e.g. within 6, 5, 4, 3, 2, or 1 nucleotides of the 5' and/or 3' ends of the strands). In one embodiment, any mismatches in the duplex region formed from the sense and antisense strands desirably occur within 6, 5, 4, 3, 2, or 1 nucleotides of the 5' end of the antisense strand.

[0024] Where the two substantially complementary strands of a dsRNA are comprised of separate RNA molecules, those molecules need not, but can be, covalently connected. Where the two strands are connected covalently by means other than an uninterrupted chain of nucleotides between the 3' -end of one strand and the 5' -end of the respective other strand forming the duplex structure, the connecting structure is referred to as a "linker." The RNA strands may have the same or a different number of nucleotides. The maximum number of base pairs in the duplex is the number of nucleotides in the shortest strand of the dsRNA minus any overhangs that are present in the duplex. In addition to the duplex structure, an RNAi may comprise one or more nucleotide overhangs.

[0025] In other embodiments, the sense strand and the antisense strand that hybridize to form a duplex region may be part of a single RNA molecule, i.e., the sense and antisense strands are part of a self-complementary region of a single RNA molecule. In such cases, a single RNA molecule comprises a duplex region (also referred to as a stem region) and a loop region. The 3' end of the sense strand is connected to the 5' end of the antisense strand by a contiguous sequence of unpaired nucleotides, which will form the loop region. The loop region is typically of a sufficient length to allow the RNA molecule to fold back on itself such that the antisense strand can base pair with the sense strand to form the duplex or stem region. The loop region can comprise from about 3 to about 25, from about 5 to about 15, or from about 8 to about 12 unpaired nucleotides. As noted herein, such RNA molecules with at least partially self-complementary regions are referred to as "short hairpin RNAs" (shRNAs). In some embodiments, the loop region can comprise at least 1, 2, 3, 4, 5, 10, 20, or 25 unpaired nucleotides. In other embodiments, the loop region can have 10, 9, 8, 7, 6, 5, 4, 3, 2, or fewer unpaired nucleotides. In certain embodiments, the RNAi constructs of the invention comprise an shRNA. The length of a single, at least partially self-complementary RNA molecule can be from about 35 nucleotides to about 100 nucleotides, from about 45 nucleotides to about 85 nucleotides, or from about 50 to about 60 nucleotides and comprise a duplex region and loop region each having the lengths recited herein.

[0026] In some embodiments, the RNAi constructs of the invention comprise a sense strand and an antisense strand, wherein the antisense strand comprises a region having a sequence that is substantially or fully complementary to a GPAM messenger RNA (mRNA)

sequence. As used herein, a “GPAM mRNA sequence” refers to any messenger RNA sequence, including splice variants, encoding a GPAM protein, including GPAM protein variants or isoforms from any species (e.g. mouse, rat, non-human primate, human). GPAM protein is also known as GPAT or GPAT1.

[0027] A GPAM mRNA sequence also includes the transcript sequence expressed as its complementary DNA (cDNA) sequence. A cDNA sequence refers to the sequence of an mRNA transcript expressed as DNA bases (e.g. guanine, adenine, thymine, and cytosine) rather than RNA bases (e.g. guanine, adenine, uracil, and cytosine). Thus, the antisense strand of the RNAi constructs of the invention may comprise a region having a sequence that is substantially or fully complementary to a target GPAM mRNA sequence or GPAM cDNA sequence. A GPAM mRNA or cDNA sequence can include, but is not limited to, any GPAM mRNA or cDNA sequence such as can be derived from the NCBI Reference sequence NM_001244949.2 or NM_020918.6.

[0028] A region of the antisense strand can be substantially complementary or fully complementary to at least 15 consecutive nucleotides of the GPAM mRNA sequence. In some embodiments, the target region of the GPAM mRNA sequence to which the antisense strand comprises a region of complementarity can range from about 15 to about 30 consecutive nucleotides, from about 16 to about 28 consecutive nucleotides, from about 18 to about 26 consecutive nucleotides, from about 17 to about 24 consecutive nucleotides, from about 19 to about 25 consecutive nucleotides, from about 19 to about 23 consecutive nucleotides, or from about 19 to about 21 consecutive nucleotides. In certain embodiments, the region of the antisense strand comprising a sequence that is substantially or fully complementary to a GPAM mRNA sequence may, in some embodiments, comprise at least 15 contiguous nucleotides from an antisense sequence listed in Table 2. In other embodiments, the antisense sequence comprises at least 16, at least 17, at least 18, or at least 19 contiguous nucleotides from an antisense sequence listed in Table 2. In some embodiments, the sense and/or antisense sequence comprises at least 15 nucleotides from a sequence listed in Table 2 with no more than 1, 2, or 3 nucleotide mismatches.

[0029] The sense strand of the RNAi construct typically comprises a sequence that is sufficiently complementary to the sequence of the antisense strand such that the two strands

hybridize under physiological conditions to form a duplex region. A “duplex region” refers to the region in two complementary or substantially complementary polynucleotides that form base pairs with one another, either by Watson-Crick base pairing or other hydrogen bonding interaction, to create a duplex between the two polynucleotides. The duplex region of the RNAi construct should be of sufficient length to allow the RNAi construct to enter the RNA interference pathway, e.g. by engaging the Dicer enzyme and/or the RISC complex (described below). For instance, in some embodiments, the duplex region is about 15 to about 30 base pairs in length. Other lengths for the duplex region within this range are also suitable, such as about 15 to about 28 base pairs, about 15 to about 26 base pairs, about 15 to about 24 base pairs, about 15 to about 22 base pairs, about 17 to about 28 base pairs, about 17 to about 26 base pairs, about 17 to about 24 base pairs, about 17 to about 23 base pairs, about 17 to about 21 base pairs, about 19 to about 25 base pairs, about 19 to about 23 base pairs, or about 19 to about 21 base pairs. In one embodiment, the duplex region is about 17 to about 24 base pairs in length. In another embodiment, the duplex region is about 19 to about 21 base pairs in length.

[0030] In some embodiments, an RNAi construct of the invention contains a duplex region of about 24 to about 30 nucleotides that interacts with a target RNA sequence, e.g., an GPAM target mRNA sequence, to direct the cleavage of the target RNA. Without wishing to be bound by theory, long double-stranded RNA introduced into cells can be broken down into siRNA by a Type III endonuclease known as Dicer (Sharp et al. (2001) *Genes Dev.* 15:485). Dicer, a ribonuclease-III-like enzyme, processes the dsRNA into 19-23 base pair short interfering RNAs with characteristic two base 3' overhangs (Bernstein, et al., (2001) *Nature* 409:363). The siRNAs are then incorporated into an RNA-induced silencing complex (RISC) where one or more helicases unwind the siRNA duplex, enabling the complementary antisense strand to guide target recognition (Nykanen, et al., (2001) *Cell* 107:309). Upon binding to the appropriate target mRNA, one or more endonucleases within the RISC cleave the target to induce silencing (Elbashir, et al., (2001) *Genes Dev.* 15: 188).

[0031] For embodiments in which the sense strand and antisense strand are two separate molecules (e.g., an siRNA RNAi construct), the sense strand and antisense strand need not be the same length as the length of the duplex region. For instance, one or both

strands may be longer than the duplex region and have one or more unpaired nucleotides or mismatches flanking the duplex region. Thus, in some embodiments, the RNAi construct comprises at least one nucleotide overhang. As used herein, a “nucleotide overhang” refers to the unpaired nucleotide or nucleotides that extend beyond the duplex region at the terminal ends of the strands. Nucleotide overhangs are typically created when the 3' end of one strand extends beyond the 5' end of the other strand or when the 5' end of one strand extends beyond the 3' end of the other strand. The length of a nucleotide overhang is generally between 1 and 6 nucleotides, 1 and 5 nucleotides, 1 and 4 nucleotides, 1 and 3 nucleotides, 2 and 6 nucleotides, 2 and 5 nucleotides, or 2 and 4 nucleotides. In some embodiments, the nucleotide overhang comprises 1, 2, 3, 4, 5, or 6 nucleotides. In one particular embodiment, the nucleotide overhang comprises 1 to 4 nucleotides. In certain embodiments, the nucleotide overhang comprises 2 nucleotides. The nucleotides in the overhang can be ribonucleotides, deoxyribonucleotides, or modified nucleotides as described herein. In some embodiments, the overhang comprises a 5'-uridine-uridine-3' (5'-UU-3') dinucleotide. In such embodiments, the UU dinucleotide may comprise ribonucleotides or modified nucleotides, e.g., 2'-modified nucleotides. In other embodiments, the overhang comprises a 5'-deoxythymidine-deoxythymidine-3' (5'-dTdT-3') dinucleotide.

[0032] The nucleotide overhang can be at the 5' end or 3' end of one or both strands. For example, in one embodiment, the RNAi construct comprises a nucleotide overhang at the 5' end and the 3' end of the antisense strand. In another embodiment, the RNAi construct comprises a nucleotide overhang at the 5' end and the 3' end of the sense strand. In some embodiments, the RNAi construct comprises a nucleotide overhang at the 5' end of the sense strand and the 5' end of the antisense strand. In other embodiments, the RNAi construct comprises a nucleotide overhang at the 3' end of the sense strand and the 3' end of the antisense strand.

[0033] The RNAi constructs may comprise a single nucleotide overhang at one end of the double-stranded RNA molecule and a blunt end at the other. A “blunt end” means that the sense strand and antisense strand are fully base-paired at the end of the molecule and there are no unpaired nucleotides that extend beyond the duplex region. In some embodiments, the RNAi construct comprises a nucleotide overhang at the 3' end of the sense

strand and a blunt end at the 5' end of the sense strand and 3' end of the antisense strand. In other embodiments, the RNAi construct comprises a nucleotide overhang at the 3' end of the antisense strand and a blunt end at the 5' end of the antisense strand and the 3' end of the sense strand. In certain embodiments, the RNAi construct comprises a blunt end at both ends of the double-stranded RNA molecule. In such embodiments, the sense strand and antisense strand have the same length and the duplex region is the same length as the sense and antisense strands (i.e., the molecule is double-stranded over its entire length).

[0034] The sense strand and antisense strand can each independently be any suitable length, such as about 15 to about 30 nucleotides in length, about 18 to about 28 nucleotides in length, about 19 to about 27 nucleotides in length, about 19 to about 25 nucleotides in length, about 19 to about 23 nucleotides in length, about 21 to about 25 nucleotides in length, or about 21 to about 23 nucleotides in length. In certain embodiments, the sense strand and antisense strand are each about 18, about 19, about 20, about 21, about 22, about 23, about 24, or about 25 nucleotides in length. In some embodiments, the sense strand and antisense strand are of the same length but form a duplex region that is shorter than the strands such that the RNAi construct has two nucleotide overhangs. For instance, in one embodiment, the RNAi construct comprises (i) a sense strand and an antisense strand that are each 21 nucleotides in length, (ii) a duplex region that is 19 base pairs in length, and (iii) nucleotide overhangs of 2 unpaired nucleotides at both the 3' end of the sense strand and the 3' end of the antisense strand. In another embodiment, the RNAi construct comprises (i) a sense strand and an antisense strand that are each 23 nucleotides in length, (ii) a duplex region that is 21 base pairs in length, and (iii) nucleotide overhangs of 2 unpaired nucleotides at both the 3' end of the sense strand and the 3' end of the antisense strand. In other embodiments, the sense strand and antisense strand have the same length and form a duplex region over their entire length such that there are no nucleotide overhangs on either end of the double-stranded molecule. In one such embodiment, the RNAi construct is blunt ended and comprises (i) a sense strand and an antisense strand, each of which is 21 nucleotides in length, and (ii) a duplex region that is 21 base pairs in length. In another embodiment, the RNAi construct is blunt ended and comprises (i) a sense strand and an antisense strand, each of which is 23 nucleotides in length, and (ii) a duplex region that is 23 base pairs in length.

[0035] In other embodiments, the sense strand or the antisense strand is longer than the other strand and the two strands form a duplex region having a length equal to that of the shorter strand such that the RNAi construct comprises at least one nucleotide overhang. For example, in one embodiment, the RNAi construct comprises (i) a sense strand that is 19 nucleotides in length, (ii) an antisense strand that is 21 nucleotides in length, (iii) a duplex region of 19 base pairs in length, and (iv) a single nucleotide overhang of 2 unpaired nucleotides at the 3' end of the antisense strand. In another embodiment, the RNAi construct comprises (i) a sense strand that is 21 nucleotides in length, (ii) an antisense strand that is 23 nucleotides in length, (iii) a duplex region of 21 base pairs in length, and (iv) a single nucleotide overhang of 2 unpaired nucleotides at the 3' end of the antisense strand.

[0036] The antisense strand of the RNAi constructs of the invention can comprise the sequence of any one of the antisense sequences listed in Table 2.

Modified Nucleotides

[0037] The RNAi constructs of the invention may comprise one or more modified nucleotides. A “modified nucleotide” refers to a nucleotide that has one or more chemical modifications to the nucleoside, nucleobase, pentose ring, or phosphate group. As used herein, modified nucleotides do not encompass ribonucleotides containing adenosine monophosphate, guanosine monophosphate, uridine monophosphate, and cytidine monophosphate, and deoxyribonucleotides containing deoxyadenosine monophosphate, deoxyguanosine monophosphate, deoxythymidine monophosphate, and deoxycytidine monophosphate. However, the RNAi constructs may comprise combinations of modified nucleotides, ribonucleotides, and deoxyribonucleotides. Incorporation of modified nucleotides into one or both strands of double-stranded RNA molecules can improve the *in vivo* stability of the RNA molecules, e.g., by reducing the molecules' susceptibility to nucleases and other degradation processes. The potency of RNAi constructs for reducing expression of the target gene can also be enhanced by incorporation of modified nucleotides.

[0038] In certain embodiments, the modified nucleotides have a modification of the ribose sugar. These sugar modifications can include modifications at the 2' and/or 5' position of the pentose ring as well as bicyclic sugar modifications. A 2'-modified

nucleotide refers to a nucleotide having a pentose ring with a substituent at the 2' position other than H or OH. Such 2' modifications include, but are not limited to, 2'-O-alkyl (e.g. O-C1-C10 or O-C1-C10 substituted alkyl), 2'-O-allyl (O-CH₂CH=CH₂), 2'-C-allyl, 2'-fluoro, 2'-O-methyl (OCH₃), 2'-O-methoxyethyl (O-(CH₂)₂OCH₃), 2'-OCF₃, 2'-O(CH₂)₂SCH₃, 2'-O-aminoalkyl, 2'-amino (e.g., NH₂), 2'-O-ethylamine, and 2'-azido. Modifications at the 5' position of the pentose ring include, but are not limited to, 5'-methyl (R or S); 5'-vinyl, and 5'-methoxy.

[0039] A “bicyclic sugar modification” refers to a modification of the pentose ring where a bridge connects two atoms of the ring to form a second ring resulting in a bicyclic sugar structure. In some embodiments, the bicyclic sugar modification comprises a bridge between the 4' and 2' carbons of the pentose ring. Nucleotides comprising a sugar moiety with a bicyclic sugar modification are referred to herein as “bicyclic nucleic acids” or “BNAs.” Exemplary bicyclic sugar modifications include, but are not limited to, α -L-Methyleneoxy (4' - CH₂-O-2') bicyclic nucleic acid (BNA); β -D-Methyleneoxy (4'-CH₂-O-2') BNA (also referred to as a locked nucleic acid or LNA); Ethyleneoxy (4'-(CH₂)₂-O-2') BNA; Aminoxy (4' - CH₂-O-N(R)-2') BNA; Oxyamino (4' - CH₂-N(R)-O-2') BNA; Methyl(methyleneoxy) (4'-CH(CH₃)-O-2') BNA (also referred to as constrained ethyl or cEt); methylene-thio (4' - CH₂-S-2') BNA; methylene-amino (4' - CH₂-N(R)-2') BNA; methyl carbocyclic (4' - CH₂-CH(CH₃)-2') BNA; propylene carbocyclic (4'-(CH₂)₃-2') BNA; and Methoxy(ethyleneoxy) (4'-CH(CH₂OMe)-O-2') BNA (also referred to as constrained MOE or cMOE). These and other sugar-modified nucleotides that can be incorporated into the RNAi constructs of the invention are described in, e.g., U.S. Patent 9,181,551, U.S. Patent Publication No. 2016/0122761, and Deleavey and Damha, *Chemistry and Biology*, 19: 937-954 (2012).

[0040] In some embodiments, the RNAi constructs comprise one or more 2'-fluoro modified nucleotides, 2'-O-methyl modified nucleotides, 2'-O-methoxyethyl modified nucleotides, 2'-O-allyl modified nucleotides, bicyclic nucleic acids (BNAs), or combinations thereof. In certain embodiments, the RNAi constructs comprise one or more 2'-fluoro modified nucleotides, 2'-O-methyl modified nucleotides, 2'-O-methoxyethyl modified nucleotides, or combinations thereof. In one particular embodiment, the RNAi constructs

comprise one or more 2'-fluoro modified nucleotides, 2'-O-methyl modified nucleotides, or combinations thereof.

[0041] Both the sense and antisense strands of the RNAi constructs can comprise one or multiple modified nucleotides. For instance, in some embodiments, the sense strand comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more modified nucleotides. In certain embodiments, all nucleotides in the sense strand are modified nucleotides. In some embodiments, the antisense strand comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more modified nucleotides. In other embodiments, all nucleotides in the antisense strand are modified nucleotides. In certain other embodiments, all nucleotides in the sense strand and all nucleotides in the antisense strand are modified nucleotides. In these and other embodiments, the modified nucleotides can be 2'-fluoro modified nucleotides, 2'-O-methyl modified nucleotides, or combinations thereof.

[0042] In some embodiments, all pyrimidine nucleotides preceding an adenosine nucleotide in the sense strand and/or in the antisense strand are modified nucleotides. For example, where the sequence 5'-CA-3' or 5'-UA-3' appears in either strand, the cytidine and uridine nucleotides are modified nucleotides, preferably 2'-O-methyl modified nucleotides. In certain embodiments, all pyrimidine nucleotides in the sense strand are modified nucleotides (e.g. 2'-O-methyl modified nucleotides), and the 5' nucleotide in all occurrences of the sequence 5'-CA-3' or 5'-UA-3' in the antisense strand are modified nucleotides (e.g. 2'-O-methyl modified nucleotides). In other embodiments, all nucleotides in the duplex region are modified nucleotides. In such embodiments, the modified nucleotides are preferably 2'-O-methyl modified nucleotides, 2'-fluoro modified nucleotides, or combinations thereof.

[0043] In embodiments in which the RNAi construct comprises a nucleotide overhang, the nucleotides in the overhang can be ribonucleotides, deoxyribonucleotides, or modified nucleotides. In one embodiment, the nucleotides in the overhang are deoxyribonucleotides, e.g., deoxythymidine. In another embodiment, the nucleotides in the overhang are modified nucleotides. For instance, in some embodiments, the nucleotides in the overhang are 2'-O-methyl modified nucleotides, 2'-fluoro modified nucleotides, 2'-methoxyethyl modified nucleotides, or combinations thereof.

[0044] The RNAi constructs of the disclosure may also comprise one or more modified internucleotide linkages. As used herein, the term “modified internucleotide linkage” refers to an internucleotide linkage other than the natural 3' to 5' phosphodiester linkage. In some embodiments, the modified internucleotide linkage is a phosphorous-containing internucleotide linkage, such as a phosphotriester, an aminoalkyl phosphotriester, an alkylphosphonate (e.g., methylphosphonate, 3'-alkylene phosphonate), a phosphinate, a phosphoramidate (e.g., 3'-aminophosphoramidate and aminoalkylphosphoramidate), a phosphorothioate (P=S), a chiralphosphorothioate, a phosphorodithioate, a thionophosphoramidate, a thionoalkylphosphonate, athionoalkylphosphotriester, and a boranophosphate. In one embodiment, a modified internucleotide linkage is a 2' to 5' phosphodiester linkage. In other embodiments, the modified internucleotide linkage is a non-phosphorous-containing internucleotide linkage and thus can be referred to as a modified internucleoside linkage. Such non-phosphorous-containing linkages include, but are not limited to, morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane linkages (-O-Si(H)₂-O-); sulfide, sulfoxide and sulfone linkages; formacetyl and thioformacetyl linkages; alkene containing backbones; sulfamate backbones; methylenemethylimino (-CH₂-N(CH₃)-O-CH₂-) and methylenehydrazino linkages; sulfonate and sulfonamide linkages; amide linkages; and others having mixed N, O, S and CH₂ component parts. In one embodiment, the modified internucleoside linkage is a peptide-based linkage (e.g., aminoethylglycine) to create a peptide nucleic acid or PNA, such as those described in U.S. Patents 5,539,082; 5,714,331; and 5,719,262. Other suitable modified internucleotide and internucleoside linkages that may be employed in the disclosed RNAi constructs are described in U.S. Patents 6,693,187 and 9,181,551, U.S. Patent Publication No. 2016/0122761, and Deleavey and Damha, *supra*.

[0045] In certain embodiments, the RNAi constructs comprise one or more phosphorothioate internucleotide linkages. The phosphorothioate internucleotide linkages may be present in the sense strand, antisense strand, or both strands of the RNAi constructs. For instance, in some embodiments, the sense strand comprises 1, 2, 3, 4, 5, 6, 7, 8, or more phosphorothioate internucleotide linkages. In other embodiments, the antisense strand comprises 1, 2, 3, 4, 5, 6, 7, 8, or more phosphorothioate internucleotide linkages. In still

other embodiments, both strands comprise 1, 2, 3, 4, 5, 6, 7, 8, or more phosphorothioate internucleotide linkages. The RNAi constructs can comprise one or more phosphorothioate internucleotide linkages at the 3'-end, the 5'-end, or both the 3'- and 5'- ends of the sense strand, the antisense strand, or both strands. For instance, in certain embodiments, the RNAi construct comprises about 1 to about 6 or more (e.g., about 1, 2, 3, 4, 5, 6 or more) consecutive phosphorothioate internucleotide linkages at the 3'-end of the sense strand, the antisense strand, or both strands. In other embodiments, the RNAi construct comprises about 1 to about 6 or more (e.g., about 1, 2, 3, 4, 5, 6 or more) consecutive phosphorothioate internucleotide linkages at the 5'-end of the sense strand, the antisense strand, or both strands. In one embodiment, the RNAi construct comprises a single phosphorothioate internucleotide linkage at the 3' end of the sense strand. In one embodiment, the RNAi construct comprises a single phosphorothioate internucleotide linkage at the 3' end of the sense strand and a single phosphorothioate internucleotide linkage at the 3' end of the antisense strand. In one embodiment, the RNAi construct comprises a single phosphorothioate internucleotide linkage at the 5' end of the sense strand and a single phosphorothioate internucleotide linkage at the 3' end of the sense strand. In one embodiment, the RNAi construct comprises a single phosphorothioate internucleotide linkage at the 5' end of the antisense strand and a single phosphorothioate internucleotide linkage at the 3' end of the antisense strand. In another embodiment, the RNAi construct comprises two consecutive phosphorothioate internucleotide linkages at the 3' end of the antisense strand (i.e., a phosphorothioate internucleotide linkage at the first and second internucleotide linkages at the 3' end of the antisense strand). In another embodiment, the RNAi construct comprises two consecutive phosphorothioate internucleotide linkages at both the 3' and 5' ends of the antisense strand. In yet another embodiment, the RNAi construct comprises two consecutive phosphorothioate internucleotide linkages at both the 3' and 5' ends of the antisense strand and two consecutive phosphorothioate internucleotide linkages at the 5' end of the sense strand. In still another embodiment, the RNAi construct comprises two consecutive phosphorothioate internucleotide linkages at both the 3' and 5' ends of the antisense strand and two consecutive phosphorothioate internucleotide linkages at both the 3' and 5' ends of the sense strand (i.e. a phosphorothioate internucleotide linkage at the first

and second internucleotide linkages at both the 5' and 3' ends of the antisense strand and a phosphorothioate internucleotide linkage at the first and second internucleotide linkages at both the 5' and 3' ends of the sense strand). In any of the embodiments in which one or both strands comprise one or more phosphorothioate internucleotide linkages, the remaining internucleotide linkages within the strands can be the natural 3' to 5' phosphodiester linkages. For instance, in some embodiments, each internucleotide linkage of the sense and antisense strands is selected from phosphodiester and phosphorothioate, wherein at least one internucleotide linkage is a phosphorothioate.

[0046] In embodiments in which the RNAi construct comprises a nucleotide overhang, two or more of the unpaired nucleotides in the overhang can be connected by a phosphorothioate internucleotide linkage. In certain embodiments, all the unpaired nucleotides in a nucleotide overhang at the 3' end of the antisense strand and/or the sense strand are connected by phosphorothioate internucleotide linkages. In other embodiments, all the unpaired nucleotides in a nucleotide overhang at the 5' end of the antisense strand and/or the sense strand are connected by phosphorothioate internucleotide linkages. In still other embodiments, all the unpaired nucleotides in any nucleotide overhang are connected by phosphorothioate internucleotide linkages.

[0047] In certain embodiments, the modified nucleotides incorporated into one or both of the strands of the RNAi constructs of the invention have a modification of the nucleobase (also referred to herein as “base”). A “modified nucleobase” or “modified base” refers to a base other than the naturally occurring purine bases adenine (A) and guanine (G) and pyrimidine bases thymine (T), cytosine (C), and uracil (U). Modified nucleobases can be synthetic or naturally occurring modifications and include, but are not limited to, universal bases, 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine (X), hypoxanthine (I), 2-aminoadenine, 6-methyladenine, 6-methylguanine, and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo, particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-

methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-daazaadenine and 3-deazaguanine, and 3-deazaadenine.

[0048] In some embodiments, the modified base is a universal base. A “universal base” refers to a base analog that indiscriminately forms base pairs with all of the natural bases in RNA and DNA without altering the double helical structure of the resulting duplex region. Universal bases are known to those of skill in the art and include, but are not limited to, inosine, C-phenyl, C-naphthyl and other aromatic derivatives, azole carboxamides, and nitroazole derivatives, such as 3-nitropyrrole, 4-nitroindole, 5-nitroindole, and 6-nitroindole.

[0049] Other suitable modified bases that can be incorporated into the RNAi constructs of the invention include those described in, for example, Herdewijn, *Antisense Nucleic Acid Drug Dev.*, 10: 297-310 (2000) and Peacock et al., *J. Org. Chem.*, 76: 7295-7300 (2011). The skilled person is well aware that guanine, cytosine, adenine, thymine, and uracil may be replaced by other nucleobases, such as the modified nucleobases described above, without substantially altering the base pairing properties of a polynucleotide comprising a nucleotide bearing such replacement nucleobase.

[0050] In some embodiments, the 5' end of the sense strand, antisense strand, or both the antisense and sense strands of the disclosed RNAi constructs comprises a phosphate moiety. As used herein, the term “phosphate moiety” refers to a terminal phosphate group that includes unmodified phosphates ($-\text{O}-\text{P}=\text{O})(\text{OH})\text{OH}$) as well as modified phosphates. Modified phosphates include phosphates in which one or more of the O and OH groups are replaced with H, O, S, N(R) or alkyl where R is H, an amino protecting group or unsubstituted or substituted alkyl. Exemplary phosphate moieties include, but are not limited to, 5'-monophosphate; 5'-diphosphate; 5'-triphosphate; 5'-guanosine cap (7-methylated or non-methylated); 5'-adenosinecap or any other modified or unmodified nucleotide cap structure; 5'-monothiophosphate (phosphorothioate); 5'-monodithiophosphate (phosphorodithioate); 5'-alpha-thiotriphosphate; 5'-gamma-thiotriphosphate, 5'-phosphoramidates; 5'-vinylphosphates; 5'-alkylphosphonates (wherein “alkyl” can be methyl, ethyl, isopropyl, propyl, etc.); and 5'-alkyletherphosphonates (wherein “alkylether” can be methoxymethyl, ethoxymethyl, etc.).

[0051] The modified nucleotides that can be incorporated into the RNAi constructs of the invention may have more than one chemical modification described herein. For instance, the modified nucleotide may have a modification to the ribose sugar as well as a modification to the nucleobase. By way of example, a modified nucleotide may comprise a 2' sugar modification (e.g., 2'-fluoro or 2'-methyl) and comprise a modified base (e.g., 5-methyl cytosine or pseudouracil). In other embodiments, the modified nucleotide may comprise a sugar modification in combination with a modification to the 5' phosphate that would create a modified internucleotide or internucleoside linkage when the modified nucleotide was incorporated into a polynucleotide. For instance, in some embodiments, the modified nucleotide may comprise a sugar modification, such as a 2'-fluoro modification, a 2'-O-methyl modification, or a bicyclic sugar modification, as well as a 5' phosphorothioate group. Accordingly, in some embodiments, one or both strands of the RNAi constructs of the invention comprise a combination of 2' modified nucleotides or BNAs and phosphorothioate internucleotide linkages. In certain embodiments, both the sense and antisense strands of the RNAi constructs of the invention comprise a combination of 2'-fluoro modified nucleotides, 2'-O-methyl modified nucleotides, and phosphorothioate internucleotide linkages. Exemplary RNAi constructs comprising modified nucleotides and internucleotide linkages are shown in Table 2.

Function of RNAi Constructs

[0052] The RNAi constructs of the invention desirably reduce or inhibit the expression of GPAM in cells, particularly liver cells. Accordingly, in one embodiment, the present invention provides a method of reducing GPAM expression in a cell by contacting the cell with any RNAi construct described herein. The cell may be *in vitro* or *in vivo*. GPAM expression can be assessed by measuring the amount or level of GPAM mRNA, GPAM protein, or another biomarker linked to GPAM expression. The reduction of GPAM expression in cells or animals treated with an RNAi construct of the invention can be determined relative to the GPAM expression in cells or animals not treated with the RNAi construct or treated with a control RNAi construct. For instance, in some embodiments, reduction of GPAM expression is assessed by (a) measuring the amount or level of GPAM

mRNA in liver cells treated with a RNAi construct of the invention, (b) measuring the amount or level of GPAM mRNA in liver cells treated with a control RNAi construct (e.g., RNAi construct directed to a RNA molecule not expressed in liver cells or a RNAi construct having a nonsense or scrambled sequence) or no construct, and (c) comparing the measured GPAM mRNA levels from treated cells in (a) to the measured GPAM mRNA levels from control cells in (b). The GPAM mRNA levels in the treated cells and controls cells can be normalized to RNA levels for a control gene (e.g., 18S ribosomal RNA) prior to comparison. GPAM mRNA levels can be measured by a variety of methods, including Northern blot analysis, nuclease protection assays, fluorescence *in situ* hybridization (FISH), reverse-transcriptase (RT)-PCR, real-time RT-PCR, quantitative PCR, and the like.

[0053] In other embodiments, reduction of GPAM expression is assessed by (a) measuring the amount or level of GPAM protein in liver cells treated with a RNAi construct of the invention, (b) measuring the amount or level of GPAM protein in liver cells treated with a control RNAi construct (e.g., RNAi construct directed to a RNA molecule not expressed in liver cells or a RNAi construct having a nonsense or scrambled sequence) or no construct, and (c) comparing the measured GPAM protein levels from treated cells in (a) to the measured GPAM protein levels from control cells in (b). GPAM protein levels can be measured using any suitable method known to those of skill in the art, including but not limited to, western blots, immunoassays (e.g., ELISA), and flow cytometry. Any suitable method of measuring GPAM mRNA or protein can be used to assess the efficacy of the RNAi constructs of the invention.

[0054] In some embodiments, the methods to assess GPAM expression levels are performed *in vitro* in cells that natively express GPAM (e.g., liver cells) or cells that have been engineered to express GPAM. In certain embodiments, the methods are performed *in vitro* in liver cells. Suitable liver cells include, but are not limited to, primary hepatocytes (e.g. human, non-human primate, or rodent hepatocytes), HepAD38 cells, HuH-6 cells, HuH-7 cells, HuH-5-2 cells, BNLCL2 cells, Hep3B cells, or HepG2 cells. In one embodiment, the liver cells are Hep3B cells. In another embodiment, the liver cells are HepG2 cells.

[0055] In other embodiments, the methods to assess GPAM expression levels are performed *in vivo*. For example, the RNAi constructs and any control RNAi constructs can be administered to an animal (e.g., rodent or non-human primate), and GPAM mRNA or protein levels may be assessed in liver tissue harvested from the animal following treatment. Alternatively or additionally, a biomarker or functional phenotype associated with GPAM expression can be assessed in the treated animals.

[0056] In certain embodiments, expression of GPAM is reduced in liver cells by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50% by an RNAi construct of the invention. In some embodiments, expression of GPAM is reduced in liver cells by at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, or at least 85% by an RNAi construct of the invention. In other embodiments, the expression of GPAM is reduced in liver cells by about 90% or more, e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more by an RNAi construct of the invention. The percent reduction of GPAM expression can be measured by any of the methods described herein or otherwise known in the art. For instance, in certain embodiments, the RNAi constructs of the invention inhibit at least 45% of GPAM expression at 5 nM in HepG2 cells (contains GPAM having an I43V mutation) *in vitro*. In related embodiments, the RNAi constructs of the invention inhibit at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or at least 75% of GPAM expression at 5 nM in HepG2 cells *in vitro*. In other embodiments, the RNAi constructs of the invention inhibit at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 96%, or at least 98% of GPAM expression at 5 nM in HepG2 cells *in vitro*. Reduction of GPAM can be measured using a variety of techniques including, for example, RNA FISH or droplet digital PCR (see, e.g., Kamitaki et al., Digital PCR. Methods in Molecular Biology, 1768: 401-422 (2018). doi:10.1007/978-1-4939-7778-9_23).

[0057] In some embodiments, an IC₅₀ value is calculated to assess the potency of an RNAi construct of the invention for inhibiting GPAM expression in liver cells. An “IC₅₀ value” is the dose/concentration required to achieve 50% inhibition of a biological or biochemical function. The IC₅₀ value of any substance or antagonist can be determined by constructing a dose-response curve and examining the effect of different concentrations of

the substance or antagonist on expression levels or functional activity in any assay. IC₅₀ values can be calculated for a given antagonist or substance by determining the concentration needed to inhibit half of the maximum biological response or native expression levels. Thus, the IC₅₀ value for any RNAi construct can be calculated by determining the concentration of the RNAi construct needed to inhibit half of the native GPAM expression level in liver cells (e.g., GPAM expression level in control liver cells) in any assay, such as an immunoassay, RNA FISH assay, or a droplet digital PCR assay. The RNAi constructs of the invention may inhibit GPAM expression in liver cells (e.g. HepG2 cells) with an IC₅₀ of less than about 20 nM (e.g., less than about 15 nM, 10 nM, 5 nM, or 1 nM). For example, the disclosed RNAi constructs may inhibit GPAM expression in liver cells with an IC₅₀ of about 0.001 nM to about 20 nM, about 0.001 nM to about 10 nM, about 0.001 nM to about 5 nM, about 0.001 nM to about 1 nM, about 0.1 nM to about 10 nM, about 0.1 nM to about 5 nM, or about 0.1 nM to about 1 nM. In certain embodiments, the RNAi construct inhibits GPAM expression in liver cells (e.g., HepG2 cells) with an IC₅₀ of about 1 nM to about 10 nM.

[0058] The RNAi constructs of the invention can readily be made using techniques known in the art, such as, for example, conventional nucleic acid solid phase synthesis. The polynucleotides of the RNAi constructs can be assembled on a suitable nucleic acid synthesizer utilizing standard nucleotide or nucleoside precursors (e.g., phosphoramidites). Automated nucleic acid synthesizers are sold commercially by several vendors, including DNA/RNA synthesizers from Applied Biosystems (Foster City, CA), MerMade synthesizers from BioAutomation (Irving, TX), and OligoPilot synthesizers from GE Healthcare Life Sciences (Pittsburgh, PA).

[0059] The 2' silyl protecting group can be used in conjunction with acid labile dimethoxytrityl (DMT) at the 5' position of ribonucleosides to synthesize oligonucleotides via phosphoramidite chemistry. Final deprotection conditions are known not to significantly degrade RNA products. All syntheses can be conducted in any automated or manual synthesizer on large, medium, or small scale. The syntheses may also be carried out in multiple well plates, columns, or glass slides.

[0060] The 2'-O-silyl group can be removed via exposure to fluoride ions, which can include any source of fluoride ion, e.g., those salts containing fluoride ion paired with

inorganic counterions, e.g., cesium fluoride and potassium fluoride or those salts containing fluoride ion paired with an organic counterion, e.g., a tetraalkylammonium fluoride. A crown ether catalyst can be utilized in combination with the inorganic fluoride in the deprotection reaction. Exemplary fluoride ion sources include, but are not limited to, tetrabutylammonium fluoride or aminohydrofluorides (e.g., combining aqueous HF with triethylamine in a dipolar aprotic solvent, e.g., dimethylformamide).

[0061] The choice of protecting groups for use on the phosphite triesters and phosphotriesters can alter the stability of the triesters towards fluoride. Methyl protection of the phosphotriester or phosphitetriester can stabilize the linkage against fluoride ions and improve process yields.

[0062] Since ribonucleosides have a reactive 2' hydroxyl substituent, it may be desirable to protect the reactive 2' position in RNA with a protecting group that is orthogonal to a 5'-O-dimethoxytrityl protecting group, e.g., one stable to treatment with acid. Silyl protecting groups meet this criterion and can be readily removed in a final fluoride deprotection step that can result in minimal RNA degradation.

[0063] Tetrazole catalysts can be used in the standard phosphoramidite coupling reaction. Exemplary catalysts include, e.g., tetrazole, S-ethyl-tetrazole, benzylthiotetrazole, and p-nitrophenyltetrazole.

[0064] Additional methods of synthesizing the RNAi constructs described herein will be evident to those of ordinary skill in the art. Additionally, the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. Other synthetic chemistry transformations, protecting groups (e.g., for hydroxyl, amino, etc., present on the bases) and protecting group methodologies (protection and deprotection) useful in synthesizing the RNAi constructs described herein are known in the art and include, for example, those described in R. Larock, *Comprehensive Organic Transformations*, VCH Publishers (1989); T. W. Greene and P. G. M. Wuts, *Protective Groups in Organic Synthesis*, 2d. Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, *Fieser and Fieser's Reagents for Organic Synthesis*, John Wiley and Sons (1994); and L. Paquette, ed., *Encyclopedia of Reagents for Organic Synthesis*, John Wiley and Sons (1995), and subsequent editions thereof. Custom synthesis of RNAi constructs is also available from

several commercial vendors, including Dharmacon, Inc. (Lafayette, CO), AxoLabs GmbH (Kulmbach, Germany), and Ambion, Inc. (Foster City, CA).

[0065] The RNAi constructs of the invention may comprise a ligand. As used herein, a “ligand” refers to any compound or molecule that can interact with another compound or molecule, either directly or indirectly. The interaction of a ligand with another compound or molecule may elicit a biological response (e.g., initiate a signal transduction cascade, induce receptor mediated endocytosis) or may just be a physical association. The ligand can modify one or more properties of the double-stranded RNA molecule to which is attached, such as the pharmacodynamic, pharmacokinetic, binding, absorption, cellular distribution, cellular uptake, charge and/or clearance properties of the RNA molecule.

[0066] The ligand may comprise a serum protein (e.g., human serum albumin, low-density lipoprotein, globulin), a cholesterol moiety, a vitamin (e.g., biotin, vitamin E, vitamin B12), a folate moiety, a steroid, a bile acid (e.g., cholic acid), a fatty acid (e.g., palmitic acid, myristic acid), a carbohydrate (e.g., a dextran, pullulan, chitin, chitosan, inulin, cyclodextrin or hyaluronic acid), a glycoside, a phospholipid, or an antibody or binding fragment thereof (e.g., a whole antibody or binding fragment that targets the RNAi construct to a specific cell type, such as liver cells). Other examples of ligands include dyes, intercalating agents (e.g., acridines), cross-linkers (e.g., psoralene, mitomycin C), porphyrins (e.g., TPPC4, texaphyrin, Sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine), artificial endonucleases (e.g., EDTA), lipophilic molecules (e.g., adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-BisO(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, 03-(oleoyl)lithocholic acid, 03-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine), peptides (e.g., antennapedia peptide, Tat peptide, RGD peptides), alkylating agents, polymers (e.g., polyethylene glycol (PEG), PEG-40K), poly amino acids, and polyamines (e.g., spermine, spermidine).

[0067] In certain embodiments, the ligands have endosomolytic properties. The endosomolytic ligands promote the lysis of the endosome and/or transport of the RNAi construct of the invention, or its components, from the endosome to the cytoplasm of the cell. The endosomolytic ligand may be a polycationic peptide or peptidomimetic which shows

pH-dependent membrane activity and fusogenicity. In one embodiment, the endosomolytic ligand assumes its active conformation at endosomal pH. The “active” conformation is that conformation in which the endosomolytic ligand promotes lysis of the endosome and/or transport of the RNAi construct of the invention, or its components, from the endosome to the cytoplasm of the cell. Exemplary endosomolytic ligands include the GALA peptide (Subbarao et al., *Biochemistry*, Vol. 26: 2964-2972, 1987), the EALA peptide (Vogel et al., *J. Am. Chem. Soc.*, Vol. 118: 1581-1586, 1996), and their derivatives (Turk et al., *Biochem. Biophys. Acta*, Vol. 1559: 56-68, 2002). In one embodiment, the endosomolytic component may contain a chemical group (e.g., an amino acid) which will undergo a change in charge or protonation in response to a change in pH. The endosomolytic component may be linear or branched.

[0068] In some embodiments, the ligand comprises a lipid or other hydrophobic molecule. In one embodiment, the ligand comprises a cholesterol moiety or other steroid. Cholesterol conjugated oligonucleotides have been reported to be more active than their unconjugated counterparts (Manoharan, *Antisense Nucleic Acid Drug Development*, Vol. 12: 103-228, 2002). Ligands comprising cholesterol moieties and other lipids for conjugation to nucleic acid molecules have also been described in U.S. Patents 7,851,615; 7,745,608; and 7,833,992. In another embodiment, the ligand may comprise a folate moiety. Polynucleotides conjugated to folate moieties can be taken up by cells via a receptor-mediated endocytosis pathway. Such folate-polynucleotide conjugates are described in, e.g., U.S. Patent 8,188,247.

[0069] Given that GPAM is expressed in liver cells (e.g., hepatocytes), in certain embodiments, it is desirable to specifically deliver the RNAi construct to liver cells. In some embodiments, RNAi constructs can be specifically targeted to the liver by employing ligands that bind to or interact with proteins expressed on the surface of liver cells. For example, in certain embodiments, a ligand may comprise one or more antigen binding proteins (e.g. antibodies or binding fragments thereof (e.g. Fab, scFv)) that specifically bind to a receptor expressed on hepatocytes.

[0070] In certain embodiments, the ligand comprises a carbohydrate. A “carbohydrate” refers to a compound made up of one or more monosaccharide units having

at least 6 carbon atoms (which can be linear, branched, or cyclic) with an oxygen, nitrogen or sulfur atom bonded to each carbon atom. Carbohydrates include, but are not limited to, sugars (e.g., monosaccharides, disaccharides, trisaccharides, tetrasaccharides, and oligosaccharides containing from about 4, 5, 6, 7, 8, or 9 monosaccharide units), and polysaccharides, such as starches, glycogen, cellulose, and polysaccharide gums. In some embodiments, the carbohydrate incorporated into the ligand is a monosaccharide selected from a pentose, hexose, or heptose and di- and tri-saccharides including such monosaccharide units. In other embodiments, the carbohydrate incorporated into the ligand is an amino sugar, such as galactosamine, glucosamine, N-acetylglucosamine, and N-acetylglucosamine.

[0071] In some embodiments, the ligand comprises a hexose or hexosamine. The hexose may be selected from glucose, galactose, mannose, fucose, or fructose. The hexosamine may be selected from fructosamine, galactosamine, glucosamine, or mannosamine. In certain embodiments, the ligand comprises glucose, galactose, galactosamine, or glucosamine. In one embodiment, the ligand comprises glucose, glucosamine, or N-acetylglucosamine. In another embodiment, the ligand comprises galactose, galactosamine, or N-acetyl-galactosamine. In particular embodiments, the ligand comprises N-acetyl-galactosamine. Ligands comprising glucose, galactose, and N-acetyl-galactosamine (GalNAc) are particularly effective in targeting compounds to liver cells (see, e.g., D'Souza and Devarajan, J. Control Release, Vol. 203: 126-139, 2015). Examples of GalNAc- or galactose-containing ligands that can be incorporated into the RNAi constructs of the invention are described in U.S. Patents 7,491,805; 8,106,022; and 8,877,917; U.S. Patent Publication No. 2003/0130186; and WIPO Publication No. WO 2013/166155.

[0072] In certain embodiments, the ligand comprises a multivalent carbohydrate moiety. As used herein, a "multivalent carbohydrate moiety" refers to a moiety comprising two or more carbohydrate units capable of independently binding or interacting with other molecules. For example, a multivalent carbohydrate moiety comprises two or more binding domains comprised of carbohydrates that can bind to two or more different molecules or two or more different sites on the same molecule. The valency of the carbohydrate moiety denotes the number of individual binding domains within the carbohydrate moiety. For

instance, the terms “monovalent,” “bivalent,” “trivalent,” and “tetravalent” with reference to the carbohydrate moiety refer to carbohydrate moieties with one, two, three, and four binding domains, respectively. The multivalent carbohydrate moiety may comprise a multivalent lactose moiety, a multivalent galactose moiety, a multivalent glucose moiety, a multivalent N-acetyl-galactosamine moiety, a multivalent N-acetyl-glucosamine moiety, a multivalent mannose moiety, or a multivalent fucose moiety. In some embodiments, the ligand comprises a multivalent galactose moiety. In other embodiments, the ligand comprises a multivalent N-acetyl-galactosamine moiety. In these and other embodiments, the multivalent carbohydrate moiety is bivalent, trivalent, or tetravalent. In such embodiments, the multivalent carbohydrate moiety can be bi-antennary or tri-antennary. In one particular embodiment, the multivalent N-acetyl-galactosamine moiety is trivalent or tetravalent. In another particular embodiment, the multivalent galactose moiety is trivalent or tetravalent. Exemplary trivalent and tetravalent GalNAc-containing ligands for incorporation into the RNAi constructs of the invention are described in detail below.

[0073] The ligand can be attached or conjugated to the RNA molecule of the RNAi construct directly or indirectly. For instance, in some embodiments, the ligand is covalently attached directly to the sense or antisense strand of the RNAi construct. In other embodiments, the ligand is covalently attached via a linker to the sense or antisense strand of the RNAi construct. The ligand can be attached to nucleobases, sugar moieties, or internucleotide linkages of polynucleotides (e.g., sense strand or antisense strand) of the RNAi constructs of the invention. Conjugation or attachment to purine nucleobases or derivatives thereof can occur at any position including, endocyclic and exocyclic atoms. In certain embodiments, the 2-, 6-, 7-, or 8-positions of a purine nucleobase are attached to a ligand. Conjugation or attachment to pyrimidine nucleobases or derivatives thereof can also occur at any position. In some embodiments, the 2, 5-, and 6-positions of a pyrimidine nucleobase can be attached to a ligand. Conjugation or attachment to sugar moieties of nucleotides can occur at any carbon atom. Example carbon atoms of a sugar moiety that can be attached to a ligand include the 2', 3', and 5' carbon atoms. The 1' position can also be attached to a ligand, such as in a basic residue. Internucleotide linkages can also support ligand attachments. For phosphorus-containing linkages (e.g., phosphodiester,

phosphorothioate, phosphorodithiotate, phosphoroamidate, and the like), the ligand can be attached directly to the phosphorus atom or to an O, N, or S atom bound to the phosphorus atom. For amine- or amide-containing internucleoside linkages (e.g., PNA), the ligand can be attached to the nitrogen atom of the amine or amide or to an adjacent carbon atom.

[0074] In certain embodiments, the ligand may be attached to the 3' or 5' end of either the sense or antisense strand. In certain embodiments, the ligand is covalently attached to the 5' end of the sense strand. In other embodiments, the ligand is covalently attached to the 3' end of the sense strand. For example, in some embodiments, the ligand is attached to the 3'-terminal nucleotide of the sense strand. In certain such embodiments, the ligand is attached at the 3'-position of the 3'-terminal nucleotide of the sense strand. In alternative embodiments, the ligand is attached near the 3' end of the sense strand, but before one or more terminal nucleotides (i.e. before 1, 2, 3, or 4 terminal nucleotides). In some embodiments, the ligand is attached at the 2'-position of the sugar of the 3'-terminal nucleotide of the sense strand.

[0075] In certain embodiments, the ligand is attached to the sense or antisense strand via a linker. A "linker" is an atom or group of atoms that covalently joins a ligand to a polynucleotide component of the RNAi construct. The linker may be from about 1 to about 30 atoms in length, from about 2 to about 28 atoms in length, from about 3 to about 26 atoms in length, from about 4 to about 24 atoms in length, from about 6 to about 20 atoms in length, from about 7 to about 20 atoms in length, from about 8 to about 20 atoms in length, from about 8 to about 18 atoms in length, from about 10 to about 18 atoms in length, and from about 12 to about 18 atoms in length. In some embodiments, the linker may comprise a bifunctional linking moiety, which generally comprises an alkyl moiety with two functional groups. One of the functional groups is selected to bind to the compound of interest (e.g., sense or antisense strand of the RNAi construct) and the other is selected to bind essentially any selected group, such as a ligand as described herein. In certain embodiments, the linker comprises a chain structure or an oligomer of repeating units, such as ethylene glycol or amino acid units. Examples of functional groups that are typically employed in a bifunctional linking moiety include, but are not limited to, electrophiles for reacting with nucleophilic groups and nucleophiles for reacting with electrophilic groups. In some

embodiments, bifunctional linking moieties include amino, hydroxyl, carboxylic acid, thiol, unsaturations (e.g., double or triple bonds), and the like.

[0076] Linkers that may be used to attach a ligand to the sense or antisense strand in the RNAi constructs of the invention include, but are not limited to, pyrrolidine, 8-amino-3,6-di oxaoctanoic acid, succinimidy 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, 6-aminohexanoic acid, substituted C₁-C₁₀ alkyl, substituted or unsubstituted C₂-C₁₀ alkenyl or substituted or unsubstituted C₂-C₁₀ alkynyl. Preferred substituent groups for such linkers include, but are not limited to, hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl, and alkynyl.

[0077] In certain embodiments, the linkers are cleavable. A cleavable linker is one which is sufficiently stable outside the cell, but which upon entry into a target cell is cleaved to release the two parts the linker is holding together. In some embodiments, the cleavable linker is cleaved at least 10 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, or more, or at least 100 times faster in the target cell or under a first reference condition (which can, e.g., be selected to mimic or represent intracellular conditions) than in the blood of a subject, or under a second reference condition (which can, e.g., be selected to mimic or represent conditions found in the blood or serum).

[0078] Cleavable linkers are susceptible to cleavage agents, e.g., pH, redox potential, or the presence of degradative molecules. Generally, cleavage agents are more prevalent or found at higher levels or activities inside cells than in serum or blood. Examples of such degradative agents include: redox agents which are selected for particular substrates or which have no substrate specificity, including, e.g., oxidative or reductive enzymes or reductive agents such as mercaptans, present in cells, that can degrade a redox cleavable linker by reduction; esterases; endosomes or agents that can create an acidic environment, e.g., those that result in a pH of five or lower; enzymes that can hydrolyze or degrade an acid cleavable linker by acting as a general acid, peptidases (which can be substrate specific), and phosphatases.

[0079] A cleavable linker may comprise a moiety that is susceptible to pH. The pH of human serum is 7.4, while the average intracellular pH is slightly lower, ranging from about 7.1-7.3. Endosomes have a more acidic pH, in the range of 5.5-6.0, and lysosomes

have an even more acidic pH at around 5.0. Some linkers will have a cleavable group that is cleaved at a preferred pH, thereby releasing the RNA molecule from the ligand inside the cell, or into the desired compartment of the cell.

[0080] A linker can include a cleavable group that is cleavable by a particular enzyme. The type of cleavable group incorporated into a linker can depend on the cell to be targeted. For example, liver-targeting ligands can be linked to RNA molecules through a linker that includes an ester group. Liver cells are rich in esterases, and therefore the linker will be cleaved more efficiently in liver cells than in cell types that are not esterase-rich. Other types of cells rich in esterases include cells of the lung, renal cortex, and testis. Linkers that contain peptide bonds can be used when targeting cells rich in peptidases, such as liver cells and synoviocytes.

[0081] In general, the suitability of a candidate cleavable linker can be evaluated by testing the ability of a degradative agent (or condition) to cleave the candidate linker. It will also be desirable to also test the candidate cleavable linker for the ability to resist cleavage in the blood or when in contact with other non-target tissue. Thus, one can determine the relative susceptibility to cleavage between a first and a second condition, where the first is selected to be indicative of cleavage in a target cell and the second is selected to be indicative of cleavage in other tissues or biological fluids, e.g., blood or serum. The evaluations can be carried out in cell free systems, in cells, in cell culture, in organ or tissue culture, or in whole animals. It may be useful to make initial evaluations in cell-free or culture conditions and to confirm by further evaluations in whole animals. In some embodiments, useful candidate linkers are cleaved at least 2, 4, 10, 20, 50, 70, or 100 times faster in the cell (or under *in vitro* conditions selected to mimic intracellular conditions) as compared to blood or serum (or under *in vitro* conditions selected to mimic extracellular conditions).

[0082] In other embodiments, redox cleavable linkers are utilized. Redox cleavable linkers are cleaved upon reduction or oxidation. An example of reductively cleavable group is a disulfide linking group (-S-S-). To determine if a candidate cleavable linker is a suitable “reductively cleavable linker,” or, for example, is suitable for use with a particular RNAi construct and particular ligand, one or more methods described herein can be used. For example, a candidate linker can be evaluated by incubation with dithiothreitol (DTT), or

other reducing agent known in the art, which mimics the rate of cleavage that would be observed in a cell, e.g., a target cell. The candidate linkers can also be evaluated under conditions which are selected to mimic blood or serum conditions. In a specific embodiment, candidate linkers are cleaved by at most 10% in the blood. In other embodiments, useful candidate linkers are degraded at least 2, 4, 10, 20, 50, 70, or 100 times faster in the cell (or under *in vitro* conditions selected to mimic intracellular conditions) as compared to blood (or under *in vitro* conditions selected to mimic extracellular conditions).

[0083] In yet other embodiments, phosphate-based cleavable linkers are cleaved by agents that degrade or hydrolyze the phosphate group. An example of an agent that hydrolyzes phosphate groups in cells are enzymes, such as phosphatases in cells. Examples of phosphate-based cleavable groups are -O-P(O)(ORk)-O-, -O-P(S)(ORk)-O-, -O-P(S)(SRk)-O-, -S-P(O)(ORk)-O-, -O-P(O)(ORk)-S-, -S-P(O)(ORk)-S-, -O-P(S)(ORk)-S-, -S-P(S)(ORk)-O-, -O-P(O)(Rk)-O-, -O-P(S)(Rk)-O-, -S-P(O)(Rk)-O-, -S-P(S)(Rk)-O-, -S-P(O)(Rk)-S-, -O-P(S)(Rk)-S-. Specific embodiments include -O-P(O)(OH)-O-, -O-P(S)(OH)-O-, -O-P(S)(SH)-O-, -S-P(O)(OH)-O-, -O-P(O)(OH)-S-, -S-P(O)(OH)-S-, -O-P(S)(OH)-S-, -SP(S)(OH)-O-, -O-P(O)(H)-O-, -O-P(S)(H)-O-, -S-P(O)(H)-O-, -S-P(S)(H)-O-, -S-P(O)(H)-S-, -O-P(S)(H)-S-. Another specific embodiment is -O-P(O)(OH)-O-. These candidate linkers can be evaluated using methods analogous to those described above.

[0084] In other embodiments, the linkers may comprise acid cleavable groups, which are groups that are cleaved under acidic conditions. In some embodiments, acid cleavable groups are cleaved in an acidic environment with a pH of about 6.5 or lower (e.g., about 6.0, 5.5, 5.0, or lower), or by agents, such as enzymes that can act as a general acid. In a cell, specific low pH organelles, such as endosomes and lysosomes, can provide a cleaving environment for acid cleavable groups. Examples of acid cleavable linking groups include, but are not limited to, hydrazones, esters, and esters of amino acids. Acid cleavable groups can have the general formula -C=NN-, C(O)O, or -OC(O). A specific embodiment is when the carbon attached to the oxygen of the ester (the alkoxy group) is an aryl group, substituted alkyl group, or tertiaryalkyl group such as dimethyl, pentyl or t-butyl. These candidates can be evaluated using methods analogous to those described above.

[0085] In other embodiments, the linkers may comprise ester-based cleavable groups, which are cleaved by enzymes, such as esterases and amidases in cells. Examples of ester-based cleavable groups include, but are not limited to, esters of alkylene, alkenylene and alkynylene groups. Ester cleavable groups have the general formula $-C(O)O-$, or $-OC(O)-$. These candidate linkers can be evaluated using methods analogous to those described above.

[0086] In further embodiments, the linkers may comprise peptide-based cleavable groups, which are cleaved by enzymes, such as peptidases and proteases in cells. Peptide-based cleavable groups are peptide bonds formed between amino acids to yield oligopeptides (e.g., dipeptides, tripeptides etc.) and polypeptides. Peptide-based cleavable groups do not include the amide group ($-C(O)NH-$). The amide group can be formed between any alkylene, alkenylene or alkynylene. A peptide bond is a special type of amide bond formed between amino acids to yield peptides and proteins. The peptide based cleavage group is generally limited to the peptide bond (i.e., the amide bond) formed between amino acids yielding peptides and proteins and does not include the entire amide functional group. Peptide-based cleavable linking groups have the general formula $-NHCHRAC(O)NHCHRBC(O)-$, where RA and RB are the R groups of the two adjacent amino acids. These candidates can be evaluated using methods analogous to those described above.

[0087] Other types of linkers suitable for attaching ligands to the sense or antisense strands in the RNAi constructs described herein are known in the art and can include the linkers described in, e.g., U.S. Patents 7,723,509; 8,017,762; 8,828,956; 8,877,917; and 9,181,551.

[0088] In certain embodiments, the ligand covalently attached to the sense or antisense strand of the RNAi constructs of the invention comprises a GalNAc moiety, e.g., a multivalent GalNAc moiety. In some embodiments, the multivalent GalNAc moiety is a trivalent GalNAc moiety and is attached to the 3' end of the sense strand. In other embodiments, the multivalent GalNAc moiety is a trivalent GalNAc moiety and is attached to the 5' end of the sense strand. In yet other embodiments, the multivalent GalNAc moiety is a tetravalent GalNAc moiety and is attached to the 3' end of the sense strand. In still other

embodiments, the multivalent GalNAc moiety is a tetravalent GalNAc moiety and is attached to the 5' end of the sense strand.

[0089] In some embodiments, the RNAi constructs of the invention may be delivered to a cell or tissue of interest by administering a vector that encodes and controls the intracellular expression of the RNAi construct. A “vector” (also referred to herein as an “expression vector”) is a composition of matter which can be used to deliver a nucleic acid of interest to the interior of a cell. Numerous vectors are known in the art including, but not limited to, linear polynucleotides, polynucleotides associated with ionic or amphiphilic compounds, plasmids, and viruses. Thus, the term “vector” includes an autonomously replicating plasmid or a virus. Examples of viral vectors include, but are not limited to, adenoviral vectors, adeno-associated viral vectors, retroviral vectors, and the like. A vector can be replicated in a living cell, or it can be made synthetically.

[0090] Generally, a vector for expressing an RNAi construct of the invention will comprise one or more promoters operably linked to sequences encoding the RNAi construct. The phrases “operably linked,” “operatively linked,” or “under transcriptional control” may be used interchangeably herein to indicate when a promoter is in the correct location and orientation in relation to a polynucleotide sequence to control the initiation of transcription by RNA polymerase and expression of the polynucleotide sequence. A “promoter” refers to a sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a gene sequence. Suitable promoters include, but are not limited to, RNA pol I, pol II, HI or U6 RNA pol III, and viral promoters (e.g., human cytomegalovirus (CMV) immediate early gene promoter, the SV40 early promoter, and the Rous sarcoma virus long terminal repeat). In some embodiments, an HI or U6RNA pol III promoter is employed. The promoter can be a tissue-specific or inducible promoter. Of particular interest are liver-specific promoters, such as promoter sequences from the human alpha-1 antitrypsin gene, albumin gene, hemopexin gene, and hepatic lipase gene. Inducible promoters include, for example, promoters regulated by ecdysone, estrogen, progesterone, tetracycline, and isopropyl-PD1-thiogalactopyranoside (IPTG).

[0091] When the RNAi construct comprises an siRNA, the two separate strands (sense and antisense strand) can be expressed from a single vector or two separate vectors. For example, in some embodiments, the sequence encoding the sense strand is operably linked to a promoter on a first vector and the sequence encoding the antisense strand is operably linked to a promoter on a second vector. In such an embodiment, the first and second vectors are co-introduced, e.g., by infection or transfection, into a target cell, such that the sense and antisense strands, once transcribed, will hybridize intracellularly to form the siRNA molecule. In another embodiment, the sense and antisense strands are transcribed from two separate promoters located in a single vector. In such embodiments, the sequence encoding the sense strand may be operably linked to a first promoter and the sequence encoding the antisense strand may be operably linked to a second promoter, wherein the first and second promoters are located in a single vector. In one embodiment, the vector comprises a first promoter operably linked to a sequence encoding the siRNA molecule, and a second promoter operably linked to the same sequence in the opposite direction, such that transcription of the sequence from the first promoter results in the synthesis of the sense strand of the siRNA molecule and transcription of the sequence from the second promoter results in synthesis of the antisense strand of the siRNA molecule.

[0092] When the RNAi construct comprises a shRNA, a sequence encoding the single, at least partially self-complementary RNA molecule is operably linked to a promoter to produce a single transcript. In some embodiments, the sequence encoding the shRNA comprises an inverted repeat joined by a linker polynucleotide sequence to produce the stem and loop structure of the shRNA following transcription.

[0093] In some embodiments, the vector encoding an RNAi construct of the invention is a viral vector. Various viral vector systems that are suitable to express the RNAi constructs described herein include, but are not limited to, adenoviral vectors, retroviral vectors (e.g., lentiviral vectors, moloney murine leukemia virus), adeno-associated viral vectors; herpes simplex viral vectors; SV40 vectors; polyoma viral vectors; papilloma viral vectors; picornaviral vectors; and pox viral vectors (e.g., vaccinia virus). In certain embodiments, the viral vector is a retroviral vector (e.g., lentiviral vector).

[0094] Various vectors suitable for use in the invention, methods for inserting nucleic acid sequences encoding siRNA or shRNA molecules into vectors, and methods of delivering the vectors to the cells of interest are known in the art (see, e.g., Dornburg, *Gene Therap.*, Vol. 2: 301-310, 1995; Eglitis, *Biotechniques*, Vol. 6: 608-614, 1988; Miller, *HumGene Therap.*, Vol. 1: 5-14, 1990; Anderson, *Nature*, Vol. 392: 25-30, 1998; Robinson D A et al., *Nat. Genet.*, Vol. 33: 401-406, 2003; Brummelkamp et al., *Science*, Vol. 296: 550-553, 2002; Brummelkamp et al., *Cancer Cell*, Vol. 2: 243-247, 2002; Lee et al., *Nat Biotechnol*, Vol. 20: 500-505, 2002; Miyagishi et al., *Nat Biotechnol*, Vol. 20: 497-500, 2002; Paddison et al., *GenesDev*, Vol. 16: 948-958, 2002; Paul et al., *Nat Biotechnol*, Vol. 20: 505-508, 2002; Sui et al., *Proc Natl Acad Sci USA*, Vol. 99: 5515-5520, 2002; and Yu et al., *Proc Natl Acad Sci USA*, Vol. 99: 6047-6052, 2002).

Compositions

[0095] The disclosure also provides compositions and formulations comprising the RNAi constructs described herein and pharmaceutically acceptable carriers, excipients, or diluents. Such compositions and formulations are useful for reducing expression of GPAM in a subject in need thereof. Where clinical applications are contemplated, pharmaceutical compositions and formulations will be prepared in a form appropriate for the intended application. Generally, this will entail preparing compositions that are essentially free of pyrogens, as well as other impurities that could be harmful to humans or animals.

[0096] The phrases “pharmaceutically acceptable” or “pharmacologically acceptable” refer to molecular entities and compositions that do not produce adverse, allergic, or other untoward reactions when administered to an animal or a human. As used herein, “pharmaceutically acceptable carrier, excipient, or diluent” includes solvents, buffers, solutions, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, etc., acceptable for use in formulating pharmaceuticals, such as pharmaceuticals suitable for administration to humans. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the RNAi constructs of the present invention, its use in therapeutic compositions is contemplated. Supplementary active

ingredients also can be incorporated into the compositions, provided they do not inactivate the vectors or RNAi constructs of the compositions.

[0097] Compositions and methods for the formulation of pharmaceutical compositions depend on several criteria, including, but not limited to, route of administration, type and extent of disease or disorder to be treated, and dose to be administered. In some embodiments, the pharmaceutical compositions are formulated based on the intended route of delivery. For instance, in certain embodiments, the pharmaceutical compositions are formulated for parenteral delivery. Parenteral forms of delivery include intravenous, intraarterial, subcutaneous, intrathecal, intraperitoneal, and intramuscular injection or infusion. In one embodiment, the pharmaceutical composition is formulated for intravenous delivery. In such an embodiment, the pharmaceutical composition may include a lipid-based delivery vehicle. In another embodiment, the pharmaceutical composition is formulated for subcutaneous delivery. In such an embodiment, the pharmaceutical composition may include a targeting ligand (e.g., GalNAc-containing ligands described herein).

[0098] In some embodiments, the pharmaceutical compositions comprise an effective amount of an RNAi construct described herein. An “effective amount” is an amount sufficient to produce a beneficial or desired clinical result. In some embodiments, an effective amount is an amount sufficient to reduce GPAM expression in hepatocytes of a subject. In some embodiments, an effective amount may be an amount sufficient to only partially reduce GPAM expression, for example, to a level comparable to expression of the wild-type GPAM allele in human heterozygotes. Human heterozygous carriers of loss of function GPAM variant alleles were reported to have lower serum levels of non-HDL cholesterol and a lower risk of coronary artery disease and myocardial infarction as compared to non-carriers (Nioi et al., New England Journal of Medicine, Vol. 374(22): 2131-2141, 2016). Thus, without being bound by theory, it is believed that partial reduction of GPAM expression may be sufficient to achieve the beneficial reduction of serum non-HDL cholesterol and reduction of risk of coronary artery disease and myocardial infarction.

[0099] An effective amount of an RNAi construct of the invention may be from about 0.01 mg/kg body weight to about 100 mg/kg body weight, about 0.05 mg/kg body weight to about 75mg/kg body weight, about 0.1 mg/kg body weight to about 50 mg/kg body

weight, about 1 mg/kg to about 30 mg/kg body weight, about 2.5 mg/kg of body weight to about 20 mg/kg bodyweight, or about 5 mg/kg body weight to about 15 mg/kg body weight. In certain embodiments, a single effective dose of an RNAi construct of the invention may be about 0.1 mg/kg, about 0.5mg/kg, about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 6mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg, or about 10 mg/kg. The pharmaceutical composition comprising an effective amount of RNAi construct can be administered weekly, biweekly, monthly, quarterly, or biannually. The precise determination of what would be considered an effective amount and frequency of administration may be based on several factors, including a patient's size, age, gender, type of disorder to be treated (e.g., myocardial infarction, heart failure, coronary artery disease, hypercholesterolemia), particular RNAi construct employed, and route of administration. Estimates of effective dosages and *in vivo* half-lives for any particular RNAi construct of the invention can be ascertained using conventional methods and/or testing in appropriate animal models.

[0100] Colloidal dispersion systems, such as macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes, may be used as delivery vehicles for the RNAi constructs of the invention or vectors encoding such constructs. Commercially available fat emulsions that are suitable for delivering the nucleic acids of the invention include INTRALIPID®, LIPOSYN®, LIPOSYN®II, LIPOSYN®III, NUTRILIPID, and other similar lipid emulsions. A preferred colloidal system for use as a delivery vehicle *in vivo* is a liposome (i.e., an artificial membrane vesicle). The RNAi constructs of the invention may be encapsulated within liposomes, such as cationic liposomes. Alternatively, RNAi constructs of the invention may be complexed to lipids, such as cationic lipids. Suitable lipids and liposomes include neutral (e.g., dioleoylphosphatidyl ethanolamine (DOPE), dimyristoylphosphatidyl choline (DMPC), and dipalmitoyl phosphatidylcholine (DPPC)), distearoylphosphatidyl choline), negative (e.g., dimyristoylphosphatidyl glycerol (DMPG)), and cationic (e.g., dioleoyltetramethylaminopropyl (DOTAP) and dioleoylphosphatidyl ethanolamine (DOTMA)). The preparation and use of such colloidal dispersion systems is well known in the art. Exemplary formulations also are disclosed in, e.g., U.S. Patents

5,783,565; 5,837,533; 5,981,505; 6,127,170; 6,217,900; 6,379,965; 6,383,512; 6,747,014; 7,202,227; and WO 03/093449.

[0101] In some embodiments, the RNAi constructs of the invention are fully encapsulated in a lipid formulation, e.g., to form a SPLP, pSPLP, SNALP, or other nucleic acid-lipid particle. As used herein, the term “SNALP” refers to a stable nucleic acid-lipid particle, including SPLP. As used herein, the term “SPLP” refers to a nucleic acid-lipid particle comprising plasmid DNA encapsulated within a lipid vesicle. SNALPs and SPLPs typically contain a cationic lipid, a noncationic lipid, and a lipid that prevents aggregation of the particle (e.g., a PEG-lipid conjugate). SNALPs and SPLPs are exceptionally useful for systemic applications, as they exhibit extended circulation lifetimes following intravenous injection and accumulate at distal sites (e.g., sites physically separated from the administration site). SPLPs include “pSPLP,” which include an encapsulated condensing agent-nucleic acid complex as set forth in PCT Publication No. WO 00/03683. The nucleic acid-lipid particles typically have a mean diameter of about 50 nm to about 150 nm, about 60 nm to about 130 nm, about 70 nm to about 110 nm, or about 70 nm to about 90 nm, and are substantially nontoxic. In addition, the nucleic acids present in the nucleic acid-lipid particles desirably are resistant in aqueous solution to degradation with a nuclease. Nucleic acid-lipid particles and their method of preparation are disclosed in, e.g., U.S. Patents 5,976,567; 5,981,501; 6,534,484; 6,586,410; and 6,815,432; and PCT Publication No. WO 96/40964.

[0102] Pharmaceutical compositions suitable for injections include, for example, sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. Generally, these preparations are sterile and fluid to the extent that easy injectability exists. Preparations should be stable under the conditions of manufacture and storage and should be preserved against the contaminating action of microorganisms, such as bacteria and fungi. Appropriate solvents or dispersion media may contain, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by using a coating (such as lecithin), by maintaining the required particle size (in the case of dispersion), and/or by

using surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, such as, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, isotonic agents (e.g., sugars or sodium chloride) may be included in the composition. Prolonged absorption of the injectable compositions can be brought about by including absorption-delaying agents, such as, for example, aluminum monostearate and gelatin.

[0103] Sterile injectable solutions may be prepared by incorporating an appropriate amount of the RNAi construct (alone or complexed with a ligand) into a solvent along with any other ingredients (such as described above) as desired, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the desired other ingredients. In the case of sterile powders for the preparation of sterile injectable solutions, suitable methods of preparation include vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient(s) plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0104] The compositions provided herein may be formulated in a neutral or salt form. Pharmaceutically-acceptable salts include, for example, acid addition salts (formed with free amino groups) derived from inorganic acids (e.g., hydrochloric or phosphoric acids), or from organic acids (e.g., acetic, oxalic, tartaric, mandelic, and the like). Salts formed with free carboxyl groups can also be derived from inorganic bases (e.g., sodium, potassium, ammonium, calcium, or ferric hydroxides) or from organic bases (e.g., isopropylamine, trimethylamine, histidine, procaine, and the like).

[0105] For parenteral administration in an aqueous solution, for example, a solution generally is suitably buffered and a liquid diluent is first rendered isotonic with, e.g., sufficient saline or glucose. Such aqueous solutions may be used, for example, for intravenous, intramuscular, subcutaneous, and intraperitoneal administration. Sterile aqueous media desirably are employed as is known to those of skill in the art. By way of illustration, a single dose may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580).

For human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA standards. In certain embodiments, a pharmaceutical composition of the invention comprises or consists of a sterile saline solution and an RNAi construct described herein. In other embodiments, a pharmaceutical composition of the invention comprises or consists of an RNAi construct described herein and sterile water (e.g. water for injection, WFI). In still other embodiments, a pharmaceutical composition of the invention comprises or consists of an RNAi construct described herein and phosphate-buffered saline (PBS).

[0106] In some embodiments, the pharmaceutical compositions of the invention are packaged with or stored within a device for administration. Devices for injectable formulations include, but are not limited to, injection ports, pre-filled syringes, auto injectors, injection pumps, on-body injectors, and injection pens. Devices for aerosolized or powder formulations include, but are not limited to, inhalers, insufflators, aspirators, and the like. Thus, the present invention includes administration devices comprising a pharmaceutical composition of the invention for treating or preventing one or more of the disorders described herein.

Methods for Inhibiting GPAM Expression

[0107] The present disclosure also provides methods of inhibiting expression of a GPAM gene in a cell. The methods include contacting a cell with an RNAi construct, e.g., double-stranded RNAi construct, in an amount effective to inhibit expression of GPAM in the cell, thereby inhibiting expression of GPAM in the cell. Contacting a cell with an RNAi construct, e.g., a double-stranded RNAi construct, may be done *in vitro* or *in vivo*.

Contacting a cell *in vivo* with the RNAi construct includes contacting a cell or group of cells within a subject, e.g., a human subject, with the RNAi construct. Combinations of *in vitro* and *in vivo* methods of contacting a cell also are within the scope of the present disclosure.

[0108] The present invention provides methods for reducing or inhibiting expression of GPAM in a subject in need thereof as well as methods of treating or preventing conditions, diseases, or disorders associated with GPAM expression or activity. A “condition, disease, or disorder associated with GPAM expression” refers to conditions, diseases, or disorders in

which GPAM expression levels are altered or where elevated expression levels of GPAM are associated with an increased risk of developing the condition, disease, or disorder.

[0109] Contacting a cell may be direct or indirect, as discussed above. Furthermore, contacting a cell may be accomplished via a targeting ligand, including any ligand described herein or known in the art. In preferred embodiments, the targeting ligand is a carbohydrate moiety, e.g., a GalNAc ligand, or a triantennary GalNAc structure, such as that shown in Example 1, or any other ligand that directs the RNAi construct to a site of interest.

[0110] In one embodiment, contacting a cell with an RNAi includes “introducing” or “delivering the RNAi into the cell” by facilitating or effecting uptake or absorption into the cell. Absorption or uptake of an RNAi can occur through unaided diffusive or active cellular processes, or by auxiliary agents or devices. For *in vivo* introduction, for example, RNAi can be injected into a tissue site or administered systemically. *In vitro* introduction into a cell may be accomplished using methods known in the art, such as electroporation and lipofection. Additional approaches are described herein below and/or are known in the art.

[0111] The term “inhibiting,” as used herein, is used interchangeably with “reducing,” “silencing,” “downregulating”, “suppressing”, and other similar terms, and includes any level of inhibition.

[0112] The phrase “inhibiting expression of a GPAM” is intended to refer to inhibition of expression of any GPAM gene (such as, e.g., a mouse GPAM gene, a rat GPAM gene, a monkey GPAM gene, or a human GPAM gene) as well as variants or mutants of a GPAM gene. Thus, the GPAM gene may be a wild-type GPAM gene, a mutant GPAM gene (such as a mutant GPAM gene giving rise to amyloid deposition), or a transgenic GPAM gene in the context of a genetically manipulated cell, group of cells, or organism.

[0113] “Inhibiting expression of a GPAM gene” includes any level of inhibition of a GPAM gene, e.g., at least partial suppression of the expression of a GPAM gene. The expression of the GPAM gene may be assessed based on the level, or the change in the level, of any variable associated with GPAM gene expression, e.g., GPAM mRNA level, GPAM protein level, or the number or extent of amyloid deposits. This level may be assessed in an individual cell or in a group of cells, including, for example, a sample derived from a subject.

[0114] Inhibition may be assessed by a decrease in an absolute or relative level of one or more variables that are associated with GPAM expression compared with a control level. The control level may be any type of control level that is utilized in the art, e.g., a pre-dose baseline level, or a level determined from a similar subject, cell, or sample that is untreated or treated with a control (such as, e.g., buffer only control or inactive agent control). In some embodiments, expression of a GPAM gene is inhibited by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%.

[0115] Inhibition of the expression of a GPAM gene may be manifested by a reduction of the amount of mRNA expressed by a first cell or group of cells (such cells may be present, for example, in a sample derived from a subject) in which a GPAM gene is transcribed and which has or have been treated (e.g., by contacting the cell or cells with an RNAi construct of the invention, or by administering an RNAi construct of the invention to a subject in which the cells are or were present), such that the expression of a GPAM gene is inhibited, as compared to a second cell or group of cells substantially identical to the first cell or group of cells but which has not or have not been so treated (control cell(s)). Inhibition may be assessed by expressing the level of mRNA in treated cells as a percentage of the level of mRNA in control cells, using the following formula:

$$\frac{(mRNA \text{ in control cells}) - (mRNA \text{ in treated cells})}{mRNA \text{ in control cells}} \times 100\%$$

[0116] Alternatively, inhibition of the expression of a GPAM gene may be assessed in terms of a reduction of a parameter that is functionally linked to GPAM gene expression, e.g., GPAM protein expression or Hedgehog pathway protein activities. GPAM gene

silencing may be determined in any cell expressing GPAM, either endogenously or recombinantly, by any assay known in the art.

[0117] Inhibition of the expression of a GPAM protein may be manifested by a reduction in the level of the GPAM protein that is expressed by a cell or group of cells (e.g., the level of protein expressed in a sample obtained from a subject). As explained above, for the assessment of mRNA suppression, the inhibition of protein expression levels in a treated cell or group of cells may similarly be expressed as a percentage of the level of protein in a control cell or group of cells.

[0118] A control cell or group of cells that may be used to assess the inhibition of the expression of a GPAM gene includes a cell or group of cells that has not yet been contacted with an RNAi construct of the invention. For example, the control cell or group of cells may be derived from an individual subject (e.g., a human or animal subject) prior to treatment of the subject with an RNAi construct.

[0119] The level of GPAM mRNA that is expressed by a cell or group of cells, or the level of circulating GPAM mRNA, may be determined using any method known in the art for assessing mRNA expression, such as those mentioned above. In some embodiments, the level of expression of GPAM in a sample is determined by detecting a transcribed polynucleotide, or portion thereof, e.g., mRNA of the GPAM gene. In this regard, for example, RNA may be extracted from cells using RNA extraction techniques including, for example, acid phenol/guanidine isothiocyanate extraction (RNAzol B; Biogenesis), RNeasy RNA preparation kits (Qiagen), or PAXgene (PreAnalytix, Switzerland). Typical assay formats utilizing ribonucleic acid hybridization include nuclear run-on assays, RT-PCR, RNase protection assays (Melton et al., Nuc. Acids Res., 12:7035), northern blotting, *in situ* hybridization, and microarray analysis. Circulating GPAM mRNA may be detected using methods described in WO 2012/177906.

[0120] In one embodiment, the level of expression of GPAM is determined using a nucleic acid probe. The term “probe,” as used herein, refers to any molecule that is capable of selectively binding to a specific GPAM sequence. Probes can be synthesized by one of skill in the art or derived from appropriate biological preparations. Probes may be

specifically designed to be labeled. Examples of molecules that can be utilized as probes include, but are not limited to, RNA, DNA, proteins, antibodies, and organic molecules.

[0121] Isolated mRNA can be used in hybridization or amplification assays that include, but are not limited to, Southern or northern analyses, polymerase chain reaction (PCR) analyses, and probe arrays. One method for the determination of mRNA levels involves contacting isolated mRNA with a nucleic acid molecule (probe) that can hybridize to GPAM mRNA. In one embodiment, the mRNA is immobilized on a solid surface and contacted with a probe, for example by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose. In an alternative embodiment, the probe(s) are immobilized on a solid surface and the mRNA is contacted with the probe(s), for example, in an Affymetrix gene chip array. A skilled artisan can readily adapt known mRNA detection methods for use in determining the level of GPAM mRNA.

[0122] An alternative method for determining the level of expression of GPAM in a sample involves the process of nucleic acid amplification and/or reverse transcriptase (to prepare cDNA) of for example mRNA in the sample, e.g., by RT-PCR (see, e.g., U.S. Patent 4,683,202), ligase chain reaction (Barany (1991) Proc. Natl. Acad. Sci. USA 88: 189-193), self-sustained sequence replication (Guatelli et al. (1990) Proc. Natl. Acad. Sci. USA 87: 1874-1878), transcriptional amplification system (Kwoh et al. (1989) Proc. Natl. Acad. Sci. USA 86: 1173-1177), Q-Beta Replicase (Lizardi et al. (1988) Bio/Technology 6: 1197), rolling circle replication (Lizardi et al., *supra*; and U.S. Patent 5,854,033) or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers. In some aspects of the invention, the level of expression of GPAM may be determined by quantitative fluorogenic RT-PCR (i.e., the TAQMAN™ System). The expression levels of GPAM mRNA may be monitored using a membrane blot (such as used in hybridization analysis such as northern, Southern, dot, and the like), or microwells, sample tubes, gels, beads or fibers (or any solid support comprising bound nucleic acids) (see, e.g., U.S. Patents 5,445,934; 5,677,195; 5,770,722; 5,744,305; and 5,874,219). The determination

of GPAM expression level may also comprise using nucleic acid probes in solution. In certain embodiments, the level of mRNA expression is assessed using branched DNA (bDNA) assays or real time PCR (qPCR).

[0123] The level of GPAM protein expression may be determined using any method known in the art for the measurement of protein levels. Such methods include, for example, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, fluid or gel precipitin reactions, absorption spectroscopy, colorimetric assays, spectrophotometric assays, flow cytometry, immunodiffusion (single or double), immunoelectrophoresis, Western blotting, radioimmunoassay (RIA), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, electrochemiluminescence assays, etc.

[0124] In some embodiments, the efficacy of the methods of the invention can be monitored by detecting or monitoring a reduction in a symptom of a GPAM disease, such as reduction in edema swelling of the extremities, face, larynx, upper respiratory tract, abdomen, trunk, and genitals, prodrome; laryngeal swelling; nonpruritic rash; nausea; vomiting; or abdominal pain. These symptoms may be assessed *in vitro* or *in vivo* using any method known in the art.

[0125] In some embodiments, the RNAi construct or a composition comprising the RNAi construct is administered to a subject such that the RNAi construct is delivered to a specific site within the subject. The inhibition of expression of GPAM may be assessed using measurements of the level or change in the level of GPAM mRNA or GPAM protein in a sample derived from fluid or tissue from the specific site within the subject. In some embodiments, the RNAi construct may be delivered to a site such as the liver, choroid plexus, retina, and pancreas. The site may also be a subsection or subgroup of cells from any one of the aforementioned sites. The site may also include cells that express a particular type of receptor.

Methods of Treating or Preventing GPAM-Associated Diseases

[0126] The present invention provides therapeutic and prophylactic methods which include administering to a subject with a GPAM -associated disease, disorder, and/or

condition, or prone to developing, a GPAM- associated disease, disorder, and/or condition, an RNAi construct, compositions (e.g., pharmaceutical compositions) comprising an RNAi construct, or vectors comprising an RNAi construct as described herein. Non-limiting examples of GPAM- associated diseases include, for example, fatty liver (steatosis), nonalcoholic steatohepatitis (NASH), cirrhosis of the liver, accumulation of fat in the liver, inflammation of the liver, hepatocellular necrosis, liver fibrosis, obesity, and nonalcoholic fatty liver disease (NAFLD). In one embodiment, the GPAM-associated disease is NAFLD. In another embodiment, the GPAM-associated disease is NASH. In another embodiment, the GPAM-associated disease is fatty liver (steatosis). In another embodiment, the GPAM-associated disease is insulin resistance. In another embodiment, the GPAM-associated disease is not insulin resistance.

[0127] In certain embodiments, the present invention provides a method for reducing the expression of GPAM in a patient in need thereof comprising administering to the patient any of the RNAi constructs described herein. The term “patient,” as used herein, refers to a mammal, including humans, and can be used interchangeably with the term “subject.” The expression level of GPAM in hepatocytes in the patient desirably is reduced following administration of the RNAi construct as compared to the GPAM expression level in a patient not receiving the RNAi construct.

[0128] The methods of the invention are useful for treating a subject having a GPAM- associated disease, e.g., a subject that would benefit from reduction in GPAM gene expression and/or GPAM protein production. In one aspect, the present invention provides methods of reducing the level of glycerol-3-phosphate acyltransferase, mitochondrial (GPAM) gene expression in a subject having nonalcoholic fatty liver disease (NAFLD). In another aspect, the present invention provides methods of reducing the level of GPAM protein in a subject with NAFLD. The present invention also provides methods of reducing the level of activity of the hedgehog pathway in a subject with NAFLD.

[0129] The treatment methods (and uses) of the invention include administering to the subject, e.g., a human, a therapeutically effective amount of the disclosed RNAi construct targeting a GPAM gene, a pharmaceutical composition comprising the RNAi construct, or a vector comprising the RNAi construct.

[0130] In one aspect, the invention provides methods of preventing at least one symptom in a subject having NAFLD, e.g., the presence of elevated hedgehog signaling pathways, fatigue, weakness, weight loss, loss of appetite, nausea, abdominal pain, spider-like blood vessels, yellowing of the skin and eyes (jaundice), itching, fluid buildup and swelling of the legs (edema), abdomen swelling (ascites), and mental confusion. The methods include administering to the subject a prophylactically effective amount of the RNAi construct, e.g., dsRNA, pharmaceutical compositions comprising the RNAi construct, or vectors encoding the RNAi construct, thereby preventing at least one symptom in the subject having a disorder that would benefit from reduction in GPAM gene expression. A “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired prophylactic result (e.g., prevention of disease onset).

[0131] In another aspect, the present invention provides uses of a therapeutically effective amount of an RNAi construct of the invention for treating a subject, e.g., a subject that would benefit from a reduction and/or inhibition of GPAM gene expression. In a further aspect, the present invention provides uses of an RNAi construct, e.g., a dsRNA, of the invention targeting an GPAM gene or pharmaceutical composition comprising an RNAi construct targeting an GPAM gene in the manufacture of a medicament for treating a subject, e.g., a subject that would benefit from a reduction and/or inhibition of GPAM gene expression and/or GPAM protein production, such as a subject having a disorder that would benefit from reduction in GPAM gene expression, e.g., a GPAM-associated disease.

[0132] The disclosure provides uses of an RNAi construct, e.g., a dsRNA, of the invention for preventing at least one symptom in a subject suffering from a disorder that would benefit from a reduction and/or inhibition of GPAM gene expression and/or GPAM protein production. For example, the disclosure provides uses of the RNAi construct described herein, compositions comprising same, and vectors comprising same, in the treatment of NAFLD.

[0133] In a further aspect, the present invention provides uses of the disclosed RNAi construct, compositions comprising same, or a vector comprising same, in the manufacture of a medicament for preventing at least one symptom in a subject suffering from a disorder that

would benefit from a reduction and/or inhibition of GPAM gene expression and/or GPAM protein production, such as a GPAM-associated disease.

[0134] In one embodiment, an RNAi construct targeting GPAM is administered to a subject having a GPAM-associated disease, e.g., nonalcoholic fatty liver disease (NAFLD), such that the expression of a GPAM gene, e.g., in a cell, tissue, blood or other tissue or fluid of the subject are reduced by at least about 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 62%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99% or more when the RNAi construct is administered to the subject.

[0135] The methods and uses of the invention include administering a composition described herein such that expression of the target GPAM gene is decreased for any suitable amount of time, such as for about 1, 2, 3, 4 5, 6, 7, 8, 12, 16, 18, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, or about 80 hours. In one embodiment, expression of the target GPAM gene is decreased for an extended duration, e.g., at least about two, three, four, five, six, seven days or more, e.g., about one week, two weeks, three weeks, or about four weeks or longer.

[0136] Administration of the RNAi construct according to the methods and uses of the invention may result in a reduction of the severity, signs, symptoms, and/or markers of such diseases or disorders in a patient with a GPAM-associated disease, e.g., NAFLD. By “reduction” in this context is meant a statistically significant decrease in such level. The reduction can be, for example, at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or about 100%. Efficacy of treatment or prevention of disease can be assessed, for example by measuring disease progression, disease remission, symptom severity, reduction in pain, quality of life, dose of a medication required to sustain a treatment effect, level of a disease marker or any other measurable parameter appropriate for a given disease being treated or targeted for prevention. It is well within the ability of one skilled in the art to monitor efficacy of

treatment or prevention by measuring any one of such parameters, or any combination of parameters. For example, efficacy of treatment of NAFLD may be assessed, for example, by periodic monitoring of NAFLD symptoms, liver fat levels, or expression of downstream genes. Comparison of the later readings with the initial readings provide a physician an indication of whether the treatment is effective. It is well within the ability of one skilled in the art to monitor efficacy of treatment or prevention by measuring any one of such parameters, or any combination of parameters. In connection with the administration of an RNAi targeting GPAM or pharmaceutical composition thereof, “effective against” an GPAM-associated disease indicates that administration in a clinically appropriate manner results in a beneficial effect for at least a statistically significant fraction of patients, such as improvement of symptoms, a cure, a reduction in disease, extension of life, improvement in quality of life, or other effect generally recognized as positive by medical doctors familiar with treating NAFLD and/or an GPAM-associated disease and the related causes.

[0137] A treatment or preventive effect is evident when there is a statistically significant improvement in one or more parameters of disease status, or by a failure to worsen or to develop symptoms where they would otherwise be anticipated. As an example, a favorable change of at least 10% in a measurable parameter of disease, and preferably at least 20%, 30%, 40%, 50% or more can be indicative of effective treatment. Efficacy for a given RNAi drug or formulation of that drug can also be judged using an experimental animal model for the given disease as known in the art. When using an experimental animal model, efficacy of treatment is evidenced when a statistically significant reduction in a marker or symptom is observed.

[0138] Subjects can be administered any therapeutically effective amount of the RNAi construct. Exemplary therapeutically effective amounts of the RNAi construct include, but are not limited to, 0.01 mg/kg, 0.02 mg/kg, 0.03 mg/kg, 0.04 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.15 mg/kg, 0.2 mg/kg, 0.25 mg/kg, 0.3 mg/kg, 0.35 mg/kg, 0.4 mg/kg, 0.45 mg/kg, 0.5 mg/kg, 0.55 mg/kg, 0.6 mg/kg, 0.65 mg/kg, 0.7 mg/kg, 0.75 mg/kg, 0.8 mg/kg, 0.85 mg/kg, 0.9 mg/kg, 0.95 mg/kg, 1.0 mg/kg, 1.1 mg/kg, 1.2 mg/kg, 1.3 mg/kg, 1.4 mg/kg, 1.5 mg/kg, 1.6 mg/kg, 1.7 mg/kg, 1.8 mg/kg, 1.9 mg/kg, 2.0 mg/kg, 2.1 mg/kg, 2.2 mg/kg, 2.3 mg/kg, 2.4 mg/kg, 2.5 mg/kg, 2.6 mg/kg, 2.7 mg/kg, 2.8 mg/kg, 2.9 mg/kg, 3.0 mg/kg,

3.1 mg/kg, 3.2 mg/kg, 3.3 mg/kg, 3.4 mg/kg, 3.5 mg/kg, 3.6 mg/kg, 3.7 mg/kg, 3.8 mg/kg, 3.9 mg/kg, 4.0 mg/kg, 4.1 mg/kg, 4.2 mg/kg, 4.3 mg/kg, 4.4 mg/kg, 4.5 mg/kg, 4.6 mg/kg, 4.7 mg/kg, 4.8 mg/kg, 4.9 mg/kg, 5.0 mg/kg, 5.1 mg/kg, 5.2 mg/kg, 5.3 mg/kg, 5.4 mg/kg, 5.5 mg/kg, 5.6 mg/kg, 5.7 mg/kg, 5.8 mg/kg dsRNA, 5.9 mg/kg, 6.0 mg/kg, 6.1 mg/kg, 6.2 mg/kg, 6.3 mg/kg, 6.4 mg/kg, 6.5 mg/kg, 6.6 mg/kg, 6.7 mg/kg, 6.8 mg/kg, 6.9 mg/kg, 7.0 mg/kg, 7.1 mg/kg, 7.2 mg/kg, 7.3 mg/kg, 7.4 mg/kg, 7.5 mg/kg, 7.6 mg/kg, 7.7 mg/kg, 7.8 mg/kg, 7.9 mg/kg, 8.0 mg/kg, 8.1 mg/kg, 8.2 mg/kg, 8.3 mg/kg, 8.4 mg/kg, 8.5 mg/kg, 8.6 mg/kg, 8.7 mg/kg, 8.8 mg/kg, 8.9 mg/kg, 9.0 mg/kg, 9.1 mg/kg, 9.2 mg/kg, 9.3 mg/kg, 9.4 mg/kg, 9.5 mg/kg, 9.6 mg/kg, 9.7 mg/kg, 9.8 mg/kg, 9.9 mg/kg, 9.0 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, or about 50 mg/kg. In one embodiment, subjects can be administered 0.5 mg/kg of the RNAi construct. Values and ranges intermediate to the recited values also are encompassed by the present disclosure.

[0139] Administration of the RNAi construct, or a composition comprising same, can reduce the presence of GPAM protein levels, e.g., in a cell, tissue, blood, urine or other compartment of the patient by at least about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31 %, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99% or more.

[0140] Before administration of a full dose of the RNAi, patients can be administered a smaller dose, such as a 5% infusion, and monitored for adverse effects, such as an allergic reaction. In another example, the patient can be monitored for unwanted immunostimulatory effects, such as increased cytokine (e.g., TNF-alpha or INF-alpha) levels.

[0141] Owing to the inhibitory effects on GPAM expression, a composition according to the invention or a pharmaceutical composition prepared therefrom can enhance the quality of life.

[0142] An RNAi of the invention may be administered in “naked” form, where the modified or unmodified RNAi construct is directly suspended in aqueous or suitable buffer

solvent, as a “free RNAi.” A free RNAi is administered in the absence of a pharmaceutical composition. The free RNAi may be in a suitable buffer solution. The buffer solution may comprise acetate, citrate, prolamine, carbonate, or phosphate, or any combination thereof. In one embodiment, the buffer solution is phosphate buffered saline (PBS). The pH and osmolality of the buffer solution containing the RNAi can be adjusted such that it is suitable for administering to a subject.

[0143] Alternatively, an RNAi of the invention may be administered as a pharmaceutical composition, such as a dsRNA liposomal formulation.

[0144] Subjects that would benefit from a reduction and/or inhibition of GPAM gene expression are those having nonalcoholic fatty liver disease (NAFLD) and/or an GPAM-associated disease or disorder as described herein.

[0145] Treatment of a subject that would benefit from a reduction and/or inhibition of GPAM gene expression includes therapeutic and prophylactic treatment.

[0146] The invention further provides methods and uses of an RNAi construct or a pharmaceutical composition thereof for treating a subject that would benefit from reduction and/or inhibition of GPAM gene expression, e.g., a subject having a GPAM-associated disease, in combination with other pharmaceuticals and/or other therapeutic methods, e.g., with known pharmaceuticals and/or known therapeutic methods, such as, for example, those which are currently employed for treating these disorders.

[0147] For example, in certain embodiments, an RNAi targeting a GPAM gene is administered in combination with, e.g., an agent useful in treating an GPAM-associated disease. For example, additional therapeutics and therapeutic methods suitable for treating a subject that would benefit from reduction in GPAM expression, e.g., a subject having a GPAM-associated disease, include an RNAi construct targeting a different portion of the GPAM gene, a therapeutic agent, and/or procedures for treating a GPAM-associated disease or a combination of any of the foregoing. In certain embodiments, a first RNAi construct targeting a GPAM gene is administered in combination with a second RNAi construct targeting a different portion of the GPAM gene. For example, the first RNAi construct may comprise a first sense strand and a first antisense strand forming a double stranded region, wherein substantially all of the nucleotides of said first sense strand and substantially all of

the nucleotides of the first antisense strand are modified nucleotides, wherein said first sense strand is conjugated to a ligand attached at the 3' - terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker; and the second RNAi construct may comprise a second sense strand and a second antisense strand forming a double stranded region, wherein substantially all of the nucleotides of the second sense strand and substantially all of the nucleotides of the second antisense strand are modified nucleotides, wherein the second sense strand is conjugated to a ligand attached at the 3' -terminus, and wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker. In one embodiment, all of the nucleotides of the first and second sense strand and/or all of the nucleotides of the first and second antisense strand comprise a modification. The modified nucleotides may be any one or combination of the modified nucleotides described herein.

[0148] In other embodiments, a first RNAi construct targeting a GPAM gene is administered in combination with a second RNAi construct targeting a gene that is different from the GPAM gene. For example, the RNAi construct targeting the GPAM gene may be administered in combination with an RNAi construct targeting the SCAP gene. SCAP (SREBP Cleavage Activating Protein) is the only known regulator of the transcription factors of the SREBP family. The SREBP (Sterol Response Element Binding Protein) family play important roles in regulating *de novo* lipogenesis and triglyceride (TG) accumulation within the liver. The first RNAi construct targeting a GPAM gene and the second RNAi construct targeting a different gene, e.g., the SCAP gene, may be administered as parts of the same pharmaceutical composition. Alternatively, the first RNAi construct targeting a GPAM gene and the second RNAi construct targeting a different gene, e.g., the SCAP gene, may be administered as parts of different pharmaceutical compositions. In addition, or alternatively, a first RNAi construct targeting a GPAM gene can be administered in combination with a second RNAi construct targeting the Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) gene, or in combination with a second RNAi that targets SCAP and a third RNAi that targets PNPLA3. Patatin-like phospholipase domain-containing 3 (PNPLA3), formerly known as adiponutrin (ADPN) and calcium-independent phospholipase A2-epsilon (iPLA(2)ε), is a type II transmembrane protein (Wilson et al (2006) J Lipid Res 47(9):1940-

9; Jenkins et al (2004) *J Biol Chem* 279(47):48968-75). Initially identified in adipose cells as a membrane-associated, adipose-enriched protein induced during adipogenesis in mice, it is now well characterized to be expressed in other tissues, including the liver (Wilson et al, supra; Baulande et al (2001) *J Biol Chem* 276(36):33336-44; Moldes et al. (2006) *Eur J Endocrinol* 155(3):461-8; Faraj et al. (2006) *J Endocrinol* 191(2):427-35; Liu et al (2004) *J Clin Endocrinol Metab* 89(6):2684-9; Lake et al (2005) *J Lipid Res* 46(11) :2477-87). In cell-free biochemical systems, recombinant PNPLA3 protein can exhibit either triacylglycerol lipase or transacylation activity (Jenkins et al., supra; Kumari et al (2012) *Cell Metab* 15(5):691-702; He et al (2010) *J Biol Chem* 285(9):6706-15). In hepatocytes, PNPLA3 is expressed on the endoplasmic reticulum and lipid membranes and predominantly exhibits triacylglycerol hydrolase activity (He et al., supra; Huang et al (2010) *Proc Natl Acad Sci USA* 107(17):7892-7; Ruhanen et al (2014) *J Lipid Res* 55(4):739-46; Pingitore et al. (2014) *Biochim Biophys Acta* 1841(4):574-80). Although lacking a secretory signal, data indicates PNPLA3 is secreted and can be found in human plasma as disulfide-bond dependent multimers (Winberg et al. (2014) *Biochem Biophys Res Commun* 446(4):1114-9).

[0149] The RNAi construct and an additional therapeutic agent and/or treatment may be administered at the same time and/or in the same combination, e.g., parenterally, or the additional therapeutic agent can be administered as part of a separate composition or at separate times and/or by another method known in the art or described herein.

[0150] The present invention also provides methods of using an RNAi construct of the invention and/or a composition containing an RNAi construct of the invention to reduce and/or inhibit GPAM expression (gene or protein expression) in a cell. In yet other aspects, use of an RNAi construct of the invention and/or a composition comprising an RNAi construct of the invention for the manufacture of a medicament for reducing and/or inhibiting GPAM gene expression in a cell are provided. In still other aspects, the present invention provides an RNAi of the invention and/or a composition comprising an RNAi construct of the invention for use in reducing and/or inhibiting GPAM protein production in a cell. In yet other aspects, use of an RNAi construct of the invention and/or a composition comprising an RNAi construct of the invention for the manufacture of a medicament for reducing and/or inhibiting GPAM protein production in a cell are provided. The methods and uses include contacting the cell with an

RNAi construct, e.g., a dsRNA, of the invention and maintaining the cell for a time sufficient to obtain degradation of the mRNA transcript of a GPAM gene, thereby inhibiting expression of the GPAM gene or inhibiting GPAM protein production in the cell. Reduction in gene expression can be assessed by any methods known in the art or described herein for determining mRNA or protein levels.

[0151] In the methods and uses of the invention the cell may be contacted *in vitro* or *in vivo*, i.e., the cell may be outside (e.g., in cell culture) or within a subject. A cell suitable for treatment using the methods of the invention may be any cell that expresses an GPAM gene, e.g., a cell from a subject having NAFLD or a cell comprising an expression vector comprising a GPAM gene or portion of a GPAM gene. A suitable cell for use in the disclosed methods includes, for example, a mammalian cell, e.g., a primate cell (such as a human cell or a non-human primate cell, e.g., a monkey cell or a chimpanzee cell), a non-primate cell (such as a cow cell, a pig cell, a camel cell, a llama cell, a horse cell, a goat cell, a rabbit cell, a sheep cell, a hamster, a guinea pig cell, a cat cell, a dog cell, a rat cell, a mouse cell, a lion cell, a tiger cell, a bear cell, or a buffalo cell), a bird cell (e.g., a duck cell or a goose cell), or a whale cell. In one embodiment, the cell is a human cell.

[0152] GPAM gene expression may be inhibited in the cell by at least about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100%.

[0153] GPAM protein production may be inhibited in the cell by at least about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100%.

[0154] The *in vivo* methods and uses of the invention may include administering to a subject a composition containing an RNAi construct, where the RNAi construct includes a nucleotide sequence that is complementary to at least a part of an RNA transcript of the GPAM gene of the subject. When the organism to be treated is a human, the composition can be administered by any means known in the art including, but not limited to subcutaneous, intravenous, oral, intraperitoneal, or parenteral routes, including intracranial (e.g., intraventricular, intraparenchymal, and intrathecal), intramuscular, transdermal, airway (aerosol), nasal, rectal, and topical (including buccal and sublingual) administration. In certain embodiments, the compositions are administered by subcutaneous or intravenous infusion or injection. In one embodiment, the compositions are administered by subcutaneous injection.

[0155] In some embodiments, the administration is via a depot injection. A depot injection may release the RNAi construct in a consistent way over a prolonged time period. Thus, a depot injection may reduce the frequency of dosing needed to obtain a desired effect, e.g., a desired inhibition of GPAM, or a therapeutic or prophylactic effect. A depot injection may also provide more consistent serum concentrations. Depot injections may include subcutaneous injections or intramuscular injections. In some embodiments, the depot injection is a subcutaneous injection.

[0156] In some embodiments, the administration is via a pump. The pump may be an external pump or a surgically implanted pump. In certain embodiments, the pump is a subcutaneously implanted osmotic pump. In other embodiments, the pump is an infusion pump. An infusion pump may be used for intravenous, subcutaneous, arterial, or epidural infusions. In preferred embodiments, the infusion pump is a subcutaneous infusion pump. In other embodiments, the pump is a surgically implanted pump that delivers the RNAi to the subject.

[0157] The mode of administration may be chosen based upon whether local or systemic treatment is desired and based upon the area to be treated. The route and site of administration may be chosen to enhance targeting.

[0158] The methods and uses include administering to the mammal, e.g., a human, a composition comprising an RNAi construct, e.g., an siRNA, that targets an GPAM gene in a

cell of the mammal and maintaining the mammal for a time sufficient to obtain degradation of the mRNA transcript of the GPAM gene, thereby inhibiting expression of the GPAM gene in the mammal. Reduction in gene expression and/or protein expression can be assessed in a sample obtained from the RNAi construct-administered subject by any method known in the art or described herein. In one embodiment, a tissue sample serves as the tissue material for monitoring the reduction in GPAM gene and/or protein expression. In another embodiment, a blood sample serves as the tissue material for monitoring the reduction in GPAM gene and/or protein expression.

[0159] In some embodiments, verification of RISC-mediated cleavage of a target mRNA (e.g., GPAM mRNA) *in vivo* following administration of an RNAi construct may be assessed by performing 5'-RACE or modifications of the protocol as known in the art (Lasham A et al., (2010) Nucleic Acid Res., 38 (3) p-e19; and Zimmermann et al. (2006) Nature 441: 111-4).

[0160] It is understood that all ribonucleic acid sequences disclosed herein can be converted to deoxyribonucleic acid sequences by substituting a thymine base for a uracil base in the sequence. Likewise, all deoxyribonucleic acid sequences disclosed herein can be converted to ribonucleic acid sequences by substituting a uracil base for a thymine base in the sequence. Deoxyribonucleic acid sequences, ribonucleic acid sequences, and sequences containing mixtures of deoxyribonucleotides and ribonucleotides of all sequences disclosed herein are encompassed by the present invention.

[0161] Additionally, any nucleic acid sequences disclosed herein may be modified with any combination of chemical modifications. One of skill in the art will readily appreciate that such designation as "RNA" or "DNA" to describe modified polynucleotides is, in certain instances, arbitrary. For example, a polynucleotide comprising a nucleotide having a 2'-OH substituent on the ribose sugar and a thymine base could be described as a DNA molecule having a modified sugar (2'-OH for the natural 2'-H of DNA) or as an RNA molecule having a modified base (thymine (methylated uracil) for natural uracil of RNA).

[0162] Accordingly, nucleic acid sequences provided herein, including but not limited to those set forth in the sequence listing, are intended to encompass nucleic acids containing any combination of natural or modified RNA and/or DNA, including, but not

limited to, such nucleic acids having modified nucleobases. By way of a further example and without limitation, a polynucleotide having the sequence “ATCGATCG” encompasses any polynucleotides having such a sequence, whether modified or unmodified, including, but not limited to, such compounds comprising RNA bases, such as those having sequence “AUCGAUCG” and those having some DNA bases and some RNA bases such as “AUCGATCG,” and polynucleotides having other modified bases, such as “ATmeCGAUCG,” wherein meC indicates a cytosine base comprising a methyl group at the 5-position.

[0163] The following examples, including the experiments conducted and the results achieved, are provided for illustrative purposes only and are not to be construed as limiting the scope of the appended claims.

EXAMPLES

[0164] All animal experiments described herein were approved by the Institutional Animal Care and Use Committee (IACUC) of Amgen and cared for in accordance to the Guide for the Care and Use of Laboratory Animals, 8th Edition (National Research Council (U.S.)). Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research (U.S.), and National Academies Press (U.S.) (2011) *Guide for the care and use of laboratory animals. 8th Ed.*, National Academies Press, Washington, D.C. Mice were single-housed in an air-conditioned room at 22±2°C with a twelve-hour light; twelve-hour darkness cycle (0600-1800 hours). Animals had *ad libitum* access to a regular chow diet (Envigo, 2920X, or a diet as stated otherwise) and to water (reverse osmosis-purified) via automatic watering system, unless otherwise indicated. At termination, blood was collected by cardiac puncture under deep anesthesia, and then, following Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) guidelines, euthanized by a secondary physical method.

EXAMPLE 1: Selection, Design and Synthesis of Modified GPAM siRNA molecules

[0165] The identification and selection of optimal sequences for therapeutic siRNA molecules targeting glycerol-3-phosphate acyltransferase, mitochondrial (GPAM) were

identified using bioinformatics analysis of a human GPAM transcript (GenBank Accession No. XM_005269998.1). Table 1 lists GPAM mRNA target sequences, having an inverted abasic nucleotide appended to the 3' end of the sense strand, identified as having therapeutic properties.

Table 1. siRNA sequences directed to GPAM

Duplex No.	Sense sequence (5'-3')	SEQ ID NO: (sense)	Antisense sequence (5'-3')	SEQ ID NO: (antisense)
1001	GGGACUCUUUCUGAGGUUAC{invAb}	1	AGUAACCUCAGAAAGAGUCCCUU	2
1002	CUUUCUGAGGUUACUGUGGA{invAb}	3	AUCCACAGUAACCUCAGAAAGUU	4
1003	CUGAGGUUACUGUGGAGCAC{invAb}	5	AGUGCUCCACAGUAACCUCAGUU	6
1004	UUUGCUAAUCGACUGAUUGG{invAb}	7	UCCAAUCAGUCGAUUAGCAAUU	8
1005	GCUAAUCGACUGAUUGGAAA{invAb}	9	AUUUCCAUCAGUCGAUUAGCUU	10
1006	CUAAUCGACUGAUUGGAAAU{invAb}	11	UAUUUCCAUCAGUCGAUUAGUU	12
1007	UAAUCGACUGAUUGGAAUA{invAb}	13	UUAUUCCAUCAGUCGAUUUUU	14
1008	AAUCGACUGAUUGGAAUAA{invAb}	15	AUUUUCCAUCAGUCGAUUUUU	16
1009	GGAAUAAUCCUCAACAC{invAb}	17	AGUGUUUGAGGAAUUAUUUCCUU	18
1010	AAUAAUCCUCAACACCAC{invAb}	19	AGUGGUGUUUGAGGAAUUAUUUU	20
1011	ACACCACCAAGUCAAGGAUA{invAb}	21	AUAUCCUUGACUUGGUGGUGUUU	22
1012	ACCACCAAGUCAAGGAUACA{invAb}	23	AUGUAUCCUUGACUUGGUGGUUU	24
1013	AGUCAAGGAUACAGGCAGCA{invAb}	25	AUGCUGCCUGUAUCCUUGACUUU	26
1014	AAGGAUACAGGCAGCAGCGG{invAb}	27	ACCGCUGCUGCCUGUAUCCUUUU	28
1015	GCAGCGGCUCUCCUGUUGUA{invAb}	29	AUACAACAGGGGAGCCGUGCUU	30
1016	AGCGGCUCUCCUGUUGUAUG{invAb}	31	ACAUACAACAGGGGAGCCGCUUU	32
1017	CGGCUCUCCUGUUGUAUGGA{invAb}	33	AUCCAUACAACAGGGGAGCCGUU	34
1018	CCCCUGUUGUAUGGACAUUC{invAb}	35	AGAAUGUCCAUACAACAGGGGUU	36
1019	UGGACAUUCUGCACCCGAAA{invAb}	37	AUUUCGGGUGCAGAAUGUCCAUU	38
1020	CUGCACCCGAAACUGAUAGC{invAb}	39	AGCUAUCAGUUUCGGGUGCAGUU	40
1021	UGCACCCGAAACUGAUAGCU{invAb}	41	AAGCUAUCAGUUUCGGGUGCAUU	42
1022	CACCCGAAACUGAUAGCUGA{invAb}	43	AUCAGCUAUCAGUUUCGGGUGUU	44
1023	CCGAAACUGAUAGCUGAGUC{invAb}	45	AGACUCAGCUAUCAGUUUCGGUU	46
1024	AACUGAUAGCUGAGUCCUGA{invAb}	47	UUCAGGACUCAGCUAUCAGUUUU	48
1025	AUAGCUGAGUCCUGAAGUUU{invAb}	49	AAAACUUCAGGACUCAGCUAUUU	50
1026	CAGCACAUGAUUUGGAAUU{invAb}	51	UAAUUCCAAUUAUGUGCUGUU	52
1027	ACAUGAUUUGGAAUUACAC{invAb}	53	AGUGUAAUUCCAAUUAUGUUU	54
1028	AUUUGGGAAUUACACUUUGU{invAb}	55	AACAAAGUGUAAUUCCAAUUU	56
1029	GGGAAUUACACUUUGUGACA{invAb}	57	AUGUCACAAAGUGUAAUUCUUU	58
1030	GAAUUACACUUUGUGACAUG{invAb}	59	ACAUGUCACAAAGUGUAAUUCUU	60

1031	ACACUUUGUGACAUGGAUGA{invAb}	61	UUCAUCCAUGUCACAAAGUGUUU	62
1032	CACUUUGUGACAUGGAUGAA{invAb}	63	AUUCAUCCAUGUCACAAAGUGUU	64
1033	AUGAAUCUGCACUGACCCUU{invAb}	65	AAAGGGUCAGUGCAGAUUCAUUU	66
1034	AUCUGCACUGACCCUUGGUA{invAb}	67	AUACCAAGGGUCAGUGCAGAUUU	68
1035	GCACUGACCCUUGGUACAAU{invAb}	69	UAUUGUACCAAGGGUCAGUGCUU	70
1036	CUGACCCUUGGUACAAUAGA{invAb}	71	AUCUAUUGUACCAAGGGUCAGUU	72
1037	AAUAGAUGUUUCUUAUCUGC{invAb}	73	AGCAGAUAAAGAAACAUUAUUUU	74
1038	AUCAGAAUACAGUGUUGGUC{invAb}	75	AGACCAACACUGUAUUCUGAUUU	76
1039	UCAGAAUACAGUGUUGGUCG{invAb}	77	UCGACCAACACUGUAUUCUGAUU	78
1040	CAGAAUACAGUGUUGGUCGA{invAb}	79	AUCGACCAACACUGUAUUCUGUU	80
1041	AGAAUACAGUGUUGGUCGAU{invAb}	81	AAUCGACCAACACUGUAUUCUUU	82
1042	GAAUACAGUGUUGGUCGAUG{invAb}	83	ACAUCGACCAACACUGUAUUCUU	84
1043	AAUACAGUGUUGGUCGAUGU{invAb}	85	UACAUCGACCAACACUGUAUUUU	86
1044	UACAGUGUUGGUCGAUGUAA{invAb}	87	AUUACAUCGACCAACACUGUAUU	88
1045	AGUGUUGGUCGAUGUAAGCA{invAb}	89	AUGCUUACAUCGACCAACACUUU	90
1046	UGUAAGCACACAAGUGAGGA{invAb}	91	UUCCUCACUUGUGUGCUUACAUU	92
1047	UAAGCACACAAGUGAGGAU{invAb}	93	AAUUCCUCACUUGUGUGCUUAUU	94
1048	GCACACAAGUGAGGAUUGGG{invAb}	95	ACCCAUUCCUCACUUGUGUGCUU	96
1049	GGAAAGAAAGCCUAAUGAGU{invAb}	97	AACUCAUUAAGGCUUUCUUUCCUU	98
1050	AAGAAAGCCUAAUGAGUCGG{invAb}	99	UCCGACUCAUUAAGGCUUUCUUUU	100
1051	AGAAAGCCUAAUGAGUCGGA{invAb}	101	UUCCGACUCAUUAAGGCUUUCUUU	102
1052	GAAAGCCUAAUGAGUCGGAA{invAb}	103	UUUCCGACUCAUUAAGGCUUUCUU	104
1053	AAGCCUAAUGAGUCGGAAAA{invAb}	105	AUUUCCGACUCAUUAAGGCUUUU	106
1054	CCUAAUGAGUCGGAAAAGGC{invAb}	107	AGCCUUUCCGACUCAUUAAGGUU	108
1055	CUAAUGAGUCGGAAAAGGCC{invAb}	109	UGGCCUUUCCGACUCAUUAAGUU	110
1056	AAUGAGUCGGAAAAGGCCAU{invAb}	111	AAUGGCCUUUCCGACUCAUUUU	112
1057	GUUGGAAGAUGUUGUUAUCUC{invAb}	113	AGAGUAACAACAUCUCCAACUU	114
1058	AAAUUUUUAACCCAGUAU{invAb}	115	AAUACUGGGGUUGAAAAUUUUU	116
1059	AAUUUUUAACCCAGUAUC{invAb}	117	AGAUACUGGGGUUGAAAAUUUUU	118
1060	UGGGUUUGCGGAUGUUAUU{invAb}	119	AAAUAACAUUCCGCAAACCAUU	120
1061	GGUUUGCGGAUGUUAUUUA{invAb}	121	AUAAAUAACAUUCCGCAAACCUU	122
1062	UGCAGGAUGUUAUUUAUAUC{invAb}	123	UGAUUAUAAUAACAUUCCGCAUU	124
1063	GCGGAUGUUAUUUAUAUCA{invAb}	125	UUGAUUAUAAUAACAUUCCGCUU	126
1064	AUUUAUAUCAAUUGAAACUCA{invAb}	127	AUGAGUUUCAUUGAUUAUAAUUU	128
1065	UUUAUAUCAAUUGAAACUCACA{invAb}	129	AUGUGAGUUUCAUUGAUUAUAAUU	130
1066	UCAAUUGAAACUCACACAAGA{invAb}	131	AUCUUGUGUGAGUUUCAUUGAUU	132
1067	UGAAACUCACACAAGACACC{invAb}	133	AGGUGUCUUGUGUGAGUUUCAUU	134
1068	GAAACUCACACAAGACACCG{invAb}	135	ACGGUGUCUUGUGUGAGUUUCUU	136
1069	CGCGGAUGGCUUGCAAGACG{invAb}	137	ACGUCUUGCAAGCAUCCGCGUU	138
1070	GCGGAUGGCUUGCAAGACGC{invAb}	139	AGCGUCUUGCAAGCAUCCGCUU	140
1071	GCUUGCAAGACGCCUUUCUU{invAb}	141	UAAGAAAGGCGUCUUGCAAGCUU	142
1072	UCUUUUUAUUAAGAGCGAG{invAb}	143	UCUCGCUCUUGAAUAAAAAGAUU	144

1073	CUUUUUUAUCAAGAGCGAGA{invAb}	145	AUCUCGCUCUUGAAUAAAAAGUU	146
1074	UUUUUAUCAAGAGCGAGAU{invAb}	147	AAUCUCGCUCUUGAAUAAAAAUU	148
1075	UUUUUAUCAAGAGCGAGAUG{invAb}	149	ACAUCUCGCUCUUGAAUAAAAUU	150
1076	UUUAUUAAGAGCGAGAUGU{invAb}	151	AACAUCUCGCUCUUGAAUAAAAU	152
1077	UUAUUAAGAGCGAGAUGUG{invAb}	153	ACACAUCUCGCUCUUGAAUAAUU	154
1078	AAGAGCGAGAUGUGCAUAAG{invAb}	155	ACUUAUGCACAUCUCGCUCUUUU	156
1079	AGAGCGAGAUGUGCAUAAGG{invAb}	157	ACCUUAUGCACAUCUCGCUCUUU	158
1080	GAGCGAGAUGUGCAUAAGGG{invAb}	159	ACCCUUAUGCACAUCUCGCUCUU	160
1081	AGAUGUGCAUAAGGGCAUGU{invAb}	161	AACAUGCCCUUAUGCACAUCUUU	162
1082	AUGUGCAUAAGGGCAUGUUU{invAb}	163	AAAACAUGCCCUUAUGCACAUUU	164
1083	GUGCAUAAGGGCAUGUUUGC{invAb}	165	AGCAAACAUGCCCUUAUGCACUU	166
1084	GGCAUGUUUGCCACCAAUGU{invAb}	167	AACAUUGGUGGCAAACAUGCCUU	168
1085	GCAUGUUUGCCACCAAUGUG{invAb}	169	UCACAUUGGUGGCAAACAUGCUU	170
1086	AUGUUUGCCACCAAUGUGAC{invAb}	171	AGUCACAUUGGUGGCAAACAUUU	172
1087	UGCUGAACAGCAGUAGAGUA{invAb}	173	AUACUCUACUGCGUUCAGCAUU	174
1088	CUGAACAGCAGUAGAGUACA{invAb}	175	UUGUACUCUACUGCGUUCAGUU	176
1089	UAGAGUACAAGAGGCAAUUG{invAb}	177	ACAAUUGCCUCUUGUACUCUAUU	178
1090	GUACAAGAGGCAAUUGCAGA{invAb}	179	UUCUGCAAUUGCCUCUUGUACUU	180
1091	AAGAGGCAAUUGCAGAAGUG{invAb}	181	ACACUUCUGCAAUUGCCUCUUUU	182
1092	UGCUGAAUUAACCCUGAUG{invAb}	183	ACAUCAGGGUUUAUUCAGCAUU	184
1093	UGAAUUAACCCUGAUGGUU{invAb}	185	AAACCAUCAGGGUUUAUUCAUU	186
1094	GAAUUAACCCUGAUGGUUC{invAb}	187	AGAACCAUCAGGGUUUAUUCUU	188
1095	UGCCAGCAGCAAUCAAAAG{invAb}	189	ACUUUUGAUUGCUGCUGGGCAUU	190
1096	GCAGCAAUCAAAAGCCGUUA{invAb}	191	UUAACGGCUUUUGAUUGCUGCUU	192
1097	AGCAAUCAAAAGCCGUUAAC{invAb}	193	UGUUAACGGCUUUUGAUUGCUIU	194
1098	CAAUCAAAAGCCGUUAACAA{invAb}	195	UUUGUUAACGGCUUUUGAUUGUU	196
1099	AAUCAAAAGCCGUUAACAAA{invAb}	197	AUUUGUUAACGGCUUUUGAUUUU	198
1100	AUCAAAAGCCGUUAACAAAG{invAb}	199	ACUUUGUUAACGGCUUUUGAUUU	200
1101	UCAAAAGCCGUUAACAAAGU{invAb}	201	AACUUUGUUAACGGCUUUUGAUU	202
1102	AAAAGCCGUUAACAAAGUGA{invAb}	203	UUCACUUUGUUAACGGCUUUUUU	204
1103	AAAGCCGUUAACAAAGUGAA{invAb}	205	UUUCACUUUGUUAACGGCUUUUU	206
1104	GCCGUUAACAAAGUGAAAAA{invAb}	207	AUUUUUCACUUUGUUAACGGCUU	208
1105	AAAGAAAGCUAAAAGGAUUC{invAb}	209	AGAAUCCUUUUAGCUUUCUUUUU	210
1106	AAAAGGAUUCUUAAGAAAU{invAb}	211	AAUUUCUUGAAGAAUCCUUUUUU	212
1107	CACUGUCUACCGGCAAUGA{invAb}	213	AUCAUUGCCGGUGAGACAGUGUU	214
1108	UGUCUACCGGCAAUGAUCA{invAb}	215	AUGAUCAUUGCCGGUGAGACAUU	216
1109	CUCACCGGCAAUGAUCAGAC{invAb}	217	AGUCUGAUCAUUGCCGGUGAGUU	218
1110	GCAAUGAUCAGACUGACUGG{invAb}	219	ACCAGUCAGUCUGAUCAUUGCUU	220
1111	AUCAGACUGACUGGGUGGGU{invAb}	221	AACCCACCGAGUCAGUCUGAUUU	222
1112	GGUGCUGCUAAAACUGUUCA{invAb}	223	UUGAACAGUUUUAGCAGCACCUU	224
1113	GUGCUGCUAAAACUGUUCAA{invAb}	225	AUUGAACAGUUUUAGCAGCACUU	226
1114	UCAAUUCACAAAGGUCAAC{invAb}	227	AGUUGACCUUUGUGAAUUGAUU	228

1115	AAUUCACAAAGGUCAACUUG{invAb}	229	UCAAGUUGACCUUUGUGAAUUUU	230
1116	ACAAAGGUCAACUUGAGAUG{invAb}	231	ACAUCUCAAGUUGACCUUUGUUU	232
1117	AGGUCAACUUGAGAUGGUUA{invAb}	233	UUAACCAUCUCAAGUUGACCUUU	234
1118	GGUUAAGCUGCAACUGAGA{invAb}	235	AUCUCAGUUGCAGCUUUAACCUU	236
1119	GUUAAAGCUGCAACUGAGAC{invAb}	237	AGUCUCAGUUGCAGCUUUAACCUU	238
1120	AAAGCUGCAACUGAGACGAA{invAb}	239	AUUCGUCUCAGUUGCAGCUUUUU	240
1121	AGCUGCAACUGAGACGAAUU{invAb}	241	AAAUUCGUCUCAGUUGCAGCUUU	242
1122	CUGCAACUGAGACGAAUUUG{invAb}	243	ACAAAUUCGUCUCAGUUGCAGUU	244
1123	CAACUGAGACGAAUUUGCCG{invAb}	245	ACGGCAAUUCGUCUCAGUUGUU	246
1124	GAGACGAAUUUGCCGCUUCU{invAb}	247	AAGAAGCGGCAAUUCGUCUCUU	248
1125	AGACGAAUUUGCCGCUUCUG{invAb}	249	ACAGAAGCGGCAAUUCGUCUUU	250
1126	GACGAAUUUGCCGCUUCUGU{invAb}	251	AACAGAAGCGGCAAUUCGUCUU	252
1127	ACGAAUUUGCCGCUUCUGUU{invAb}	253	AAACAGAAGCGGCAAUUCGUUU	254
1128	CGAAUUUGCCGCUUCUGUUU{invAb}	255	AAAACAGAAGCGGCAAUUCGUU	256
1129	UUUGCCGCUUCUGUUUCUAC{invAb}	257	AGUAGAAACAGAAGCGGCAAUU	258
1130	UUCUGUUUCUACCAGUUCAU{invAb}	259	UAUGAACUGGUAGAAACAGAAUU	260
1131	UCUGUUUCUACCAGUUCAUA{invAb}	261	AUAUGAACUGGUAGAAACAGAUU	262
1132	CUGUUUCUACCAGUUCAUAG{invAb}	263	UCUAUGAACUGGUAGAAACAGUU	264
1133	UUUCUACCAGUUCAUAGAU{invAb}	265	AGAUCUAUGAACUGGUAGAAUU	266
1134	UUCUACCAGUUCAUAGAUCC{invAb}	267	AGGAUCUAUGAACUGGUAGAAUU	268
1135	CAUAGAUCCCAUAUUGACUA{invAb}	269	AUAGUCAUAUGGGAUUCUAGUU	270
1136	AUAGAUCCCAUAUUGACUAU{invAb}	271	AAUAGUCAUAUGGGAUUCUUUU	272
1137	UAGAUCCCAUAUUGACUAUC{invAb}	273	AGAUAGUCAUAUGGGAUUCUUU	274
1138	AGAUCCCAUAUUGACUAUCU{invAb}	275	AAGAUAGUCAUAUGGGAUUCUUU	276
1139	AUCCCAUAUUGACUAUCUGC{invAb}	277	AGCAGAUAGUCAUAUGGGAUUU	278
1140	UCCCAUAUUGACUAUCUGCU{invAb}	279	AAGCAGAUAGUCAUAUGGGAUU	280
1141	CCAUAACAUAAGCACCAU{invAb}	281	UAUGGUGCUUUGAUUUUUGGUU	282
1142	CAUCAAGCACCAUACAUUG{invAb}	283	ACAAUGUAUGGUGCUUUGAUUU	284
1143	CAUUGCUUCAGGCAUAAUC{invAb}	285	AGAUUAUUGCCUGAAGCAAUGUU	286
1144	AUUGCUUCAGGCAUAAUCU{invAb}	287	AAGAUUAUUGCCUGAAGCAAUUU	288
1145	UUGGGGGCUUCUUCUACGA{invAb}	289	AUCGUUAUGAAGAAGCCCCAAUU	290
1146	CUUCAUACGACGAAGGCUCG{invAb}	291	UCGAGCCUUCGUCGUUAUGAGUU	292
1147	AUACGACGAAGGCUCGAUGA{invAb}	293	UUCAUCGAGCCUUCGUCGUUUU	294
1148	UACGACGAAGGCUCGAUGAA{invAb}	295	UUUCAUCGAGCCUUCGUCGUUU	296
1149	CGACGAAGGCUCGAUGAAAC{invAb}	297	UGUUUCAUCGAGCCUUCGUCGUU	298
1150	ACGAAGGCUCGAUGAAACAC{invAb}	299	AGUGUUUCAUCGAGCCUUCGUUU	300
1151	GAAGGCUCGAUGAAACACCA{invAb}	301	AUGGUGUUUCAUCGAGCCUUCUU	302
1152	CAGAUGGACGGAAAGAUUU{invAb}	303	AAACAUCUUUCCGUCCAUCUGUU	304
1153	GGACGGAAAGAUUUUCUCUA{invAb}	305	AUAGAGAACAUCUUUCCGUCCUU	306
1154	GCUUUGCUCCAUGGGCAUAU{invAb}	307	UAUAUGCCCAUGGAGCAAAGCUU	308
1155	UUUGCUCCAUGGGCAUAUAG{invAb}	309	ACUAUAUGCCCAUGGAGCAAUU	310
1156	UGCUGCAUGGGCAUAUAGUU{invAb}	311	AAACUAUAUGCCCAUGGAGCAUU	312

1157	GGGCAUUAUAGUUGAAUUACU{invAb}	313	AAGUAAUUAACUAUAUGCCCUU	314
1158	CAUAUAGUUGAAUUACUUCG{invAb}	315	UCGAAGUAAUUAACUAUAUGUU	316
1159	AUAGUUGAAUUACUUCGACA{invAb}	317	AUGUCGAAGUAAUUAACUAUUU	318
1160	GUUGAAUUAUUCGACAGCA{invAb}	319	AUGCUGUCGAAGUAAUUAACUU	320
1161	ACUUCGACAGCAGCAAUUCU{invAb}	321	AAGAAUUGCUGCUGUGCAAGUUU	322
1162	CGUUCUAGGAGUGGAAAAAC{invAb}	323	AGUUUUUCCACUCCUAGAACGUU	324
1163	GUUCUAGGAGUGGAAAAACC{invAb}	325	AGGUUUUUCCACUCCUAGAACUU	326
1164	UUUUGUCAGUUGUGGUAGAU{invAb}	327	UAUCUACCACAACUGACAAAAUU	328
1165	UUGUCAGUUGUGGUAGAUAC{invAb}	329	AGUAUCUACCACAACUGACAAUU	330
1166	UCAGUUGUGGUAGAUACUCU{invAb}	331	AAGAGUAUCUACCACAACUGAUU	332
1167	CUACCAUGUCAUCCCAGAC{invAb}	333	UGUCUGGGAUGACAUUGGUAGUU	334
1168	AUGUCAUCCCAGACAUCUUG{invAb}	335	UCAAGAUGUCUGGGAUGACAUUU	336
1169	UGUCAUCCCAGACAUCUUGA{invAb}	337	AUCAAGAUGUCUGGGAUGACAUU	338
1170	GUCAUCCCAGACAUCUUGAU{invAb}	339	UAUCAAGAUGUCUGGGAUGACUU	340
1171	CCCAGACAUCUUGAUAAUAC{invAb}	341	AGUAUUAUCAAGAUGUCUGGGUU	342
1172	UCUUGAUAAUACCGUUGGA{invAb}	343	UUCCAACAGGUAAUUAUCAAGUU	344
1173	CUUGAUAAUACCGUUGGAA{invAb}	345	AUCCAACAGGUAAUUAUCAAGUU	346
1174	GUUGGAAUCUCCUAUGAUCG{invAb}	347	ACGAUCAUAGGAGAUUCCAACUU	348
1175	CAUUAUCGAAGGUCACUACA{invAb}	349	UUGUAGUGACCUUCGAUAAUGUU	350
1176	UUAUCGAAGGUCACUACAAU{invAb}	351	AAUUGUAGUGACCUUCGAUAAUU	352
1177	GUGUAGCAAGAGGUGUUAUU{invAb}	353	UAAUAAACCCUCUUGCUACACUU	354
1178	GUGUUAUUAGAAUGUUAACGA{invAb}	355	UUCGUAACAUUCUAAUAAACUU	356
1179	UGUUAUUAGAAUGUUAACGAA{invAb}	357	UUUCGUAACAUUCUAAUAAACUU	358
1180	GUUAUUAGAAUGUUAACGAAA{invAb}	359	UUUUCGUAACAUUCUAAUAAACUU	360
1181	UUAUUAGAAUGUUAACGAAAA{invAb}	361	UUUUUCGUAACAUUCUAAUAAUU	362
1182	UUAGAAUGUUAACGAAAAAAC{invAb}	363	AGUUUUUUUCGUAACAUUCUAAUU	364
1183	UAGAAUGUUAACGAAAAACU{invAb}	365	UAGUUUUUUUCGUAACAUUCUAAU	366
1184	AGAAUGUUAACGAAAAACUA{invAb}	367	AUAGUUUUUUUCGUAACAUUCUUU	368
1185	AAUGUUAACGAAAAACUAUG{invAb}	369	ACAUAGUUUUUUUCGUAACAUUUU	370
1186	AUGUUAACGAAAAACUAUGG{invAb}	371	ACCAUAGUUUUUUUCGUAACAUUU	372
1187	UGUUAACGAAAAACUAUGGU{invAb}	373	AACCAUAGUUUUUUUCGUAACAUU	374
1188	UUACGAAAAACUAUGGUUG{invAb}	375	ACAACCAUAGUUUUUUUCGUAAUU	376
1189	UACGAAAAACUAUGGUUGU{invAb}	377	AACAACCAUAGUUUUUUUCGUUUU	378
1190	AAAAACUAUGGUUGUGUCCG{invAb}	379	UCGGACACAACCAUAGUUUUUUU	380
1191	AACUAUGGUUGUGUCCGAGU{invAb}	381	AACUCGGACACAACCAUAGUUUUU	382
1192	AAGGAAUUAUUAGAAAGCCA{invAb}	383	UUGGCUUUCUAAAUUAUCCUUUU	384
1193	AGGAAUUAUUAGAAAGCCAA{invAb}	385	UUUGGCUUUCUAAAUUAUCCUUU	386
1194	GGAAUUAUUAGAAAGCCAAA{invAb}	387	AUUUGGCUUUCUAAAUUAUCCUU	388
1195	UAGAAAGCCAAAGUCAGAAA{invAb}	389	AUUUCUGACUUUGGCUUUCUAAU	390
1196	AGAAAGCCAAAGUCAGAAAC{invAb}	391	AGUUUCUGACUUUGGCUUUCUUU	392
1197	AGCCAAAGUCAGAAACCGGU{invAb}	393	AACCGGUUUCUGACUUUGGCUUU	394
1198	AGCAAGCGUUGUUAACAGCU{invAb}	395	UAGCUGGUAAACAACGCUUGCUUU	396

1199	GCAAGCGUUGUUACCAGCUA{invAb}	397	AUAGCUGGUAAACAACGCUUGCUU	398
1200	AAGCGUUGUUACCAGCUAUA{invAb}	399	AUAUAGCUGGUAAACAACGCUUUU	400
1201	AGCGUUGUUACCAGCUAUAC{invAb}	401	AGUAUAGCUGGUAAACAACGCUUU	402
1202	GUCCAUAUAUGAGUCCAGAA{invAb}	403	UUUCUGGACUCAUUAUUGGACUU	404
1203	CCAUUAUAUGAGUCCAGAAU{invAb}	405	AAUUUCUGGACUCAUUAUUGGUU	406
1204	GAGUCCAGAAUUGCAACAGA{invAb}	407	AUCUGUUGCAUUUCUGGACUCUU	408
1205	CUACGAAGGAGGUUGAUUGC{invAb}	409	UGCAAUCAACCUCCUUCGUAGUU	410
1206	ACGAAGGAGGUUGAUUGCAA{invAb}	411	UUUGCAAUCAACCUCCUUCGUUU	412
1207	CUGAGCAUAUUCUAUUCACU{invAb}	413	AAGUGAAUAGAAUAGCUCAGUU	414
1208	UUCUAUUCACUGCUAGCAAG{invAb}	415	ACUUGCUAGCAGUGAAUAGAAUU	416
1209	CUAUUCACUGCUAGCAAGUC{invAb}	417	AGACUUGCUAGCAGUGAAUAGUU	418
1210	UAUUCACUGCUAGCAAGUCC{invAb}	419	AGGACUUGCUAGCAGUGAAUAAU	420
1211	ACUGCUAGCAAGUCCUGUGC{invAb}	421	AGCACAGGACUUGCUAGCAGUUU	422
1212	CAAGUCCUGUGCCAUUAUGU{invAb}	423	AACAUAUUGGCACAGGACUUGUU	424
1213	AGUCCUGUGCCAUUAUGUCC{invAb}	425	UGGACAUAUUGGCACAGGACUUU	426
1214	CAUUAUGUCCACACACAUUG{invAb}	427	ACAUGUGUGUGGACAUAUUGUU	428
1215	UCCACACACAUUGUGGCUUG{invAb}	429	ACAAGCCACAUGUGUGUGGAUU	430
1216	CAGACACAGGCAGGGAUUG{invAb}	431	UCAAUUCCUGGCCUGUGUCUGUU	432
1217	ACACAGGCAGGGAUUGAUC{invAb}	433	AGAUAUUAUCCUGGCCUGUGUUU	434
1218	GAAUUGAUCUCUCCACAUUG{invAb}	435	ACAUGUGGAGAGAUCAAUUCUU	436
1219	AGGAAGUCCUGGCUCGUGAU{invAb}	437	AAUCACGAGCCAGGACUCCUUU	438
1220	CGUGAUUUUGACCUGGGGUU{invAb}	439	AAACCCAGGUCAAAAUCACGUU	440
1221	GUGAUUUUGACCUGGGGUUC{invAb}	441	AGAACCCAGGUCAAAAUCACUU	442
1222	UGAUUUUGACCUGGGGUUCU{invAb}	443	AAGAACCCAGGUCAAAAUCAUU	444
1223	UUCAGAAGAUAGUAAUUGC{invAb}	445	UGCAUUAUACAUCUUCUGAAUU	446
1224	UGUAGUAAUGCAUGCCAUAC{invAb}	447	UGUAUGGCAUGCAUUAUACAUU	448
1225	CAUGCCAUACAGCUGCUGGG{invAb}	449	UCCAGCAGCUGUAUGGCAUGUU	450
1226	CCAUACAGCUGCUGGGAAAU{invAb}	451	AAUUUCCAGCAGCUGUAUGGUU	452
1227	CAUACAGCUGCUGGGAAAUU{invAb}	453	AAAUUCCAGCAGCUGUAUGUU	454
1228	GUUUUUUAUACCCCCAGCA{invAb}	455	AUGCUGGGGGUGAUAAAAACUU	456
1229	UUUUUUUAUACCCCCAGCAC{invAb}	457	UGUGCUGGGGGUGAUAAAAAUU	458
1230	UUAUACCCCCAGCACAAUCU{invAb}	459	AAGUUGUGCUGGGGGUGAUAAUU	460
1231	UAUACCCCCAGCACAAUCUG{invAb}	461	ACAGUUGUGCUGGGGGUGAUUUU	462
1232	AUCAGUCUUCGAACUCAACU{invAb}	463	AAGUUGAGUUCGAAGACUGAUUU	464
1233	GUCUUCGAACUCAACUUCUA{invAb}	465	AUAGAAGUUGAGUUCGAAGACUU	466
1234	UCUUCGAACUCAACUUCUAC{invAb}	467	UGUAGAAGUUGAGUUCGAAGAUU	468
1235	CUUCGAACUCAACUUCUACA{invAb}	469	AUGUAGAAGUUGAGUUCGAAGUU	470
1236	CGAACUCAACUUCUACAGCA{invAb}	471	UUGCUGUAGAAGUUGAGUUCGUU	472
1237	AACUCAACUUCUACAGCAAU{invAb}	473	AAUUGCUGUAGAAGUUGAGUUUU	474
1238	AACUUCUACAGCAAUGGGGU{invAb}	475	UACCCCAUUGCUGUAGAAGUUUU	476
1239	CUUCUACAGCAAUGGGGUAC{invAb}	477	AGUACCCCAUUGCUGUAGAAGUU	478
1240	AGCAAUGGGGUACUUCAUGU{invAb}	479	AACAUGAAGUACCCCAUUGC UU	480

1241	GCAAUGGGGUACUUCAUGUC{invAb}	481	AGACAUGAAGUACCCAUUGC UU	482
1242	UACUUCAUGUCUUUAUCAUG{invAb}	483	ACAUGAUAAAGACAUGAAGUAUU	484
1243	ACUUCAUGUCUUUAUCAUGG{invAb}	485	UCCAUGAUAAAGACAUGAAGUUU	486
1244	UCUUUAUCAUGGAGGCCAUC{invAb}	487	UGAUGGCCUCCAUGAUAAAGAUU	488
1245	GCCUUUAUGCAGUUCUGAAC{invAb}	489	UGUUCAGAACUGCAUAAAGGCUU	490
1246	AGCACCCACCUAACCUGAU{invAb}	491	AAUCAGGUUAGGUGGGGUGCUUU	492
1247	CACCCACCUAACCUGAUCA{invAb}	493	AUGAUCAGGUUAGGUGGGGUGUU	494
1248	CCCACCUAACCUGAUCAGCC{invAb}	495	UGGCUGAUCAGGUUAGGUGGGUU	496
1249	UGUGCUACCUUCUCUCCA AU{invAb}	497	AAUUGGAGAGAAGGUAGCACA UU	498
1250	ACCAUCUCACUGCCUUGCCA{invAb}	499	AUGGCAAGGCAGUGAGAUGGUUU	500
1251	CUGCCUUGCCAGACAUUUUA{invAb}	501	AUAAAUGUCUGGCAAGGCAGUU	502
1252	CAUGAAACAGUAGGAAAGUU{invAb}	503	AAACUUCCUACUGUUUCAUGUU	504
1253	GAAACAGUAGGAAAGUUUAU{invAb}	505	AAUAAACUUCCUACUGUUUCUU	506
1254	GUAGGAAAGUUUAUCCAGUA{invAb}	507	AUACUGGAUAAACUUCCUACUU	508
1255	GUUUUAUCCAGUAUGGCAUUC{invAb}	509	AGAAUGCCAUACUGGAUAAACUU	510
1256	UUCUUAACAGUGGCAGAGCAC{invAb}	511	AGUGCUCUGCCACUGUAAGAAUU	512
1257	UACAGUGGCAGAGCACGAUG{invAb}	513	UCAUCGUGCUCUGCCACUGUAUU	514
1258	GAUGACCAGGAAGAUUAUCAG{invAb}	515	ACUGAUAUUCUCCUGGUCAUUU	516
1259	GAAGAUUAUCAGUCCUAGUCU{invAb}	517	AAGACUAGGACUGAUUUCUUCUU	518
1260	UAGUCUUGCUGAGCAGCAGU{invAb}	519	AACUGCUGCUCAGCAAGACUAUU	520
1261	UUUGUCUUGGAGAAGUGAUG{invAb}	521	UCAUCACUUCUCCAAGACAAAUU	522
1262	AGGAACAGCGAGAUUGCUAC{invAb}	523	AGUAGCAAUCUCGCGUUCUUUU	524
1263	CAGCGAGAUUGCUACCUGAA{invAb}	525	AUUCAGGUAGCAAUCUCGCGUUU	526
1264	GCUACCUGAAGGUGAGCCAA{invAb}	527	AUUGGCUCACCUUCAGGUAGCUU	528
1265	CUACCUGAAGGUGAGCCAAU{invAb}	529	AAUUGGCUCACCUUCAGGUAGUU	530
1266	CCUGAAGGUGAGCCAAUCCA{invAb}	531	UUGGAUUGGCUCACCUUCAGGUU	532
1267	GAGACUCCUUGGGCCUUGC{invAb}	533	AGCAAAGGCCAAGGAGUCUCUU	534
1268	AGAAAUGUUGCAGUAUAUGC{invAb}	535	AGCAUAUACUGCAACAUUUCUUU	536
1269	GAAAUGUUGCAGUAUAUGCU{invAb}	537	AAGCAUAUACUGCAACAUUUCUU	538
1270	CAGUAUAUGCUGAGAGUGCC{invAb}	539	UGGCACUCUCAGCAUAUACUGUU	540
1271	UAUUGUCUUGUGAAGAAUGC{invAb}	541	AGCAUUCUUCACAAGACAAUAUU	542
1272	UGAAAUGUUUAAGGAUAUU{invAb}	543	AAAUAUCCUUAACAUUUUCAUU	544
1273	GACCAAACAAAGAGAGUGU{invAb}	545	AACACUCUCUUUUGUUUGGUCUU	546
1274	ACAAAAGAGAGUGUCUGUUU{invAb}	547	AAAACAGACACUCUCUUUUGUUU	548
1275	CAAAAGAGAGUGUCUGUUUU{invAb}	549	UAAAACAGACACUCUCUUUUGUU	550
1276	GUUUUAGAACUGAGCAGCAC{invAb}	551	AGUGCUCUCAGUUCUAAAACUU	552
1277	AGAACUGAGCAGCACUUUUC{invAb}	553	AGAAAAGUGCUGCUCAGUUCUUU	554
1278	AGCACUUUUCUACCUCAAUG{invAb}	555	ACAUUGAGGUAGAAAAGUGCUUU	556
1279	UUUCUACCUCAAUGCAACCG{invAb}	557	UCGGUUGCAUUGAGGUAGAAA UU	558
1280	GUUUUGUGGUGCUGUAGGUA{invAb}	559	UUACCUACAGCACCACAAACUU	560
1281	UUGUGGUGCUGUAGGUAACG{invAb}	561	ACGUUACCUACAGCACCACAAUU	562
1282	GUGGUGCUGUAGGUAACGUG{invAb}	563	ACACGUUACCUACAGCACCACUU	564

1283	GGUGCUGUAGGUAACGUGUG{invAb}	565	ACACACGUUACCUACAGCACCUU	566
1284	UGCUGUAGGUAACGUGUGGC{invAb}	567	UGCCACACGUUACCUACAGCAUU	568
1285	GGCAAAUGAAGGUCAUGAGA{invAb}	569	AUCUCAUGACCUUCAUUUGCCUU	570
1286	GAUCUGUGAUCUUCCCAGCU{invAb}	571	AAGCUGGGAAGAUCACAGAUUU	572
1287	GCAGAUAAACUUGGGGGGA{invAb}	573	AUCCCCCAAGUGUUAUCUGCUU	574
1288	AUAACACUUGGGGGGACCUC{invAb}	575	UGAGGUCCCCCAAGUGUUAUUU	576
1289	GACCUCAGCCUCUAUUCGCA{invAb}	577	UUGCGAAUAGAGGCUGAGGUCUU	578
1290	ACCUCAGCCUCUAUUCGCAA{invAb}	579	AUUGCGAAUAGAGGCUGAGGUUU	580
1291	AUAAUCCGUAGACUACAAGA{invAb}	581	AUCUUGUAGUCUACGGAUUAUUU	582
1292	CCGUAGACUACAAGAUGAAA{invAb}	583	AUUUCAUCUUGUAGUCUACGGUU	584
1293	UAGACUACAAGAUGAAAUCU{invAb}	585	AAGAUUUCAUCUUGUAGUCUAUU	586
1294	UUGUUGGUAUAUUAUCUGGU{invAb}	587	AACCAGAUAAUAUACCAACAAUU	588
1295	UGUUGGUAUAUUAUCUGGUU{invAb}	589	UAACCAGAUAAUAUACCAACAUU	590
1296	GUUGGUAUAUUAUCUGGUUA{invAb}	591	AUAACCAGAUAAUAUACCAACUU	592
1297	AAAUAAUUGAGUCAUCCAUU{invAb}	593	AAAUUGAUGACUAAUUAUUUUU	594
1298	CUGUCAAUAGUAGCUACAUU{invAb}	595	AAAUUGUAGCUACUAUUGACAGUU	596
1299	UGUCAAUAGUAGCUACAUUU{invAb}	597	AAAAUGUAGCUACUAUUGACAUU	598
1300	CAAUAGUAGCUACAUUUUUA{invAb}	599	UUAAAAUUGUAGCUACUAUUGUU	600
1301	GUAGCUACAUUUUUAAUGGG{invAb}	601	UCCCAUUAAAAUUGUAGCUACUU	602
1302	UAGCUACAUUUUUAAUGGGA{invAb}	603	AUCCCAUUAAAAUUGUAGCUAUU	604
1303	CAAUUUUAGUUUAGGUCGGG{invAb}	605	UCCCGACCUAAACUAAUUAUUGUU	606
1304	AUUAGUUUAGGUCGGGAACU{invAb}	607	AAGUUCCCGACCUAAACUAAUUU	608
1305	UUAGGUCGGGAACUGAGAU{invAb}	609	AUAUCUCAGUUCGACCUAAUU	610
1306	AGGUCGGGAACUGAGAUUU{invAb}	611	AAAUUUCUCAGUUCGACCUUU	612
1307	UCGGGAACUGAGAUUUUGUA{invAb}	613	UUACAAUUCUCAGUUCGCAUU	614
1308	GGAACUGAGAUUUUGUAAUC{invAb}	615	UGAUUACAAUUCUCAGUUCUU	616
1309	GAACUGAGAUUUUGUAAUCA{invAb}	617	UUGAUUACAAUUCUCAGUUCUU	618
1310	AACUGAGAUUUUGUAAUCAA{invAb}	619	UUUGAUUACAAUUCUCAGUUUU	620
1311	CUGAGAUUUUGUAAUCAAAU{invAb}	621	UAUUUGAUUACAAUUCUCAGUU	622
1312	UAUUGUAAUCAAAUAGUUA{invAb}	623	AUUAAUUAUUUGAUUACAAUUU	624
1313	UGUAAUCAAAUAGUUAACAU{invAb}	625	AAUGUUAACUUAUUUGAUUACAUU	626
1314	GUAUUAUAAUAGUUAACAUC{invAb}	627	UGAUGUUAACUUAUUUGAUUACUU	628
1315	UAAUCAAAUAGUUAACAUCA{invAb}	629	AUGAUGUUAACUUAUUUGAUUAAU	630
1316	AAUAGUUAACAUCAGGAAGU{invAb}	631	AACUCCUGAUGUUAACUUAUUU	632
1317	AUAGUUAACAUCAGGAAGUU{invAb}	633	UAACUCCUGAUGUUAACUUAUUU	634
1318	UAGUUAACAUCAGGAAGUUA{invAb}	635	UUAACUCCUGAUGUUAACUUAUU	636
1319	AGUUAACAUCAGGAAGUUA{invAb}	637	AUUAAUCCUGAUGUUAACUUU	638
1320	AAGUUAUUUGGCUGGCAAA{invAb}	639	UUUUGCCAGCCAAUUAACUUUU	640
1321	UAAUUUGGCUGGCAAAUUC{invAb}	641	AGAAUUUUGCCAGCCAAUUAUU	642
1322	UCUAGGGAAACUUGGCCAGA{invAb}	643	UUCUGGCCAAGUUUCCCUAGAUAU	644
1323	UGGCCAGAAACUGGUGUUG{invAb}	645	UCAACACCAGUUUUCUGGCCAUU	646
1324	UUUAGAACCCUCCUGUUUU{invAb}	647	UAAAACAGGAAGGGUUCUAAAUU	648

1325	AAUCCUCCAACCAAUAGCA{invAb}	649	AUGCUAUUUUGGUUGGAGGAUUUU	650
1326	AGUUUUCCUAACUUGAUUAG{invAb}	651	ACUAAUCAAGUUAGGAAAACUUU	652
1327	UUUUCCUAACUUGAUUAGCU{invAb}	653	AAGCUAAUCAAGUUAGGAAAUU	654
1328	UCCUAACUUGAUUAGCUUGA{invAb}	655	AUCAAGCUAAUCAAGUUAGGAUU	656
1329	ACUUGAUUAGCUUGAGCUGA{invAb}	657	AUCAGCUCAAGCUAAUCAAGUUU	658
1330	CUUGAUUAGCUUGAGCUGAC{invAb}	659	UGUCAGCUCAAGCUAAUCAAGUU	660
1331	CUUUCUGUACUGCACACAGA{invAb}	661	AUCUGUGUGCAGUACAGAAAGUU	662
1332	UCUGUACUGCACACAGAUUG{invAb}	663	ACAAUCUGUGUGCAGUACAGAUU	664
1333	CUGUACUGCACACAGAUUGU{invAb}	665	AACAAUCUGUGUGCAGUACAGUU	666
1334	GCACCCAGUCCAGGUGACU{invAb}	667	AAGUCACCUGGACUGGGGUGCUU	668
1335	UCGAGUUGUGCCGUGCACAA{invAb}	669	AUUGUGCACGGCACAACUGGAUU	670
1336	AGUUGUGCCGUGCACAACCU{invAb}	671	AAGGUUGUGCACGGCACAACUUU	672
1337	GUGCACAACUGUCCAGUAU{invAb}	673	UAUACUGGACAGGUUGUGCACUU	674
1338	UGCACAACUGUCCAGUAUA{invAb}	675	AUAUACUGGACAGGUUGUGCAUU	676
1339	CCUGUCCAGUAUAUGCAUGU{invAb}	677	AACAUGCAUAUACUGGACAGGUU	678
1340	UGGCCCUACUGACUGGUAAU{invAb}	679	AAUUACCAGUCAGUAGGGCCAUU	680
1341	GCUUUGAGGAAAAACCAUGA{invAb}	681	AUCAUGGUUUUUCCUCAAGCUU	682
1342	AAACCAUGACUUUUAACAAA{invAb}	683	AUUUGUUAAAAGUCAUGGUUUUU	684
1343	ACAAAUUUUUAUGGGUUAUA{invAb}	685	AUAUAACCAUAAAAAUUGUUU	686
1344	UUUUUAUGGGUUAUAUGCCU{invAb}	687	UAGGCAUAUAACCAUAAAAAUU	688
1345	UAUGGGUUAUAUGCCUAAAC{invAb}	689	AGUUUAGGCAUAUAACCAUAUU	690
1346	AAUGGUCUGUUAUAAUUGG{invAb}	691	ACCAAUUAUGAACAGACCAUUUU	692
1347	GGUCUGUUAUAAUUGGUAG{invAb}	693	ACUACCAUUAUGAACAGACCUU	694
1348	CUGUUAUAAUUGGUAGGUG{invAb}	695	ACACCUACCAUUAUGAACAGUU	696
1349	UAAUUGGUAGGUGCCUUUUG{invAb}	697	ACAAAAGGCACCUACCAUUAUU	698
1350	AGUUUACUGUUGCUUAUCUC{invAb}	699	AGAGAUAAAGCAACAGUAAACUUU	700
1351	UUUUCCAGAUAGUGUUACA{invAb}	701	AUGUAAACACUCAUCUGGAAAUU	702
1352	AGUACUGAGAAUUAAGUUUG{invAb}	703	ACAAACUUAUUUCUCAGUACUUU	704
1353	GUACUGAGAAUUAAGUUUGU{invAb}	705	UACAAACUUAUUUCUCAGUACUU	706
1354	CUGAUUGAUUUUCACAUUG{invAb}	707	ACAAUGUGAAAUUAUCAUCAGUU	708
1355	UGAUUGAUUUUCACAUUGU{invAb}	709	UACAAUGUGAAAUUAUCAUCAUU	710
1356	GUCAGUUGUAGUAGCUCUGA{invAb}	711	AUCAGAGCUACUACAACUGACUU	712
1357	CAGUUGUAGUAGCUCUGAUG{invAb}	713	ACAUCAGAGCUACUACAACUGUU	714
1358	GCAUCCAUUUUACUGACUA{invAb}	715	AUAGUCAGUAAAAUGGAAUGCUU	716
1359	UUGGCUACAUUUGGAGGAUA{invAb}	717	AUAUCCUCCAAUGUAGCCAAUU	718
1360	AGGAUACCCAGGGAGUCUUG{invAb}	719	ACAAGACUCCUGGGUAUCCUUU	720
1361	GGAUACCCAGGGAGUCUUGG{invAb}	721	ACCAAGACUCCUGGGUAUCCUU	722
1362	AGCAAACAUUUCACUAGUCU{invAb}	723	AAGACUAGUGAAUGUUUGCUUU	724
1363	ACAUUUCACUAGUCUCUUUU{invAb}	725	AAAAAGAGACUAGUGAAUGUUU	726
1364	UUUUCAUCCUUUAAAUUGUA{invAb}	727	UUACA AUUUAAAGGAUGAAA AUU	728
1365	UAAAUUAAGGAUUAUCAAG{invAb}	729	ACUUGAGUAAUCCUUAUUUUUU	730
1366	AAAUUAAGGAUUAUCAAGC{invAb}	731	AGCUUGAGUAAUCCUUAUUUUUU	732

1367	UUAAGGAUUACUCAAGCUCA{invAb}	733	AUGAGCUUGAGUAAUCCUAAUU	734
1368	ACUCAAGCUCACCAUUUUAUUC{invAb}	735	UGAAUAAUGGUGAGCUUGAGUUU	736
1369	UCAAGCUCACCAUUUUAUCAA{invAb}	737	AUUGAAUAAUGGUGAGCUUGAUU	738
1370	UUUUUUUCCUUUUUGGUUGG{invAb}	739	ACCAACCAAAAGGGAAAAUAAUU	740
1371	CAAUGUAUGAUUUUGCUAGCU{invAb}	741	AAGCUAGCAAAUCAUACAUGUU	742
1372	UGUAUGAUUUUGCUAGCUCUC{invAb}	743	AGAGAGCUAGCAAAUCAUACAUU	744
1373	GCUUUUUGUAAUUAAACUGGU{invAb}	745	AACCAGUUAAUUACAAAAAGCUU	746
1374	UUUGUAAUUAAACUGGUGCUU{invAb}	747	AAAGCACCAGUUAAUUACAAAUU	748
1375	GUAAUUAAACUGGUGCUUUGA{invAb}	749	UUCAAAGCACCAGUUAAUUACUU	750
1376	UUGAAAAUCUUUUUUAAGGG{invAb}	751	UCCCUUAAAAAAGAUUUUCAAUU	752
1377	AAAAUCUCAACCAAAGUUUAU{invAb}	753	AAUAACUUUGGUUGAGAUUUUUU	754
1378	UCUCAACCAAAGUUAUGCUC{invAb}	755	UGAGCAUAACUUUGGUUGAGAUU	756
1379	CAACCAAAGUUAUGCUCUUC{invAb}	757	AGAUGAGCAUAACUUUGGUUGUU	758
1380	AAAGUUAUGCUCUCCAGAC{invAb}	759	UGUCUGGAUGAGCAUAACUUUUU	760
1381	AGUUAUGCUCUCCAGACAA{invAb}	761	AUUGUCUGGAUGAGCAUAACUUU	762
1382	GUUAAUUUCAGCACAAUCUA{invAb}	763	AUGAGUUGUGCUGAAAUUAACUU	764
1383	GAUAGCACC GUUUUGCUAAA{invAb}	765	UUUUAGCAAAACGGUGCUAUCUU	766
1384	UAGCACC GUUUUGCUAAAAG{invAb}	767	UCUUUAGCAAAACGGUGCUAUU	768
1385	AGCACC GUUUUGCUAAAAGA{invAb}	769	AUCUUUAGCAAAACGGUGCUUU	770
1386	GCACC GUUUUGCUAAAAGAU{invAb}	771	UAUCUUUAGCAAAACGGUGCUU	772
1387	CACCGUUUUGCUAAAAGAUUA{invAb}	773	AUAUCUUUAGCAAAACGGUGUU	774
1388	ACCGUUUUGCUAAAAGAUAC{invAb}	775	UGUAUCUUUAGCAAAACGGUUU	776
1389	CAUUCUCAUUGUUUUCCAAC{invAb}	777	UGUUGGAAAACAAUGAGAAUGUU	778
1390	AUUCUCAUUGUUUUCCAACA{invAb}	779	AUGUUGGAAAACAAUGAGAAUUU	780
1391	UGUUUUCCAACAGUGAUGGC{invAb}	781	AGCCAUCACUGUUGGAAAACAUU	782
1392	ACAUAAGGUUAAACAAACUA{invAb}	783	AUAGUUUGUUUAACCUUAUGUUU	784
1393	CAUAAGGUUAAACAAACUAG{invAb}	785	ACUAGUUUGUUUAACCUUAUGUU	786
1394	AUAAGGUUAAACAAACUAGG{invAb}	787	ACCUAGUUUGUUUAACCUUAUUU	788
1395	UAAGGUUAAACAAACUAGGU{invAb}	789	AACCUAGUUUGUUUAACCUUAUU	790
1396	GUUAAACAAACUAGGUGCUU{invAb}	791	AAAGCACCAGUUUGUUUAACUU	792
1397	UUAAACAAACUAGGUGCUUG{invAb}	793	ACAAGCACCAGUUUGUUUAAUU	794
1398	AAUUUAUUACAGUUUACUCU{invAb}	795	UAGAGUAAACUGUAAUAAAUUUU	796
1399	CUGUAACAUGAAAUUGCAUGC{invAb}	797	AGCAUGCAUUUCAUGUUACAGUU	798
1400	AACAUGAAAUGCAUGCCCUU{invAb}	799	AAAGGGCAUGCAUUUCAUGUUUU	800
1401	AAAUGAGAAUGUCCUAAGUG{invAb}	801	UCACUUAGGACAUUCUCAUUUUU	802
1402	AGAAUGUCCUAAGUGAUUCA{invAb}	803	AUGAAUCACUUAGGACAUUCUUU	804
1403	GGAAUUGUGUAGAACUGUUA{invAb}	805	UUAACAGUUCUACACAUUCCUU	806
1404	UUUCACAAAGUCAUGAGGGU{invAb}	807	UACCCUCAUGACUUUGUGAAAUU	808
1405	AGCACUCCAUGUAAUAUGAG{invAb}	809	ACUCAUAUUACAUGGAGUGCUUU	810
1406	UGUAAUAUGAGUGCUCUGUG{invAb}	811	UCACAGAGCACUCAUUAUACAUU	812
1407	UAUGAGUGCUCUGUGAGAUG{invAb}	813	ACAUCUCACAGAGCACUCAUAUU	814
1408	GUUUUAUAGAAAUGGUGUUG{invAb}	815	ACAACACCAUUUCUAUAAAACUU	816

1409	UUUUUAUAGAAAUGGUGUUGC{invAb}	817	AGCAACACCAUUCUUAUAAAAUU	818
1410	UAUGUUAGAUAGUUCUUUAA{invAb}	819	AUUAAAAGAACUAUCUAACAUUU	820
1411	AUAGUUCUUUAAGGAGACAA{invAb}	821	UUUGUCUCCUUAAGAACUUUU	822
1412	UUCUUUAAGGAGACAAAACG{invAb}	823	ACGUUUUGUCUCCUUAAGAAUU	824
1413	UUAAGGAGACAAAACGGUAA{invAb}	825	AUUACCGUUUUGUCUCCUUAUU	826
1414	AGACAAAACGGUAAUGAACA{invAb}	827	AUGUUCAUUACCGUUUUGUCUUU	828
1415	GUUGAAUAGAUGUGUAUUUC{invAb}	829	AGAAAUACACAUCUAUUCAACUU	830
1416	UAAUGUAGGUGAUCGGAGCU{invAb}	831	AAGCUCCGAUCACCUACAUAUU	832
1417	UGAUCGGAGCUCUUUCCUUU{invAb}	833	AAAAGGAAAGAGCUCCGAUCAUU	834
1418	GAGCUCUUUCCUUUGAUAGA{invAb}	835	AUCUAUCAAAGGAAAGAGCUCUU	836
1419	UGUAGCAAGAGGUGUUAUUA{invAb}	837	AUAAUAACACCUCUUGCUACAUU	838
1420	GUUACGAAAAACUAUGGUU{invAb}	839	AAACCAUAGUUUUUUCGUAACUU	840
1421	ACUAUGGUUGUGUCCGAGUG{invAb}	841	ACACUCGGACACAACCAUAGUUU	842
1422	AUAUUUAGAAAGCCAAAGUC{invAb}	843	UGACUUUGGCUUUCUAAAUAUUU	844
1423	GUUUUCCAACAGUGAUGGCU{invAb}	845	AAGCCAUCACUGUUGGAAAACUU	846
1424	UAUUGACUAUCUGCUGCUCA{invAb}	847	AUGAGCAGCAGAUAGUCAUAUU	848
1425	AUCAAAGCACCAUACAUUGC{invAb}	849	AGCAAUGUAUGGUGCUUUGAUUU	850
1426	AAAGCACCAUACAUUGCUUC{invAb}	851	UGAAGCAAUGUAUGGUGCUUUUU	852
1427	ACCUUGAUCCAUAAGCUUGG{invAb}	853	ACCAAGCUUAUGGAUCAAGGUUU	854
1428	CCAUAAGCUUGGGGGCUUCU{invAb}	855	AAGAAGCCCCAAGCUUAUGGUU	856
1429	UUCAUACGACGAAGGCUCGA{invAb}	857	AUCGAGCCUUCGUCGUAUGAAUU	858
1430	UCAUACGACGAAGGCUCGAU{invAb}	859	AAUCGAGCCUUCGUCGUAUGAUU	860
1431	ACGACGAAGGCUCGAUGAAA{invAb}	861	AUUUCAUCGAGCCUUCGUCGUUU	862
1432	GAUGAAACACCAGAUGGACG{invAb}	863	ACGUCCAUCUGGUGUUUCAUCUU	864
1433	GAAACACCAGAUGGACGGAA{invAb}	865	UUUCCGUCCAUCUGGUGUUUCUU	866
1434	AUAGAGCUUUGCUCUUGGG{invAb}	867	ACCCAUGGAGCAAAGCUCUAUUU	868
1435	UCCAUGGGCAUAUAGUUGAA{invAb}	869	AUUCAACUAUAGCCCAUGGAUU	870
1436	AUGGGCAUAUAGUUGAAUUA{invAb}	871	AUAAUUAACUAUAGCCCAUUU	872
1437	AUAUAGUUGAAUUAUUCGA{invAb}	873	AUCGAAGUAAUUAACUAUUAUU	874
1438	AUUUCUGGGAUUACAAUGAA{invAb}	875	AUUCAUUGUAAUCCAGAAAUUU	876
1439	CUGUGAGAUGUUAUCAGUG{invAb}	877	ACACUGAUGAACAUCUCACAGUU	878
1440	GAAACUUAUAAUGCACUUUA{invAb}	879	AUAAAGUGCAUUGUAAGUUUCUU	880
1441	CUUACAAUGCACUUUAGCGC{invAb}	881	UGCGCUAAAGUGCAUUGUAAGUU	882
1442	UUACAAUGCACUUUAGCGCA{invAb}	883	AUGCGCUAAAGUGCAUUGUAAUU	884
1443	ACAAUGCACUUUAGCGCAGU{invAb}	885	UACUGCGCUAAAGUGCAUUGUUU	886
1444	UGCACUUUAGCGCAGUAAGG{invAb}	887	ACCUUACUGCGCUAAAGUGCAUU	888
1445	GCACUUUAGCGCAGUAAGGG{invAb}	889	ACCCUACUGCGCUAAAGUGCUU	890
1446	UUUAGCGCAGUAAGGGCUUG{invAb}	891	ACAAGCCCUUACUGCGCUAAAUU	892
1447	UUAGCGCAGUAAGGGCUUGG{invAb}	893	ACCAAGCCCUUACUGCGCUAAUU	894
1448	CGCAGUAAGGGCUUGGCAUC{invAb}	895	AGAUGCCAAGCCCUUACUGCGUU	896
1449	ACCCAGCAUUGCCCAAACUA{invAb}	897	AUAGUUUGGGCAAUGCUGGGUUU	898
1450	AUUGCCCAAACUAUUUUGAC{invAb}	899	UGUCAAAAUAGUUUGGGCAAUUU	900

1451	UUGCCCAAACUAAUUUUGACA{invAb}	901	AUGUCAAAAUAGUUUUGGGCAAUU	902
1452	UGUUAGAUAGUUCUUUAAGG{invAb}	903	UCCUAAAAGAACUAUCUAACAUU	904
1453	UAGGUGAUCGGAGCUCUUUC{invAb}	905	AGAAAGAGCUCCGAUCACCUAUU	906
1454	AGGUGAUCGGAGCUCUUUCC{invAb}	907	AGGAAAGAGCUCCGAUCACCUUU	908
1455	UAUAGUUGAAUUAUUCGAC{invAb}	909	UGUCGAAGUAAUUAACUAUAUU	910
1456	UGAAUUAUUCGACAGCAGC{invAb}	911	UGCUGCUGUCGAAGUAAUUAUU	912
1457	AAUUACUUCGACAGCAGCAA{invAb}	913	AUUGCUGCUGUCGAAGUAAUUUU	914
1458	UUCGACAGCAGCAAUUCUUG{invAb}	915	ACAAGAAUUGCUGCUGUCGAAUU	916
1459	UCUCCUGGAAGGCACACGU{invAb}	917	AACGUGUGCCUCCAGGAAGAUU	918
1460	UUUGUCAGUUGUGGUAGAUUA{invAb}	919	AUAUCUACCACAACUGACAAUU	920
1461	GUCCACACACAUUGUGGCUU{invAb}	921	AAAGCCACAAUGUGUGUGGACUU	922
1462	CUCGUGAUUUUGACCUGGGG{invAb}	923	ACCCAGGUCAAAAUCACGAGUU	924
1463	GUUGAAGGCUUUUGCUCAUA{invAb}	925	AUAUGAGCAAAAGCCUUAACUU	926
1464	UAUUUAGAACCCUCCUGUU{invAb}	927	AAACAGGAAGGGUUCUAAAUUU	928
1465	AUUUAGAACCCUCCUGUUU{invAb}	929	AAAACAGGAAGGGUUCUAAAUUU	930
1466	UUCCUGUUUAUGUCUGUAC{invAb}	931	AGUACAGACAUAAAACAGGAUU	932
1467	CAGGUACAGCUGUUUCUUGG{invAb}	933	UCCAAGAAACAGCUGUACCUGUU	934
1468	GGAAUCCUCCAACCAAUA{invAb}	935	AUAUUUGGUUGGAGGAUUUCCUU	936
1469	GUUUUCCUAAUUGAUUAGC{invAb}	937	AGCUAAUCAAGUUAGGAAAACUU	938
1470	UUCCUAAUUGAUUAGCUUG{invAb}	939	UCAAGCUAAUCAAGUUAGGAAUU	940
1471	CCUAAUUGAUUAGCUUGAG{invAb}	941	ACUCAAGCUAAUCAAGUUAGGUU	942
1472	UUGAUUAGCUUGAGCUGACA{invAb}	943	AUGUCAGCUCAAGCUAAUCAUU	944
1473	GCUUUCUGUACUGCACACAG{invAb}	945	UCUGUGUGCAGUACAGAAAGCUU	946
1474	GCACACAGAUUGUGUACUGC{invAb}	947	UGCAGUACACAAUCUGUGUGCUU	948
1475	CGUGCACAACCUGUCCAGUA{invAb}	949	AUACUGGACAGGUUGUGCACGUU	950
1476	CAGUAUAUGCAUGUGGUGGC{invAb}	951	AGCCACCACAUGCAUAUACUGUU	952
1477	ACCAUGACUUUAACAAAUU{invAb}	953	AAAUUUGUUAAGUCAUGGUUU	954
1478	ACAUAGUGGUAAAUAUUUAU{invAb}	955	AAUAAUUAUUUACCACUAUGUUU	956
1479	CAUAGUGGUAAAUAUUUAUG{invAb}	957	UCAUAAUUAUUUACCACUAUGUU	958
1480	GUCUGUUAUAAUUGGUAGG{invAb}	959	ACCUACCAUUAUGAACAGACUU	960
1481	AUUUUUCCAGAUAGUGUUA{invAb}	961	AUAACACUCAUCUGGAAAAAUUU	962
1482	GGGAUGCUGAUUGAUUUUC{invAb}	963	UGAAAUAUCAUACAGCAUCCUU	964
1483	UUGAUUUUACAUUGUAUG{invAb}	965	UCAUACAAUGUGAAAUUCAUU	966
1484	UCUCAAGUUCUGCAUUUAAA{invAb}	967	UUUUAAAUGCAGAACUUGAGAUU	968
1485	UUCCAUUUUACUGACUAGGG{invAb}	969	ACCCUAGUCAGUAAAUGGAAUU	970
1486	UCCAUUUUACUGACUAGGGU{invAb}	971	UACCCUAGUCAGUAAAUGGAAUU	972
1487	AAGUUUAUCCAGUAUGGCAU{invAb}	973	AAUGCCAUACUGGAUAAACUUUU	974
1488	UUUAUCCAGUAUGGCAUUCU{invAb}	975	AAGAAUGCCAUACUGGAUAAUU	976
1489	ACAGCGAGAUUGCUACCUGA{invAb}	977	UUCAGGUAGCAAUCUCGCGUUUU	978
1490	CAGUUUAUCACCUUCUACA{invAb}	979	AUGUAAGAAGGUGAUAAACUGUU	980
1491	CUUACAGAGACUCCUUGGGC{invAb}	981	AGCCCAAGGAGUCUCUGUAAGUU	982
1492	AAAGAGAGUGUCUGUUUUAG{invAb}	983	UCUAAAACAGACACUCUUUUUU	984

1493	CGACAAAACUUCUAGAAUA{invAb}	985	AUAUUCUAGAAGUUUUUGUCGUU	986
1494	AUAUAUUCUGAGUUUUUGUGG{invAb}	987	ACCACAAAACUCAGAAUAUAUUU	988
1495	UUUGUGGUGCUGUAGGUAAC{invAb}	989	AGUUACCUACAGCACCACAAUU	990
1496	UGUGGUGCUGUAGGUAACGU{invAb}	991	AACGUUACCUACAGCACCACAUU	992
1497	GUGCUGUAGGUAACGUGUGG{invAb}	993	ACCACACGUUACCUACAGCACUU	994
1498	UGCAGUAACACUUGGGGGG{invAb}	995	UCCCCCAAGUGUUAUCUGCAUU	996
1499	GAACAGCCCCAAUGAUCCUG{invAb}	997	ACAGGAUCAUUGGGGCGUUCUU	998
1500	AAUGAUCCUGGCUUUUUCAC{invAb}	999	AGUGAAAAAGCCAGGAUCAUUUU	1000
1501	CGUAUCAGAAUACAUGGAUG{invAb}	1001	UCAUCCAUGUAUUCUGAUACGUU	1002
1502	ACAUGACAGGACCUAUCGUU{invAb}	1003	AAACGAUAGGUCCUGUCAUUUU	1004
1503	UGACAGGACCUAUCGUUGAG{invAb}	1005	ACUCAACGAUAGGUCCUGUCAUU	1006
1504	AGGACCUAUCGUUGAGGUUU{invAb}	1007	AAAACCUCAACGAUAGGUCCUUU	1008
1505	UCUAAGACUUAUAUGGGCU{invAb}	1009	AAGCCCAUAGUAAGUCUUAUAUU	1010
1506	AAGACUUAUAUGGGCUGUA{invAb}	1011	UUACAGCCCAUAGUAAGUCUUUU	1012
1507	AGACUUAUAUGGGCUGUAA{invAb}	1013	UUUACAGCCCAUAGUAAGUCUUU	1014
1508	GACUUAUAUGGGCUGUAAA{invAb}	1015	AUUUACAGCCCAUAGUAAGUCUU	1016
1509	UAUUUUAGAAACCUGAGACU{invAb}	1017	AAGUCUCAGGUUUCUAAAAUAUU	1018
1510	CAUUUGAAAGAGAUUCUUGA{invAb}	1019	AUCAAGAUCUCUUUCAAAGUUU	1020
1511	AAAGAGAUUCUUGACCUUAU{invAb}	1021	AAUAAGGUCAAGAAUCUCUUUUU	1022
1512	AAGAGAUUCUUGACCUUAUU{invAb}	1023	AAUAAGGUCAAGAAUCUCUUUUU	1024
1513	CUUGAUGGAAGGUAAUAAAAC{invAb}	1025	AGUUUAAUACCUUCCAUCAGUU	1026
1514	UUGAUGGAAGGUAAUAAACU{invAb}	1027	UAGUUUAAUACCUUCCAUCAAUU	1028
1515	UAUUAACUAUUUUGCCUGUU{invAb}	1029	AAACAGGCAAAUAGUUUAAUAUU	1030
1516	GUGUAUUGCAAGAAACACAG{invAb}	1031	UCUGUGUUUCUUGCAAUACACUU	1032
1517	AGAAAAACUCAACCAAAGU{invAb}	1033	AACUUUGGUUGAGAUUUUUCUUU	1034
1518	GAUAACACUUGGGGGGACCU{invAb}	1035	AAGGUCCCCCAAGUGUUAUCUU	1036
1519	UGAGUUUAUUAAGAUUGAC{invAb}	1037	UGUCAUUCUUUAAUAAACUCAUU	1038
1520	AAAGAUUGACAUUUUAAGUA{invAb}	1039	AUACUUAUUUUGUCAUUCUUUUU	1040
1521	AAGAUUGACAUUUUAAGUAC{invAb}	1041	UGUACUUAUUUUGUCAUUCUUUUU	1042
1522	UAAUUUGUUGGUAAUUAUC{invAb}	1043	AGAUAUAUACCAACAAAUUAUU	1044
1523	GUUCAUAGAUCCCAUAUUGA{invAb}	1045	AUCAUAUUGGAUCUAUGAACUU	1046
1524	AGCAUUGCCCAAACUAUUUU{invAb}	1047	AAAAUAGUUUUGGGCAAUGCUUU	1048
1525	AAAGCCAAAGUCAGAAACCG{invAb}	1049	ACGGUUUCUGACUUUGGCUUUUU	1050
1526	GCGGAUUGUUAUUUAUAUCA{invAb}	2101	UUGAUUAUUUAACAUUCCGCUU	2102
1527	CAGCGAGAUUGCUACCUGAA{invAb}	2103	AUUCAGGUAGCAAUCUCGCGUUU	2104
1528	ACGAUUUUGCCGCUUCUGUU{invAb}	2105	AAACAGAAGCGGCAAAUUCGUUU	2106
1529	ACCUCAGCCUCUAUUCGCAA{invAb}	2107	AUUGCGAAUAGAGGCUGAGGUUU	2108
1530	AUCAAAGCCGUUAACAAAG{invAb}	2109	ACUUUGUUAACGGCUUUUGAUUU	2110
1531	UAGCUACAUUUUUUAUGGGA{invAb}	2111	AUCCCAUUAUUUUUGUAGCUUU	2112
1532	UUCAGAAGAUGUAGUAAUGC{invAb}	2113	UGCAUUACUACAUCUUCUGAAUU	2114
1533	AGCGUUGUUAACAGCUAUAC{invAb}	2115	AGUAUAGCUGGUAAACACGCUUU	2116
1534	GUGUUAUAAGAAUGUACGA{invAb}	2117	UUCGUAACAUUCUAAUAACACUU	2118

1535	UCCUAACUUGAUUAGCUUGA{invAb}	2119	AUCAAGCUAAUCAAGUUAGGAUU	2120
1536	CAUAUAGUUGAAUACUUCG{invAb}	2121	UCGAAGUAAUUCACUAUAUGUU	2122
1537	GGGCAUAUAGUUGAAUACU{invAb}	2123	AAGUAAUUCACUAUAUGCCCUU	2124
1538	UGUCAUCCAGACAUUCUUGA{invAb}	2125	AUCAAGAUGUCUGGGAUGACAUU	2126
1539	UACGAAAAACUAUGGUUGU{invAb}	2127	AACAACCAUAGUUUUUUCGUUU	2128
1540	CUGCCUUGCCAGACAUUUUA{invAb}	2129	AUAAAUGUCUGGCAAGGCAGUU	2130
1541	UUUUGUCAGUUGUGGUAGAU{invAb}	2131	UAUCUACCACAACUGACAAAAUU	2132
1542	AGAAUGUACGAAAAACUA{invAb}	2133	AUAGUUUUUUCGUAACAUUCUUU	2134
1543	UGUAAUAUGAGUGCUCUGUG{invAb}	2135	UCACAGAGCACUCAUAUACAUAU	2136
1544	CACUUUGUGACAUGGAUGAA{invAb}	2137	AUUCAUCCAUGUCACAAAGUGUU	2138
1545	AUUUGGGAAUACACUUUGU{invAb}	2139	AACAAAGUGUAAUUCGCAAUUU	2140
1546	AUAGCUGAGUCCUGAAGUUU{invAb}	2141	AAAACUUCAGGACUCAGCUAUUU	2142
1547	CUGACCCUUGGUACAAUAGA{invAb}	2143	AUCUAUUGUACCAAGGGUCAGUU	2144
1548	UAAUCGACUGAUUGGAAUA{invAb}	2145	UUUUUCCAAUCAGUCGAUUUUU	2146
1549	AACUGAUAGCUGAGUCCUGA{invAb}	2147	UUCAGGACUCAGCUAUCAGUUUU	2148
1550	CAGCACAUGAUUUGGGAAUU{invAb}	2149	UAAUUCGCAAUCAUGUGCUGUU	2150
1551	ACAUGAUUUGGGAAUACAC{invAb}	2151	AGUGUAAUUCGCAAUCAUGUUU	2152
1552	CAGAAUACAGUGUUGGUCGA{invAb}	2153	AUCGACCAACACUGUAUUCUGUU	2154
1553	CCCAGACAUUCUGAUAAUAC{invAb}	2155	AGUAUUUAUCAAGUUGCUGGUU	2156
1554	UCUUGAUAAUACCUUGUUGGA{invAb}	2157	UCCAACAGGUAAUUAUCAAGUU	2158
1555	UGUUAUUGAAUGUACGAA{invAb}	2159	UUUCGUAAACAUUCUAAUAACAUAU	2160
1556	UGUACGAAAAACUAUGGU{invAb}	2161	AACCAUAGUUUUUUCGUAACAUAU	2162
1557	UUACGAAAAACUAUGGUUG{invAb}	2163	ACAACCAUAGUUUUUUCGUAUUU	2164
1558	AGGAAUUAUUAGAAAGCCAA{invAb}	2165	UUUGGCUUUCUAAAUUUUCCUUU	2166
1559	ACGAAGGAGGUUGAUUGCAA{invAb}	2167	UUUGCAAUCAACCUCCUUCGUUU	2168
1560	UGUUUCCAACAGUGAUGGC{invAb}	2169	AGCCAUCACUGUUGGAAACAUAU	2170
1561	CAUAAGGUUAAACAAACUAG{invAb}	2171	ACUAGUUUGUUUAACCUUAUGUU	2172
1562	GGACGGAAAGAUGUUCUCUA{invAb}	2173	AUAGAGAACAUCUUUCCGUCCUU	2174
1563	GGAAUUGUGUAGAACUGUUA{invAb}	2175	UUAACAGUUCUACACAUUCCUU	2176
1564	AUAGUUGAAUACUUCGACA{invAb}	2177	AUGUCGAAGUAAUUCACUAUUU	2178
1565	UCUUCGAACUCAACUUCUAC{invAb}	2179	UGUAGAAGUUGAGUUCGAAGUU	2180
1566	CUUCGAACUCAACUUCUACA{invAb}	2181	AUGUAGAAGUUGAGUUCGAAGUU	2182
1567	UUCUGUUUUUUGUCUGUAC{invAb}	2183	AGUACAGACAUAAAACAGGAAUU	2184
1568	CAGGUACAGCUGUUUCUUGG{invAb}	2185	UCCAAGAAACAGCUGUACCUGUU	2186
1569	CCUAAUUGAUUAGCUUGAG{invAb}	2187	ACUCAAGCUAAUCAAGUUAGGUU	2188
1570	CGUGCACAACCGUCCAGUA{invAb}	2189	AUACUGGACAGGUUGUGCACGUU	2190
1571	CAGUAUAUGCAUGUGGUGGC{invAb}	2191	AGCCACCACAUCAUAUACUGUU	2192
1572	ACCAUGACUUUUAACAAAUU{invAb}	2193	AAAUUUGUUAAAAGUCAUGGUUU	2194
1573	ACAUAGUGGUAAAUAAUUAU{invAb}	2195	AAUAAUUAUUUACCACUAUGUUU	2196
1574	CAUAGUGGUAAAUAAUUAUG{invAb}	2197	UCAUAAUUAUUUACCACUAUGUU	2198
1575	AUUUUUCCAGAUGAGUGUUA{invAb}	2199	AUAACACUCAUCUGGAAAAAUUU	2200
1576	GGGAUGCUGAUUGAUUUUC{invAb}	2201	UGAAAUUAUCAUACAGCAUCCUU	2202


1577	UCUCAAGUUCUGCAUUUAAA{invAb}	2203	UUUUAAAUGCAGAACUUGAGAUU	2204
1578	UUCCAUUUUACUGACUAGGG{invAb}	2205	ACCCUAGUCAGUAAAAUGGAAUU	2206
1579	CAGUUUAUCACCUUCUACA{invAb}	2207	AUGUAAGAAGGUGAUAAACUGUU	2208
1580	CGACAAAACUUCUAGAAUA{invAb}	2209	AUAUUCUAGAAGUUUUUGUCGUU	2210
1581	AUAUAUUCUGAGUUUUUGUGG{invAb}	2211	ACCACAAAACUCAGAAUAUUAUU	2212
1582	AAUGAUCCUGGCUUUUUCAC{invAb}	2213	AGUGAAAAAGCCAGGAUCAUUUU	2214
1583	UGACAGGACCUAUCGUUGAG{invAb}	2215	ACUCAACGAUAGGUCCUGUCAUU	2216
1584	UAUGGGUUAUAUGCCUAAAC{invAb}	2217	AGUUUAGGCAUAUAACCAUAUU	2218
1585	UAAUUGGUAGGUGCCUUUUG{invAb}	2219	ACAAAAGGCACCUACCAAUUAUU	2220
1586	ACUAUGGUUGUGUCCGAGUG{invAb}	2221	ACACUCGGACACAACCAUAGUUU	2222
1587	AAGACUUAUAUGGGCUGUA{invAb}	2223	UUACAGCCCAUAGUAAGUCUUUU	2224
1588	GACUUAUAUGGGCUGUAAA{invAb}	2225	AUUUACAGCCCAUAGUAAGUCUU	2226
1589	UAAAUUAAGGAUUACUCAAG{invAb}	2227	ACUUGAGUAAUCCUUAUUUUUUU	2228
1590	CAACCAAAGUUAUGCUCAUC{invAb}	2229	AGAUGAGCAUAACUUUGGUUGUU	2230
1591	UAGACUACAAGAUGAAUCU{invAb}	2231	AAGAUUUCAUCUUGUAGUCUAUU	2232
1592	CAAUAGUAGCUACAUUUUUA{invAb}	2233	UUAAAAAUGUAGCUACUAUUGUU	2234
1593	AAAAGCCGUUAACAAAGUGA{invAb}	2235	UUCACUUUGUUAACGGCUUUUUU	2236
1594	AAAGCCGUUAACAAAGUGAA{invAb}	2237	UUUCACUUUGUUAACGGCUUUUU	2238
1595	CAUAGAUGCCAUUUGACUA{invAb}	2239	AUAGUCAUAUGGGAUCUAUGUU	2240
1596	ACCUUGAUCCAUAAGCUUGG{invAb}	2241	ACCAAGCUUAUGGAUCAAGGUUU	2242
1597	UUCAUACGACGAAGGCUCGA{invAb}	2243	AUCGAGCCUUCGUCGUAUGAAUU	2244
1598	UCCAUGGGCAUAUAGUUGAA{invAb}	2245	AUUCAACUAUAUGCCCAUGGAUU	2246
1599	AUGGGCAUAUAGUUGAAUUA{invAb}	2247	AUAAUUAACUAUAUGCCCAUUU	2248
1600	AUAUAGUUGAAUUAUUCGA{invAb}	2249	AUCGAAGUAAUUAACUAUAUUUU	2250
1601	CUUACAAUGCACUUUAGCGC{invAb}	2251	UGCGCUAAAGUGCAUUGUAAGUU	2252
1602	UUACAAUGCACUUUAGCGCA{invAb}	2253	AUGCGCUAAAGUGCAUUGUAAUU	2254
1603	ACAAUGCACUUUAGCGCAGU{invAb}	2255	UACUGCGCUAAAGUGCAUUGUUU	2256
1604	UUUAGCGCAGUAAGGGCUUG{invAb}	2257	ACAAGCCCUUACUGCGCUAAAUU	2258
1605	AUUGCCCAAACUAUUUUGAC{invAb}	2259	UGUCAAAAUAGUUUUGGGCAUUU	2260
1606	AGGUGAUCGGAGCUCUUUCC{invAb}	2261	AGGAAAGAGCUCGGAUCACCUUU	2262
1607	UAUAGUUGAAUACUUCGAC{invAb}	2263	UGUCGAAGUAAUUAACUAUAUU	2264
1608	UGAAUUAUUCGACAGCAGC{invAb}	2265	UGCUGCUGUCGAAGUAAUUCAUU	2266
1609	UUUGUCAGUUGUGGUAGAUA{invAb}	2267	AUAUCUACCACAACUGACAAAUU	2268
1610	CUUGAUGGAAGGUAAUAAAC{invAb}	2269	AGUUUAAUACCUUCCAUCAGUU	2270
1611	GUGUAUUGCAAGAAACACAG{invAb}	2271	UCUGUGUUUCUUGCAAUACACUU	2272
1612	AGAAAAUCUCAACCAAAGU{invAb}	2273	AACUUUGGUUGAGAUUUUUCUUU	2274
1613	AAGAAAGCCUAAUGAGUCGG{invAb}	2275	UCCGACUCAUAGGCUUUCUUUU	2276
1614	UGCGGAAUGUUAUUUAUAUC{invAb}	2277	UGAUUAAAAUAACAUUCCGCAUU	2278
1615	UUAUUCAAGAGCGAGAUGUG{invAb}	2279	ACACAUCUCGCUCUUGAAUAAUU	2280
1616	AAGAGCGAGAUGUGCAUAAG{invAb}	2281	ACUUAUGCACAUCUCGCUCUUUU	2282
1617	AUGUUUGCCACCAAUGUGAC{invAb}	2283	AGUCACAUUGGUGGCAACAUUU	2284
1618	ACAUGAUUUGGGAAUACAC{invAb}	2285	AGUGUAAUCCCAAUUAUGUUU	2286

1619	AUGAUUUUGGGAUUACAC{invAb}	2287	AGUGUAAUUCCCAAUCAUUU	2288
1620	ACAUGAUUUUGGGAUUACAC{invAb}	2289	AGUGUAAUUCCCAAUCAUGUUU	2290
1621	AUGAUUUUGGGAUUACAC{invAb}	2291	AGUGUAAUUCCCAAUCAUUU	2292
1622	AUUUUUCCAGAUAGUGUUA{invAb}	2293	AUAACACUCAUCUGGAAAAAUU	2294
1623	UUUUCAGAUAGUGUUA{invAb}	2295	AUAACACUCAUCUGGAAAAAUU	2296
1624	UUUUCAGAUAGUGUUA{invAb}	2297	AUAACACUCAUCUGGAAAAAUU	2298
1625	AUUUUUCCAGAUAGUGUUA{invAb}	2299	AUAACACUCAUCUGGAAAAAUU	2300
1626	ACCAUGACUUUUAACAAAUU{invAb}	2301	AAAUUUGUUAAAAGUCAUGUUU	2302
1627	CAUGACUUUUAACAAAUU{invAb}	2303	AAAUUUGUUAAAAGUCAUGUU	2304
1628	CAUGACUUUUAACAAAUU{invAb}	2305	AAAUUUGUUAAAAGUCAUGUU	2306
1629	ACCAUGACUUUUAACAAAUU{invAb}	2307	AAAUUUGUUAAAAGUCAUGUUU	2308
1630	UAGCUACAUUUUUAUUGGA{invAb}	2309	AUCCCAUUAAAAUGUAGCUAUU	2310
1631	GCUACAUUUUUAUUGGA{invAb}	2311	AUCCCAUUAAAAUGUAGCUU	2312
1632	GCUACAUUUUUAUUGGA{invAb}	2313	AUCCCAUUAAAAUGUAGCUU	2314
1633	UAGCUACAUUUUUAUUGGA{invAb}	2315	AUCCCAUUAAAAUGUAGCUAUU	2316
1634	UCUCAAGUUCUGCAUUUAAA{invAb}	2317	UUUUAAAUGCAGAACUUGAGAUU	2318
1635	UCAAGUUCUGCAUUUAAA{invAb}	2319	UUUUAAAUGCAGAACUUGAUU	2320
1636	UCAAGUUCUGCAUUUAAA{invAb}	2321	UUUUAAAUGCAGAACUUGAUU	2322
1637	UCUCAAGUUCUGCAUUUAAA{invAb}	2323	UUUUAAAUGCAGAACUUGAGAUU	2324
1638	AACUGAUAGCUGAGUCCUGA{invAb}	2325	UUCAGGACUCAGCUAUCAGUUU	2326
1639	CUGAUAGCUGAGUCCUGA{invAb}	2327	UUCAGGACUCAGCUAUCAGUU	2328
1640	CUGAUAGCUGAGUCCUGA{invAb}	2329	UUCAGGACUCAGCUAUCAGUU	2330
1641	AACUGAUAGCUGAGUCCUGA{invAb}	2331	UUCAGGACUCAGCUAUCAGUUU	2332
1642	UCUUGAUAAUACCGUUGGA{invAb}	2333	UUCCAACAGGUUUUAUCAAGAUU	2334
1643	GUGUUAUUAGAAUGUUACGA{invAb}	2335	UUCGUAACAUUCUAAUAACACUU	2336
1644	UAUAGUUGAAUACUUCGAC{invAb}	2337	UGUCGAAGUAAUUAACUUAUU	2338
1645	CACUUUGUGACAUGGAUGAA{invAb}	2339	AUUCAUCCAUGUCACAAAGUGUU	2340
1646	UGUCAUCCAGACAUCUUGA{invAb}	2341	AUCAAGAUGUCUGGGAUGACAUU	2342
1647	UCUUGAUAAUACCGUUGGA{invAb}	2343	UUCCAACAGGUUUUAUCAAGAUU	2344
1648	GUGUUAUUAGAAUGUUACGA{invAb}	2345	UUCGUAACAUUCUAAUAACACUU	2346
1649	UAUAGUUGAAUACUUCGAC{invAb}	2347	UGUCGAAGUAAUUAACUUAUU	2348
1650	CACUUUGUGACAUGGAUGAA{invAb}	2349	AUUCAUCCAUGUCACAAAGUGUU	2350
1651	UGUCAUCCAGACAUCUUGA{invAb}	2351	AUCAAGAUGUCUGGGAUGACAUU	2352
1652	UUGAUAAUACCGUUGGA{invAb}	2353	UUCCAACAGGUUUUAUCAAUU	2354
1653	GUUAAUAGAAUGUUACGA{invAb}	2355	UUCGUAACAUUCUAAUAACUU	2356
1654	UAGUUGAAUACUUCGAC{invAb}	2357	UGUCGAAGUAAUUAACUUAUU	2358
1655	CUUUGUGACAUGGAUGAA{invAb}	2359	AUUCAUCCAUGUCACAAAGUU	2360
1656	UCAUCCAGACAUCUUGA{invAb}	2361	AUCAAGAUGUCUGGGAUGAUU	2362
1657	UUGAUAAUACCGUUGGA{invAb}	2363	UUCCAACAGGUUUUAUCAAUU	2364
1658	GUUAAUAGAAUGUUACGA{invAb}	2365	UUCGUAACAUUCUAAUAACUU	2366
1659	UAGUUGAAUACUUCGAC{invAb}	2367	UGUCGAAGUAAUUAACUUAUU	2368
1660	CUUUGUGACAUGGAUGAA{invAb}	2369	AUUCAUCCAUGUCACAAAGUU	2370

1661	UCAUCCAGACAUCUUGA{invAb}	2371	AUCAAGAUGUCUGGGAUGAUU	2372
1662	GUUUUAUACCUUCUUACA{invAb}	2645	AUGUAAGAAGGUGAUAAACUU	2646
1663	GUUUUAUACCUUCUUACA{invAb}	2647	AUGUAAGAAGGUGAUAAACUU	2648
1664	CAGUUUAUACCUUCUUACA{invAb}	2649	AUGUAAGAAGGUGAUAAACUGUU	2650
1665	CAGUUUAUACCUUCUUACA{invAb}	2651	AUGUAAGAAGGUGAUAAACUGUU	2652
1666	CAGUUUAUACCUUCUUACA{invAb}	2653	AUGUAAGAAGGUGAUAAACUGUU	2654
1667	CAGUUUAUACCUUCUUACA{invAb}	2655	AUGUAAGAAGGUGAUAAACUGUU	2656
1668	GUUUUAUACCUUCUUACA{invAb}	2657	AUGUAAGAAGGUGAUAAACUU	2658
1669	CAGUUUAUACCUUCUUACA{invAb}	2659	AUGUAAGAAGGUGAUAAACUGUU	2660
1670	CAGUUUAUACCUUCUUACA{invAb}	2661	AUGUAAGAAGGUGAUAAACUGUU	2662
1671	GUGUUUUAGAAUGUUACGA{invAb}	2663	UUCGUAACAUUCUAAUAACACUU	2664
1672	GUGUUUUAGAAUGUUACGA{invAb}	2665	UUCGUAACAUUCUAAUAACACUU	2666
1673	GUUUUAUAGAAUGUUACGAU{invAb}	2667	UUCGUAACAUUCUAAUAACUU	2668
1674	GUGUUUUAGAAUGUUACGA{invAb}	2669	UUCGUAACAUUCUAAUAACACUU	2670
1675	GUGUUUUAGAAUGUUACGA{invAb}	2671	UUCGUAACAUUCUAAUAACACUU	2672
1676	UAUAGUUGAAUACUUCGAC{invAb}	2673	UGUCGAAGUAAUUCACUUAUUU	2674
1677	UAUAGUUGAAUACUUCGAC{invAb}	2675	UGUCGAAGUAAUUCACUUAUUU	2676
1678	UAGUUGAAUACUUCGACAU{invAb}	2677	UGUCGAAGUAAUUCACUUAUU	2678
1679	UAUAGUUGAAUACUUCGAC{invAb}	2679	UGUCGAAGUAAUUCACUUAUUU	2680
1680	UAUAGUUGAAUACUUCGAC{invAb}	2681	UGUCGAAGUAAUUCACUUAUUU	2682
1681	UGUCAUCCAGACAUCUUGA{invAb}	2683	AUCAAGAUGUCUGGGAUGACAUU	2684
1682	UGUCAUCCAGACAUCUUGA{invAb}	2685	AUCAAGAUGUCUGGGAUGACAUU	2686
1683	UCAUCCAGACAUCUUGAUU{invAb}	2687	AUCAAGAUGUCUGGGAUGAUU	2688
1684	UGUCAUCCAGACAUCUUGA{invAb}	2689	AUCAAGAUGUCUGGGAUGACAUU	2690
1685	UGUCAUCCAGACAUCUUGA{invAb}	2691	AUCAAGAUGUCUGGGAUGACAUU	2692
1686	AACUGAUAGCUGAGUCCUGA{invAb}	2693	UUCAGGACUCAGCUAUCAGUUUU	2694
1687	UAGCUACAUUUUUAUUGGGA{invAb}	2695	AUCCCAUUAAAAUUGUAGCUAUU	2696
1688	ACAUGAUUUGGGAAUACAC{invAb}	2697	AGUGUAAUUCCCAAUUCAGUUU	2698
1689	AUUUUUCCAGAUAGAGUGUUA{invAb}	2699	AUAACACUCAUCUGGAAAAAUUU	2700
1690	AACUGAUAGCUGAGUCCUGA{invAb}	2701	UUCAGGACUCAGCUAUCAGUUUU	2702
1691	UAGCUACAUUUUUAUUGGGA{invAb}	2703	AUCCCAUUAAAAUUGUAGCUAUU	2704
1692	ACAUGAUUUGGGAAUACAC{invAb}	2705	AGUGUAAUUCCCAAUUCAGUUU	2706
1693	AUUUUUCCAGAUAGAGUGUUA{invAb}	2707	AUAACACUCAUCUGGAAAAAUUU	2708
1694	CUGAUAGCUGAGUCCUGAAU{invAb}	2709	UUCAGGACUCAGCUAUCAGUU	2710
1695	GCUACAUUUUUAUUGGGAU{invAb}	2711	AUCCCAUUAAAAUUGUAGCUU	2712
1696	AUGAUUUGGGAAUACACUU{invAb}	2713	AGUGUAAUUCCCAAUUCAUUU	2714
1697	UUUUUCCAGAUAGAGUGUUAU{invAb}	2715	AUAACACUCAUCUGGAAAAAUU	2716
1698	AACUGAUAGCUGAGUCCUGA{invAb}	2717	UUCAGGACUCAGCUAUCAGUUUU	2718
1699	UAGCUACAUUUUUAUUGGGA{invAb}	2719	AUCCCAUUAAAAUUGUAGCUAUU	2720
1700	ACAUGAUUUGGGAAUACAC{invAb}	2721	AGUGUAAUUCCCAAUUCAGUUU	2722

[0166] To improve the potency and in vivo stability of GPAM siRNA sequences, chemical modifications were incorporated into GPAM siRNA molecules. Specifically, 2'-O-methyl and 2'-fluoro modifications of the ribose sugar were incorporated at specific positions within the GPAM siRNAs. Phosphorothioate internucleotide linkages were also incorporated at the terminal ends of the antisense and/ or sense sequences.

[0167] The antisense and sense siRNA sequences generated are shown in Table 2. The nucleotide sequences in Table 2 and other parts of the application are listed according to the following notations: A, U, G, and C = corresponding ribonucleotide; dT = deoxythymidine; dA = deoxyadenosine; dC = deoxycytidine; dG = deoxyguanosine; invDT = inverted deoxythymidine; invDA = inverted deoxyadenosine; invDC = inverted deoxycytidine; invDG = inverted deoxyguanosine; a, u, g, and c = corresponding 2'-O-methyl ribonucleotide; Af, Uf, Gf, and Cf = corresponding 2'-deoxy-2'-fluoro ("2'-fluoro") ribonucleotide; Ab = Abasic; invAb = inverted abasic; MeO-I = 2' methoxy inosine; GNA = glycol nucleic acid; sGNA = glycol nucleic acid with 3' phosphorothioate; LNA = locked nucleic acid. Insertion of an "s" in the sequence indicates that the two adjacent nucleotides are connected by a phosphorothiodiester group (e.g. a phosphorothioate internucleotide linkage). Unless indicated otherwise, all other nucleotides are connected by 3'-5' phosphodiester groups. Each of the siRNA compounds in Table 2 comprises a 19-21 base pair duplex region with either a 2 nucleotide overhang at the 3' end of both strands or bluntmer at one or both ends. Each [Phosphate] has been linked to the GalNAc structure below (sGalNAc3):



, wherein X = O or S.

Table 2. siRNA sequences directed to GPAM with modifications

Duplex No.	Sense sequence (5'-3')	SEQ ID NO: (sense)	Antisense sequence (5'-3')	SEQ ID NO: (anti-sense)
2001	gsgsgacuCfuUfCfUfgagguuacs{invAb}	1051	asGfsuaacCfucagaaAfgAfgucccsusu	1052
2002	csusuucuGfaGfGfUfUfacuguggas{invAb}	1053	asUfscacAfguaaccUfcAfgaaagsusu	1054
2003	csusgaggUfuAfCfUfGfugaggacacs{invAb}	1055	asGfsugcuCfcacaguAfaCfcucagsusu	1056
2004	ususugcuAfaUfCfGfAfcugauuggs{invAb}	1057	usCfscaauCfagucgaUfuAfgcaasusu	1058
2005	gscsuaauCfGfCfUfGfauuggaaas{invAb}	1059	asUfsuuccAfaucaguCfGfuuagcsusu	1060
2006	csusaauCfGfCfUfGfauuggaaaus{invAb}	1061	usAfsuuucCfaucagUfcGfauuagsusu	1062
2007	usasaucGfCfUfGfAfuuggaaaas{invAb}	1063	usUfsauuuCfcaaucaGfuCfGauuasusu	1064
2008	asasucgaCfuGfAfuUfGfGaaauaas{invAb}	1065	asUfsuaauUfccaucAfgUfcgaaususu	1066
2009	gsgsaaauAfaUfUfCfCfcaaacacs{invAb}	1067	asGfsuguuUfgaggaaUfuAfuuuccsusu	1068
2010	asasuaauUfcCfUfCfAfaaccacs{invAb}	1069	asGfsugguGfuuuagGfaAfuuaususu	1070
2011	ascsaccaCfCfAfuUfCfcaaggauas{invAb}	1071	asUfsauccUfugacuuGfgUfggugususu	1072
2012	ascsaccAfaGfUfCfAfaaggauacas{invAb}	1073	asUfsguauCfcuugacUfuGfguggususu	1074
2013	asgsucaGfGfAfuUfCfagggcagcas{invAb}	1075	asUfsgcugCfcuguauCfcUfugacususu	1076
2014	asasggauAfcAfuGfGfCfagcagcggs{invAb}	1077	asCfscgcuGfcugccuGfuAfuuccususu	1078
2015	gscsagcgGfcUfCfCfCfcuguuguas{invAb}	1079	asUfsacaaCfaggggaGfcCfcugcsusu	1080
2016	asgscggcUfcCfCfCfUfguuguuugs{invAb}	1081	asCfsauacAfacaggGfaGfcgcgcsusu	1082
2017	csgsgcucCfcCfUfGfUfugauuggas{invAb}	1083	asUfscacuAfaacagGfgGfagccgsusu	1084
2018	cscscugUfuGfUfAfuUfggacauucs{invAb}	1085	asGfsaaugUfccauacAfaCfaggggsusu	1086
2019	usgsgacaUfuCfUfGfCfaccgaaas{invAb}	1087	asUfsuucGfgugcagAfaUfguccasusu	1088
2020	csusgcacCfCfAfuUfCfagcagauagcs{invAb}	1089	asGfscuauCfaguucGfgGfugcagsusu	1090
2021	usgscaccCfGfAfuUfCfagcagauagcs{invAb}	1091	asAfsucaUfcaguuUfcGfgugcasusu	1092
2022	csascccgAfaAfuUfGfauagcugas{invAb}	1093	asUfscagcUfauagauUfuCfgggugsusu	1094
2023	cscsgaaaCfuGfAfuUfAfcugaguc{invAb}	1095	asGfsacucAfgcuauCfGfuucggsusu	1096
2024	asascugaUfaGfCfUfGfaguccugas{invAb}	1097	usUfscaggAfcucagcUfaUfcaguuusu	1098
2025	asusagcuGfaGfUfCfCfugaaguuus{invAb}	1099	asAfsaacUfcaggacUfcAfgcuauusu	1100
2026	csasgcacAfuGfAfuUfUfgggaaus{invAb}	1101	usAfsauucCfcaauCfuGfugcgsusu	1102
2027	ascsaugaUfuUfGfGfGfaauuacacs{invAb}	1103	asGfsuguaAfuucccaAfaUfcaugususu	1104
2028	asusuuggGfaAfuUfAfcacuuugus{invAb}	1105	asAfscaaaGfugaaUfcCfcaauusu	1106
2029	gsgsgaaUfaCfAfuUfuugagacas{invAb}	1107	asUfsgucaCfaaagUfaAfuucccsusu	1108
2030	gsasauuaCfaCfUfUfUfgugacaugs{invAb}	1109	asCfsauguCfcaaaUfgUfaauucsusu	1110
2031	ascsacuuUfgUfGfAfuUfCfaggaugas{invAb}	1111	usUfscuacCfagucAfaAfaugususu	1112
2032	csascuuGfuGfAfuUfUfggaugaas{invAb}	1113	asUfsucaCfcaugucAfaAfaugususu	1114
2033	asusgaauCfuGfCfAfuUfUfgaccuus{invAb}	1115	asAfsagggUfcagucAfgAfuucaususu	1116
2034	asuscugCfCfUfGfAfuUfUfgcugguas{invAb}	1117	asUfsaccaAfgggucaGfuGfcagaususu	1118

2035	gscsacugAfcCfCfUfUfgguacaaus{invAb}	1119	usAfsuuguAfccaaggGfuCfagugcsusu	1120
2036	csusgaccCfuUfGfGfUfacaauagas{invAb}	1121	asUfscuuUfguaccaAfgGfgucagsusu	1122
2037	asasuagaUfgUfUfUfCfuuaucugcs{invAb}	1123	asGfscagaUfaagaaaCfaUfcuauususu	1124
2038	asuscagaAfuAfCfAfGfugugguccs{invAb}	1125	asGfsaccaAfcacuguAfuUfcugaususu	1126
2039	uscscagaaUfaCfAfGfUfgugguccs{invAb}	1127	usCfsgaccAfacacugUfaUfucugasusu	1128
2040	csasgaauAfcAfGfUfGfuugguccgas{invAb}	1129	asUfscgacCfaacacuGfuAfuucugsusu	1130
2041	asgsaauaCfaGfUfGfUfgguccgaus{invAb}	1131	asAfsucgaCfaacacUfgUfauucususu	1132
2042	gsasauacAfgUfGfUfUfgguccgaugs{invAb}	1133	asCfsaucgAfccaacaCfuGfuauucususu	1134
2043	asasuacaGfuGfUfUfGfguccaugus{invAb}	1135	usAfscaucGfaccaacAfcUfguauususu	1136
2044	usascaguGfuUfGfGfUfGgauguaas{invAb}	1137	asUfsuacaUfcgaccaAfcAfcuguasusu	1138
2045	asgsuguuGfgUfCfGfAfuguaagcas{invAb}	1139	asUfsgcuUfcaucgaCfcAfacacususu	1140
2046	usgsuaagCfaCfAfCfAfagugaggas{invAb}	1141	usUfscucAfcuugugUfgCfuucacusu	1142
2047	usasagcaCfaCfAfAfGfugaggaaus{invAb}	1143	asAfsuuccUfcacuugUfgUfgcuuasusu	1144
2048	gscsacacAfaGfUfGfAfaggaugggs{invAb}	1145	asCfscuUfuccucUfuGfugugcsusu	1146
2049	gsgsaaagAfaAfGfCfCfuuaugagus{invAb}	1147	asAfsucaUfuaggcuUfuCfuuccususu	1148
2050	asasgaaaGfcCfUfAfAfugagucggs{invAb}	1149	usCfscgacUfcauugGfcUfuucususu	1150
2051	asgsaaagCfcUfAfAfUfgagucggas{invAb}	1151	usUfscgaCfucauuUfgCfuucususu	1152
2052	gsasaagcCfuAfAfUfGfagucggaas{invAb}	1153	usUfsuccgAfcucauuAfgGfcuucususu	1154
2053	asasgccuAfaUfGfAfGfucggaaas{invAb}	1155	asUfsuucCfagacucaUfuAfgguususu	1156
2054	cscsuaauGfaGfUfCfGfGfaaaggcs{invAb}	1157	asGfscuuUfuccgacUfcAfuaggcsusu	1158
2055	csusaauGfGfUfCfGfGfaaaggccs{invAb}	1159	usGfsgcuUfuuccgaCfuCfauuagsusu	1160
2056	asasugagUfcGfGfAfAfaaggcaus{invAb}	1161	asAfsuggcCfuuuuccGfaCfucuuususu	1162
2057	gsusuggaAfgAfUfGfUfuguuacucs{invAb}	1163	asGfsaguaAfaacauCfuUfccaacsusu	1164
2058	asasaauUfuCfAfAfCfcccaguuas{invAb}	1165	asAfsuacuGfgguugAfaAfaauususu	1166
2059	asasuauUfcAfAfCfCfcaguuacs{invAb}	1167	asGfsauacUfgggguGfaAfaauususu	1168
2060	usgsgguUfgCfGfGfAfauguauus{invAb}	1169	asAfsauaaCfauccgCfaAfaccasusu	1170
2061	gsgsuuugCfGfAfAfUfuguauuuas{invAb}	1171	asUfsaaauAfcauucCfGfaaaccsusu	1172
2062	usgscggaAfuGfUfUfAfuuuauuacs{invAb}	1173	usGfsauauAfaauaacAfuUfccgcasusu	1174
2063	gscsggaUfgUfUfAfUfuuaucacs{invAb}	1175	usUfsgauUfaaauaCfaUfuccgcusu	1176
2064	asusuauAfuCfAfAfUfgaaucacs{invAb}	1177	asUfsgaguUfcauugAfuAfaaaususu	1178
2065	ususauuAfaUfGfAfaacucacas{invAb}	1179	asUfsgugaGfuucuuUfgAfuuaasusu	1180
2066	uscsaaugAfaAfCfUfCfacaagas{invAb}	1181	asUfscuugUfgugaguUfuCfaugagasusu	1182
2067	usgsaaacUfcAfCfAfCfaagacaccs{invAb}	1183	asGfsguguCfuuguguGfaGfuucacusu	1184
2068	gsasaacuCfaCfAfCfAfagacaccgs{invAb}	1185	asCfsggugUfcuugugUfgAfguuucusu	1186
2069	csgscggaUfgGfCfUfUfgcaagacgs{invAb}	1187	asCfsgucuUfgcaagCfaUfccgcgsusu	1188
2070	gscsggauGfgCfUfUfGfcaagacgs{invAb}	1189	asGfscgucUfgcaagCfcAfuccgcusu	1190
2071	gscsuugcAfaGfAfCfGfccuuucuu{invAb}	1191	usAfsagaaAfggcgucUfuGfcaagcsusu	1192
2072	uscuuuuUfaUfUfCfAfagagcgags{invAb}	1193	usCfsucgcUfcuugaaUfaAfaagagasusu	1194
2073	csuuuuuAfuUfCfAfAfagagcgagas{invAb}	1195	asUfscucGfcuugaAfuAfaaaagsusu	1196
2074	ususuuuUfuCfAfAfGfagcgagaus{invAb}	1197	asAfsucucGfcucuugAfaUfaaaasusu	1198
2075	ususuuuUfcAfAfGfAfgcgagaus{invAb}	1199	asCfsaucuCfucucuGfaUfaaaasusu	1200
2076	ususuuuUfaAfGfAfGfagagaus{invAb}	1201	asAfsaucUfcgcucuUfgAfaaaasusu	1202

2077	ususauucAfaGfAfGfCfAgauugs{invAb}	1203	asCfsacauCfucgcucUfuGfaauasusu	1204
2078	asasgagcGfaGfAfUfGfugcauaags{invAb}	1205	asCfsuuauGfcacauCfCfucucususu	1206
2079	asgsagcgAfgAfUfGfUfgcauaaggs{invAb}	1207	asCfscuuUfgcacaUfuCfCfucucususu	1208
2080	gsasgcgaGfaUfGfUfGfcauaaggs{invAb}	1209	asCfscuuUfgcacaUfuCfCfucucususu	1210
2081	asgsauguGfAfUfAfAfggcaugus{invAb}	1211	asAfscaugCfccuuUfuGfcaucususu	1212
2082	asusgugcAfuAfAfGfGfcauguuus{invAb}	1213	asAfsaacaUfgccuuUfuGfcacaususu	1214
2083	gsusgcauAfaGfGfGfCfauguuugcs{invAb}	1215	asGfscaaaCfaugcccUfuUfgcacsusu	1216
2084	gsgscaugUfuUfGfCfCfcaaugus{invAb}	1217	asAfscauuGfuggcaAfaCfaugccsusu	1218
2085	gscsauguUfuGfCfCfAfccauugs{invAb}	1219	usCfsacauUfggugcAfaAfaugcsusu	1220
2086	asusguuuGfCfAfCfCfaaugugacs{invAb}	1221	asGfsucacAfuuggugGfCfaacaususu	1222
2087	usgscugaAfcAfGfCfAfguagaguas{invAb}	1223	asUfsacucUfacugcuGfuUfcagcasusu	1224
2088	csusgaacAfgCfAfGfUfagaguacas{invAb}	1225	usUfsguacUfcuacugCfuGfuucagsusu	1226
2089	usasgaguAfcAfAfGfAfggcauugs{invAb}	1227	asCfsaaauGfcucuuGfuAfcucuasusu	1228
2090	gsusacaaGfaGfGfCfAfaugcaggs{invAb}	1229	usUfscugcAfaugccUfuUfuguacsusu	1230
2091	asasgaggCfaAfUfUfGfcagaaggs{invAb}	1231	asCfsacuuCfugcaauUfgCfcucucususu	1232
2092	usgscugaAfuUfAfAfAfccugaugs{invAb}	1233	asCfsaucaGfgguuuAfuUfcagcasusu	1234
2093	usgsaaauAfaAfCfCfCfugaugguus{invAb}	1235	asAfsaccaUfcaggguUfuAfaucasusu	1236
2094	gsasauuaAfaCfCfCfUfgaugguucs{invAb}	1237	asGfsaaccAfucagggUfuUfaauucususu	1238
2095	usgscccaGfCfGfCfAfaucaaaags{invAb}	1239	asCfsuuuuGfaugcuGfCfuggcasusu	1240
2096	gscsagcaAfuCfAfAfAfcgcuuacs{invAb}	1241	usUfsaacgGfcuuuUfuUfgcucgcsusu	1242
2097	asgscaauCfaAfAfAfGfcguuaacs{invAb}	1243	usGfsuuuaCfggcuUfuUfgauggcususu	1244
2098	csasaucaAfaAfGfCfCfguuaacaas{invAb}	1245	usUfsuguUfagggcuUfuUfgauugsusu	1246
2099	asasucaaAfaGfCfCfGfuuaacaas{invAb}	1247	asUfsuuguUfaacggcUfuUfugaucususu	1248
2100	asuscaaaAfgCfCfGfUfuaacaaggs{invAb}	1249	asCfsuuugUfuaacggCfuUfuugaususu	1250
2101	uscsaaaaGfCfGfUfUfaacaaggs{invAb}	1251	asAfsuuuGfuuaacgGfCfuuuucasusu	1252
2102	asasaagcCfGfUfUfAfAfaaagugas{invAb}	1253	usUfscacuUfuguuaaCfGfcuuucususu	1254
2103	asasagccGfuUfAfAfCfaaagugaas{invAb}	1255	usUfsucacUfuuguuaAfcGfgcuucususu	1256
2104	gscscguuAfaCfAfAfAfgugaaaaas{invAb}	1257	asUfsuuuuCfacuuUfuUfagggcsusu	1258
2105	asasagaaAfgCfUfAfAfaaggaucgs{invAb}	1259	asGfsaaucCfuuuuagCfuUfucuuucususu	1260
2106	asasaaggAfuUfCfUfUfcaagaaus{invAb}	1261	asAfsuuucUfugaagaAfuCfuuucususu	1262
2107	csascuguCfuCfAfCfCfaggcaugas{invAb}	1263	asUfscuuGfcggugAfgAfcagugsusu	1264
2108	usgscucAfcCfGfGfCfaugaucas{invAb}	1265	asUfsgaucAfuugccGfuGfagacacususu	1266
2109	csuscaccGfGfAfAfUfgaucagacs{invAb}	1267	asGfsucugAfucauugCfCfugagcsusu	1268
2110	gscsaaugAfuCfAfGfAfcugacuggs{invAb}	1269	asCfscaguCfagucugAfuCfaugcsusu	1270
2111	asuscagaCfuGfAfCfUfggugggus{invAb}	1271	asAfscccaCfcagucAfgUfcugaususu	1272
2112	gsgsugcuGfCfAfAfAfacuguucas{invAb}	1273	usUfsgaacAfguuuaGfCfagcacsusu	1274
2113	gsusgcugCfuAfAfAfAfcuguucaas{invAb}	1275	asUfsugaaCfaguuuAfgCfagcacsusu	1276
2114	uscsaaauUfCfAfCfAfAfgguacaas{invAb}	1277	asGfsuugaCfcuuuguGfaAfuugacususu	1278
2115	asasuucaCfaAfAfGfGfcaacuugs{invAb}	1279	usCfsaaguUfgaccuuUfgUfgaauucususu	1280
2116	ascsaaagGfuCfAfAfCfuugagaugs{invAb}	1281	asCfsaucuCfaaguugAfcCfuugacususu	1282
2117	asgsuugaAfcUfUfGfAfgaugguacs{invAb}	1283	usUfsaaccAfcucaaGfuUfgaccususu	1284
2118	gsgsuuaaAfgCfUfGfCfaacugagas{invAb}	1285	asUfscucaGfuugcagCfuUfaaacususu	1286

SUBSTITUTE SHEET (RULE 26)

2161	ascsuucgAfcAfGfCfAfgcaauucus{invAb}	1371	asAfsgaauUfgcugcuGfuCfgaagususu	1372
2162	csgsuucuAfgGfAfGfUfggaaaaacs{invAb}	1373	asGfsuuuuUfccacucCfuAfgaacgsusu	1374
2163	gsusucuaGfgAfGfUfGfgaaaaaccs{invAb}	1375	asGfsguuuUfuccacuCfcUfagaacsusu	1376
2164	ususuuuguCfaGfUfUfGfugguagauss{invAb}	1377	usAfsucuaCfcacaacUfgAfcaaaasusu	1378
2165	ususgucaGfuUfGfUfGfguagauacs{invAb}	1379	asGfsuauUfaccacaAfcUfgacaasusu	1380
2166	uscsaguuGfuGfGfUfAfgauacucus{invAb}	1381	asAfsagauAfuacuaccAfcAfacugasusu	1382
2167	csusaccaAfuGfUfCfAfuccagacs{invAb}	1383	usGfsucugGfgaugacAfuUfgguagsusu	1384
2168	asusgucaUfcCfCfAfGfAfaucuuugs{invAb}	1385	usCfsaagaUfgucuggGfaUfgacausus	1386
2169	usgsucaUfcCfCfAfGfAfaucuuugs{invAb}	1387	asUfscaagAfugucugGfgAfugacasusu	1388
2170	gsuscaucCfCfAfGfAfaucuuugs{invAb}	1389	usAfsucaaGfaugucuGfgGfaugacsusu	1390
2171	cscscagaCfaUfCfUfUfgauaaacs{invAb}	1391	asGfsuauUfucaagaUfgUfcugggsusu	1392
2172	uscsuugaUfaAfUfAfCfcuguuggas{invAb}	1393	usUfsccaaCfagguaUfaUfcaagasusu	1394
2173	csusugauAfaUfAfCfCfuguuggaas{invAb}	1395	asUfsuccaAfcagguaUfuAfucaagsusu	1396
2174	gsusuggaAfuCfUfCfAfaugaucgs{invAb}	1397	asCfsgaucAfuaggagAfuUfccaacsusu	1398
2175	csasuauCfGfAfGfGfucacuacas{invAb}	1399	usUfsguagUfgaccuuCfGfuaaugsusu	1400
2176	ususaucgAfaGfGfUfCfacuacaas{invAb}	1401	asAfsuuguAfgugaccUfuCfauaasusu	1402
2177	gsusguagCfaAfGfAfGfguguuauus{invAb}	1403	usAfsauaaCfaccucuUfgCfuacacsusu	1404
2178	gsusguuaUfuAfGfAfAfuuuacgas{invAb}	1405	usUfscguaAfaucuuUfaUfaacacsusu	1406
2179	usgsuuauUfaGfAfAfUfguuacgaas{invAb}	1407	usUfsucguAfaucuuUfaUfaaacasusu	1408
2180	gsusuauUfGfAfAfUfGfuacgaas{invAb}	1409	usUfsuucgUfaacauUfuAfaaacasusu	1410
2181	ususauuaGfaAfUfGfUfuacgaaaas{invAb}	1411	usUfsuuucGfuaacauUfuUfaaasusu	1412
2182	ususagaaUfgUfUfAfCfGfaaaaaacs{invAb}	1413	asGfsuuuuUfucguaaCfaUfucuaasusu	1414
2183	usasgaauGfuUfAfCfGfaaaaaacus{invAb}	1415	usAfsguuuUfuucguaAfcAfuucuasusu	1416
2184	asgsaaugUfuAfCfGfAfaaaacuas{invAb}	1417	asUfsaguuUfuuuucuAfaCfaucuasusu	1418
2185	asasuguuAfcGfAfAfAfaaacuugs{invAb}	1419	asCfsauagUfuuuuuGfuAfaucuasusu	1420
2186	asusguuaCfGfAfAfAfaacuauggs{invAb}	1421	asCfscuaGfuuuuuCfGfuaacuasusu	1422
2187	usgsuuacGfaAfAfAfAfaucuauggs{invAb}	1423	asAfsccauAfguuuuUfcGfuaacuasusu	1424
2188	ususacgaAfaAfAfAfCfaugguugs{invAb}	1425	asCfsaaccAfuaguuUfuUfcguuasusu	1426
2189	usascgaaAfaAfAfCfAfaugguugs{invAb}	1427	asAfscaacCfauguuUfuUfcguuasusu	1428
2190	asasaaacUfaUfGfGfUfuguguccgs{invAb}	1429	usCfsggacAfaaccaUfaGfuuuuususu	1430
2191	asascuauGfgUfUfGfUfguccgagus{invAb}	1431	asAfsucugGfacacaaCfcAfuaguususu	1432
2192	asasggaaUfaUfUfUfAfgaaagccas{invAb}	1433	usUfsggcuUfucuaaaUfaUfuccuusus	1434
2193	asgsgaauAfuUfUfAfGfaaagccaas{invAb}	1435	usUfsuggcUfuucuaaAfuAfuuccususu	1436
2194	gsgsaauUfuUfAfGfAfaagccaaas{invAb}	1437	asUfsuuggCfuucuaAfaUfauccususu	1438
2195	usasgaaaGfcCfAfAfAfgucagaaas{invAb}	1439	asUfsuucuGfacuugGfcUfuucuasusu	1440
2196	asgsaaagCfcAfAfAfGfucagaaacs{invAb}	1441	asGfsuuucUfgacuuUfgCfuucuasusu	1442
2197	asgsccaaAfgUfCfAfGfaaaccggus{invAb}	1443	asAfsccggUfuucugaCfuUfuggcususu	1444
2198	asgscaagCfGfUfGfUfuaccagcus{invAb}	1445	usAfsugcuGfuaacaaCfGfuugcususu	1446
2199	gscsaagCfGfUfGfUfuaccagcuas{invAb}	1447	asUfsagcuGfguaacaaCfGfuugcususu	1448
2200	asasgcguUfgUfUfAfCfcagcuauas{invAb}	1449	asUfsauagCfugguaaCfaAfcgcuususu	1450
2201	asgscguUfuUfAfCfCfagcuauacs{invAb}	1451	asGfsuuaGfcugguaAfcAfacgcuususu	1452
2202	gsusccauUfaAfUfGfAfguccagaas{invAb}	1453	usUfsucugGfacuauUfaUfuggacsusu	1454

2203	cscsauuaAfuGfAfGfUfccagaaus{invAb}	1455	asAfsuuucUfggacucAfuUfaaugsusu	1456
2204	gsasguccAfgAfAfUfgcaacagas{invAb}	1457	asUfscuguUfgcauuuCfuGfgacucsusu	1458
2205	csusacgaAfgGfAfGfGfuugauugcs{invAb}	1459	usGfscaauCfaaccucCfuUfcguagsusu	1460
2206	ascsaagGfaGfGfUfGauugcaas{invAb}	1461	usUfsugcaAfucaaccUfcCfuucgususu	1462
2207	csusgagcAfuAfUfUfcfuaucacus{invAb}	1463	asAfsaugaAfuagaauAfuGfcucagsusu	1464
2208	ususcuaUfcAfCfUfGfcuagcaags{invAb}	1465	asCfsuugcUfagcaguGfaAfuagaasusu	1466
2209	csusauucAfcUfGfCfUfagcaagucs{invAb}	1467	asGfsacuuGfcuagcaGfuGfaauagsusu	1468
2210	usasuuaCfuGfCfUfAfgcaaguccs{invAb}	1469	asGfsgacuUfgcuagcAfgUfgaauasusu	1470
2211	ascsugcuAfgCfAfAfGfuccugugcs{invAb}	1471	asGfscacaGfgacuugCfuAfgcagususu	1472
2212	csasagucCfuGfUfGfCfauuugus{invAb}	1473	asAfscauaAfuaggcacAfgGfacuugsusu	1474
2213	asgsuccuGfuGfCfCfAfuuauguccs{invAb}	1475	usGfsgacaUfaauggcAfcAfggacususu	1476
2214	csasuuaGfuCfCfAfCfacacauugs{invAb}	1477	asCfsaaugUfguguggAfcAfuuaugsusu	1478
2215	uscscacaCfaCfAfUfUfguggcuugs{invAb}	1479	asCfsaagcCfacaugUfgUfguggasusu	1480
2216	csasgacaCfaGfGfCfAfggaaugs{invAb}	1481	usCfsaaauCfccugccUfgUfgucugsusu	1482
2217	ascsacagGfcAfGfGfGfaauugaucs{invAb}	1483	asGfsaucaAfuucccuGfcCfugugususu	1484
2218	gsasauugAfuCfUfCfUfccacauugs{invAb}	1485	asCfsaaugUfggagagAfuCfaauucsusu	1486
2219	asgsaagUfcCfUfGfGfcucgugaus{invAb}	1487	asAfsucacGfagccagGfaCfuuccususu	1488
2220	csgsugauUfuUfGfAfCfcuggguus{invAb}	1489	asAfsaccCfaggucaAfaAfuacgsusu	1490
2221	gsusgaauUfuGfAfCfCfuggguucs{invAb}	1491	asGfsaaccCfcaggucAfaAfaucacsusu	1492
2222	usgsauuuUfgAfCfCfUfgggguucus{invAb}	1493	asAfsaacCfccagguCfaAfaucasusu	1494
2223	ususcagaAfgAfUfGfUfaguauugcs{invAb}	1495	usGfscauuAfcuacauCfuUfcugaasusu	1496
2224	usgsuaguAfaUfGfCfAfugccauacs{invAb}	1497	usGfsuauGfcaugcaUfuAfcuacasusu	1498
2225	csasugccAfuAfCfAfGfcucguggs{invAb}	1499	usCfscagCfagcuguAfuGfgcaugsusu	1500
2226	cscsauacAfgCfUfGfCfugggaaus{invAb}	1501	asAfsuuucCfcagcagCfuGfuauugsusu	1502
2227	csasuacaGfcUfGfCfUfgggaaus{invAb}	1503	asAfsauuuCfccagcaGfcUfguauugsusu	1504
2228	gsusuuuuUfaUfCfAfCfcccagcas{invAb}	1505	asUfsgcugGfgggugaUfaAfaaaacsusu	1506
2229	usuuuuuAfuCfAfCfCfcccagcacs{invAb}	1507	usGfsugcuGfgggugAfuAfaaaasusu	1508
2230	ususaucCfCfCfCfAfgcacaacus{invAb}	1509	asAfsuugUfgcugggGfgUfgauaasusu	1510
2231	usasucacCfCfCfAfGfcacaacugs{invAb}	1511	asCfsaguuGfugcuggGfgGfugauasusu	1512
2232	asuscaguCfuUfCfGfAfacuacacus{invAb}	1513	asAfsuugAfguucgaAfgAfcugaususu	1514
2233	gsuscuucGfaAfCfUfCfaacuucuas{invAb}	1515	asUfsagaaGfuugaguUfcGfaagacsusu	1516
2234	uscuucGfaCfUfCfAfacuucuas{invAb}	1517	usGfsuagaAfguugagUfuCfagaasusu	1518
2235	csusucgaAfcUfCfAfAfcuucuas{invAb}	1519	asUfsguagAfgauugaGfuUfcgaagsusu	1520
2236	csgsaacuCfaAfCfUfUfcuacagcas{invAb}	1521	usUfsgcugUfagaaguUfgAfguucgsusu	1522
2237	asascucaAfcUfUfCfUfagcaaus{invAb}	1523	asAfsuugcUfguagaaGfuUfgaguususu	1524
2238	asascuucUfaCfAfGfCfaaugggus{invAb}	1525	usAfsccccAfuugcugUfaGfaaguususu	1526
2239	csusucuaCfaGfCfAfAfgggguacs{invAb}	1527	asGfsuaccCfauugcUfgUfagaagsusu	1528
2240	asgscaauGfgGfGfUfAfcuucugus{invAb}	1529	asAfscaugAfguaccCfcAfuucgususu	1530
2241	gscsaauGfgGfUfAfCfuucugus{invAb}	1531	asGfsacauGfaaguacCfcCfaugcsusu	1532
2242	usascuucAfuGfUfCfUfuaucaugus{invAb}	1533	asCfsaugaUfaaagacAfuGfaaguasusu	1534
2243	ascsuuaUfgUfCfUfUfuaucaugus{invAb}	1535	usCfscaugAfuuaagaCfaUfagaugsusu	1536
2244	uscsuuuaUfcAfUfGfGfaggccaucs{invAb}	1537	usGfsauggCfcuccauGfaUfaaagasusu	1538

2245	gscscuuuAfuGfCfAfGfuucugaacs{invAb}	1539	usGfsuuccaGfaacugcAfuAfaagcsusu	1540
2246	asgscaccCfCfCfUfaaccugaus{invAb}	1541	asAfsucagGfuuaagguGfgGfgugcsusu	1542
2247	csasccccAfcCfUfAfAfcuugaucas{invAb}	1543	asUfsgaucAfgguuagGfuGfgggugsusu	1544
2248	cscscaccUfaAfCfCfUfgaucagccs{invAb}	1545	usGfsgcugAfucagguUfaGfgugggsusu	1546
2249	usgsugcuAfcCfUfUfCfucuccaas{invAb}	1547	asAfsuuggAfgagaagGfuAfgcacasusu	1548
2250	ascscaucUfcAfCfUfGfccuugccas{invAb}	1549	asUfsggcaAfggcaguGfaGfauggsusu	1550
2251	csusgccuUfgCfCfAfGfacuuuuas{invAb}	1551	asUfsaaaaUfgucuggCfaAfggcagsusu	1552
2252	csasugaaAfcAfGfUfAfggaauguus{invAb}	1553	asAfsacuuUfccuacuGfuUfucagsusu	1554
2253	gsasaacaGfuAfGfGfAfaaguuuas{invAb}	1555	asAfsuaaaCfuuuuccAfcUfguuucsusu	1556
2254	gsusaggaAfaGfUfUfUfauccaguas{invAb}	1557	asUfsacugGfauaaacUfuUfccuacsusu	1558
2255	gsusuauCfCfAfGfUfAfggcauucs{invAb}	1559	asGfsaaugCfcauacuGfgAfuuaacsusu	1560
2256	ususcuuaCfaGfUfGfGfcagagcacs{invAb}	1561	asGfsugcuCfugccacUfgUfaagaasusu	1562
2257	usascaguGfgCfAfGfAfgcacgaugs{invAb}	1563	usCfsaucgUfgcucugCfcAfcuguasusu	1564
2258	gsasugacCfaGfGfAfAfgauaucags{invAb}	1565	asCfsugauAfucuuuccUfgGfucaucsusu	1566
2259	gsasagauAfuCfAfGfUfccuagucus{invAb}	1567	asAfsagacuAfggacugAfuAfucuuacsusu	1568
2260	usasgucuUfgCfUfGfAfgcagcagus{invAb}	1569	asAfsucugUfgcucagCfaAfgacuasusu	1570
2261	ususugucUfuGfGfAfGfaagugaugs{invAb}	1571	usCfsaucaCfuuccuccAfaGfacaasusu	1572
2262	asgsgaacAfgCfGfAfGfauugcuacs{invAb}	1573	asGfsuagcAfaucucgCfuGfuuccususu	1574
2263	csasgcgaGfaUfUfGfCfuaccugaas{invAb}	1575	asUfsucagGfuagcaaUfcUfcgcugsusu	1576
2264	gscsuaccUfgAfAfGfGfugagccaas{invAb}	1577	asUfsuggcUfcaccuuCfaGfguagcsusu	1578
2265	csusaccuGfaAfGfGfUfgagccaaus{invAb}	1579	asAfsuuggCfucaccuUfcAfgguagsusu	1580
2266	cscsugaaGfgUfGfAfGfccauccas{invAb}	1581	usUfsggauUfggcucaCfcUfucaggsusu	1582
2267	gsasgacuCfcUfUfGfGfgccuuugcs{invAb}	1583	asGfscaaaGfgcccaaGfgAfgucucsusu	1584
2268	asgsaaaGfuUfGfCfAfguauugcs{invAb}	1585	asGfscauaUfacugcaAfcAfuuuacsusu	1586
2269	gsasaaugUfuGfCfAfGfuauaugcus{invAb}	1587	asAfsgcAuAfuacugcAfaCfauuacsusu	1588
2270	csasguauAfuGfCfUfGfagagugccs{invAb}	1589	usGfsgcacUfcucagcAfuAfuacugsusu	1590
2271	usasuuuguCfuUfGfUfGfaagaugcs{invAb}	1591	asGfscauuCfuucacaAfgAfaauasusu	1592
2272	usgsaaaaUfgUfUfUfAfgagauuuus{invAb}	1593	asAfsauauCfcuuaaaCfaUfuuuacsusu	1594
2273	gsasccaaAfcAfAfAfAfgagagugus{invAb}	1595	asAfscacuCfucuuuuGfuUfuggucsusu	1596
2274	ascsaAAAaGfaGfAfGfUfgucuguuus{invAb}	1597	asAfsaacaGfacacucUfcUfuuuugsusu	1598
2275	csasaaagAfgAfGfUfGfucuguuuus{invAb}	1599	usAfsaaacAfgacacuCfuCfuuuugsusu	1600
2276	gsusuuaaGfaAfCfUfGfagcagcacs{invAb}	1601	asGfsugcuGfcucaguUfcUfaaaacsusu	1602
2277	asgsaacuGfaGfCfAfGfcacuuuucs{invAb}	1603	asGfsaaaaGfugcugcUfcAfguucsususu	1604
2278	asgscacuUfuUfCfUfAfcucaaugs{invAb}	1605	asCfsauugAfgguagaAfaAfgugcsusu	1606
2279	ususucuaCfcUfCfAfAfgucaaccgs{invAb}	1607	usCfsgguuGfcauugaGfgUfagaaasusu	1608
2280	gsusuuuUfgGfUfGfCfuguagguas{invAb}	1609	usUfsaccuAfcagcacCfaCfaaaacsusu	1610
2281	ususguggUfgCfUfGfUfagguaacgs{invAb}	1611	asCfsguuuAfcuacagCfaCfcacaasusu	1612
2282	gsusggugCfuGfUfAfGfguaacgugs{invAb}	1613	asCfsacguUfaccuacAfgCfaccacsusu	1614
2283	gsgsugcuGfuAfGfGfUfaacgugugs{invAb}	1615	asCfsacacGfuuaacuAfcAfgcaccsusu	1616
2284	usgscuguAfgGfUfAfAfcguguggcs{invAb}	1617	usGfscacAfcguuacCfuAfcagcasusu	1618
2285	gsgscaaaUfgAfAfGfGfucaugagas{invAb}	1619	asUfscucaUfgaccuuCfaUfuugccsusu	1620
2286	gsasucugUfgAfUfCfUfuuccagcus{invAb}	1621	asAfsugcGfgaagauCfaCfagaucsusu	1622

2287	gscsagauAfaCfAfCfUfugggggas{invAb}	1623	asUfsccccCfcaagugUfuAfucugcsusu	1624
2288	asusaacaCfuUfGfGfGfgggaccucs{invAb}	1625	usGfsagguCfcccccaAfgUfguuasusu	1626
2289	gsasccucAfgCfCfUfCfuauucgas{invAb}	1627	usUfsgcgaAfuagaggCfuGfaggucsusu	1628
2290	ascscucaGfcCfUfCfUfauucgcaas{invAb}	1629	asUfsugcgAfauagagGfcUfgaggususu	1630
2291	asusaauCfGfUfAfGfAfcuacaagas{invAb}	1631	asUfscuugUfagucuaCfGfauuauasusu	1632
2292	cscsguagAfcUfAfCfAfagaugaaas{invAb}	1633	asUfsuucUfcuuguaGfuCfuacggsusu	1634
2293	usasgacuAfcAfAfGfAfugaaucus{invAb}	1635	asAfsgauUfcaucuuGfuAfgucuasusu	1636
2294	ususguugGfuAfUfAfUfauucuggus{invAb}	1637	asAfsccagAfuaauauAfcCfaacaasusu	1638
2295	usgsuuggUfaUfAfUfUfauucugguus{invAb}	1639	usAfsaccaGfauaauaUfaCfcaacasusu	1640
2296	gsusugguAfuAfUfUfAfucugguuaas{invAb}	1641	asUfsaaccAfgauauuAfuAfcacaasusu	1642
2297	asasauaaUfuGfAfGfUfcauccauus{invAb}	1643	asAfsauggAfugacucAfaUfauuuasusu	1644
2298	csusgucaAfuAfGfUfAfgcuacauus{invAb}	1645	asAfsauguAfgcuacuAfuUfgacagsusu	1646
2299	usgsucaaUfaGfUfAfGfcauacauus{invAb}	1647	asAfsaaugUfagcuacUfaUfugacasusu	1648
2300	csasauagUfaGfCfUfAfcuuuuuuaas{invAb}	1649	usUfsaaaaAfuguagcUfaCfuauugsusu	1650
2301	gsusagcuAfcAfUfUfUfuaauugggs{invAb}	1651	usCfscgauUfaaaaaUfuAfgcuacsusu	1652
2302	usasgcuaCfaUfUfUfUfuaauugggas{invAb}	1653	asUfscccaUfuaaaaaUfgUfagcuasusu	1654
2303	csasauauUfaGfUfUfUfagguccggs{invAb}	1655	usCfscgcaCfcuaaacUfaAfuauugsusu	1656
2304	asusuaguUfuAfGfGfUfcgggaacus{invAb}	1657	asAfsguucCfcgaccuAfaAfcuaasusu	1658
2305	ususagguCfGfGfAfAfcugagauas{invAb}	1659	asUfsaucuCfaguuccCfAfcuaasusu	1660
2306	asgsgucGfGfAfCfUfgagauuus{invAb}	1661	asAfsauauCfucaguuCfcCfagaccususu	1662
2307	uscsgggaAfcUfGfAfGfauuuguuas{invAb}	1663	usUfsacaaUfaucucaGfuUfcccgasusu	1664
2308	gsgsaacuGfaGfAfUfAfuuguaaacs{invAb}	1665	usGfsauuaCfaauaucUfcAfguucssusu	1666
2309	gsasacugAfgAfUfAfUfuguaaucas{invAb}	1667	usUfsgauuAfcuaauCfuCfaguucssusu	1668
2310	asascugaGfaUfAfUfUfguaaucaas{invAb}	1669	usUfsugauUfacaauaUfcUfcaguususu	1670
2311	csusgagaUfaUfUfGfUfaaucaaaus{invAb}	1671	usAfsuuugAfuuaaaUfaUfcucagsusu	1672
2312	usasuuuAfaUfCfAfAfauaguuaas{invAb}	1673	asUfsuaacUfauuugaUfuAfcuaasusu	1674
2313	usgsuaauCfaAfAfUfAfguaaacaas{invAb}	1675	asAfsuguuAfacuauUfgAfuuaasusu	1676
2314	gsusaauCfaAfUfAfGfuaaacaacs{invAb}	1677	usGfsauguUfaacuauUfuGfaauacsusu	1678
2315	usasaucaAfaUfAfGfUfaaacaacs{invAb}	1679	asUfsgaugUfuaacuaUfuUfgauuasusu	1680
2316	asasuaguUfaAfCfAfUfcaggaagus{invAb}	1681	asAfsuucCfugauguUfaAfcuaasusu	1682
2317	asusaguuAfaCfAfUfcaggaaguus{invAb}	1683	usAfsacuuCfcugaugUfuAfcuaasusu	1684
2318	usasguuaAfcAfUfCfAfggaaguuaas{invAb}	1685	usUfsaacuUfccugauGfuUfaacuasusu	1686
2319	asgsuuaaCfaUfCfAfGfagauguuaas{invAb}	1687	asUfsuaacUfuccugaUfgUfuaacussusu	1688
2320	asasguuaAfuUfUfGfGfcuggcaas{invAb}	1689	usUfsuugcCfagccaaAfuUfaacussusu	1690
2321	usasauuuGfGfUfGfGfcaaaauacs{invAb}	1691	asGfsauuuUfugccagCfcAfaauuasusu	1692
2322	uscsguagGfaAfCfUfUfggaccagas{invAb}	1693	usUfscuggCfcaaguuUfcCfcuagassusu	1694
2323	usgsaccaGfaAfAfAfCfugguguugs{invAb}	1695	usCfsaacaCfcaguuUfcUfggaccasusu	1696
2324	ususugaAfcCfCfUfUfccuguuuus{invAb}	1697	usAfsaaacAfggaaggGfuUfcuaaasusu	1698
2325	asasuccuCfCfAfCfCfaauagcas{invAb}	1699	asUfsgcuUfuugguuGfgAfggaususu	1700
2326	asgsuuuuCfCfUfAfCfUfgauuaggs{invAb}	1701	asCfsuaauCfaaguuaGfgAfaaacussusu	1702
2327	ususuuuUfaAfCfUfUfgauuagcus{invAb}	1703	asAfsgcuaAfucaaguUfaGfgaaaasusu	1704
2328	uscscuaaCfuUfGfAfUfagcuugas{invAb}	1705	asUfscaagCfuaaucaAfgUfuaggassusu	1706

2329	ascsuugaUfuAfGfCfUfugagcugas{invAb}	1707	asUfscagcUfcaagcuAfaUfcaagususu	1708
2330	csusugauUfaGfCfUfUfgagcugacs{invAb}	1709	usGfsucagCfucaagcUfaAfucaagsusu	1710
2331	csusuucuGfuAfCfUfGfcacacagas{invAb}	1711	asUfscuguGfugcaguAfcAfgaaagsusu	1712
2332	uscsuguaCfuGfCfAfCfagcagauugs{invAb}	1713	asCfsaaucUfgugugcAfgUfagagasusu	1714
2333	csusguacUfgCfAfCfAfcagauugus{invAb}	1715	asAfscaauCfugugugCfaGfuacagsusu	1716
2334	gscsacccCfaGfUfCfCfaggugacus{invAb}	1717	asAfsgucaCfcuggacUfgGfggugcsusu	1718
2335	uscsagauUfgUfGfCfCfugcacaas{invAb}	1719	asUfsugugCfacggcaCfaAfcucgasusu	1720
2336	asgsuuguGfcCfGfUfGfcacaaccus{invAb}	1721	asAfsgguuGfugcacgGfcAfaacususu	1722
2337	gsusgcacAfaCfCfUfGfuccaguuas{invAb}	1723	usAfsuacuGfgacaggUfuGfugcacsusu	1724
2338	usgsacacAfcCfUfGfUfccaguuas{invAb}	1725	asUfsauacUfggacagGfuUfgugcasusu	1726
2339	cscsugucCfaGfUfAfUfaucaugus{invAb}	1727	asAfscaugCfauauacUfgGfacaggsusu	1728
2340	usgsgccUfaCfUfGfAfcugguauas{invAb}	1729	asAfsuuacCfagucagUfaGfggccasusu	1730
2341	gscsuuugAfgGfAfAfAfaaccaugas{invAb}	1731	asUfscaugGfuuuuucCfuCfaaagcsusu	1732
2342	asasaccaUfgAfCfUfUfuaacaaas{invAb}	1733	asUfsuuguUfaaaaguCfaUfgguuususu	1734
2343	ascsaaaUfuUfUfAfUfgguuauas{invAb}	1735	asUfsauaaCfccauaaAfaAfuuugususu	1736
2344	ususuuuUfgGfGfUfUfauaugccus{invAb}	1737	usAfsggcaUfauaaccCfaUfaaaaasusu	1738
2345	usasugggUfuAfUfAfUfgccuaaacs{invAb}	1739	asGfsuuuaGfgcauauAfaCfccauasusu	1740
2346	asasugguCfuGfUfUfCfaauuuggs{invAb}	1741	asCfscaauUfauaacAfgAfcuauususu	1742
2347	gsgsucugUfuCfAfUfAfaauugguags{invAb}	1743	asCfsuaccAfaauaugAfaCfagaccsusu	1744
2348	csusguucAfuAfAfUfUfgguaggugs{invAb}	1745	asCfsaccuAfcuuuAfuGfaacagsusu	1746
2349	usasauugGfuAfGfGfUfgccuuuugs{invAb}	1747	asCfsaaaaGfgcacuAfcCfaauuasusu	1748
2350	asgsuuuUcGfUfUfGfcuuauucus{invAb}	1749	asGfsagauAfgcaacAfgUfaaacususu	1750
2351	ususuuuUcAfgAfUfGfAfguguuacas{invAb}	1751	asUfsguuaCfacuauCfuGfgaaaasusu	1752
2352	asgsuacuGfaGfAfAfUfuaaguuugs{invAb}	1753	asCfsaaacUfuaauucUfcAfguacususu	1754
2353	gsusacugAfgAfAfUfUfaaguuugus{invAb}	1755	usAfscaaaCfuuaauCfuCfaguacsusu	1756
2354	csusgauUgfaUfAfUfUfucacauugs{invAb}	1757	asCfsaaugUfgaaauUfcAfaucagsusu	1758
2355	usgsauugAfuAfUfUfUfcacauugus{invAb}	1759	usAfscaauGfugaauAfuCfaaucasusu	1760
2356	gsuscaguUfgUfAfGfUfagcucugas{invAb}	1761	asUfscagaGfcuacuaCfaAfcugacsusu	1762
2357	csasguugUfaGfUfAfGfucugaugus{invAb}	1763	asCfsaucaGfagcuacUfaCfaucagsusu	1764
2358	gscsauucCfaUfUfUfUfacugacuas{invAb}	1765	asUfsagucAfguaaaaUfgGfaaugsusu	1766
2359	ususggcuAfcAfUfUfUfgaggauas{invAb}	1767	asUfsauccUfccaaauGfuAfgccaasusu	1768
2360	asgsgauCfcCfAfGfGfagucuuugs{invAb}	1769	asCfsaagaCfuccugGfgUfauccususu	1770
2361	gsgsauacCfcAfGfGfGfagucuuugs{invAb}	1771	asCfscaagAfcuccuGfgGfuauccsusu	1772
2362	asgscaaCfaUfUfUfUfcuagucus{invAb}	1773	asAfsgacuAfgugaaaUfgUfuugcsusu	1774
2363	ascsauuuCfaCfUfAfGfucucuuus{invAb}	1775	asAfsaaagAfgacuagUfgAfaaugususu	1776
2364	ususuucaUfcCfUfUfUfaaauguas{invAb}	1777	usUfsacaaUfuuaaagGfaUfgaaaasusu	1778
2365	usasaauAfaGfGfAfUfuacucaags{invAb}	1779	asCfsuugaGfuaauccUfuAfauuuasusu	1780
2366	asasaauAfgGfAfUfUfucucaagcs{invAb}	1781	asGfscuugAfguaucCfuUfaauuususu	1782
2367	ususaaggAfuUfAfCfUfcaagcucas{invAb}	1783	asUfsgagcUfugaguaAfuCfcuaasusu	1784
2368	ascsucaaGfcUfCfAfCfcauuuucs{invAb}	1785	usGfsaauaAfggugaGfcUfugagususu	1786
2369	uscsaagcUfcAfCfCfAfuaauucaas{invAb}	1787	asUfsugaaUfaaugguGfaGfcuugasusu	1788
2370	ususauuuUfcCfCfUfUfuugguuggs{invAb}	1789	asCfscaacCfaaaaggGfaAfaauaasusu	1790

2371	csasauguAfuGfAfUfUfugcuagcus{invAb}	1791	asAfsgcuaGfcaaaucAfuAfcuugsusu	1792
2372	usgsuaugAfuUfUfGfCfuagcucucs{invAb}	1793	asGfsagagCfuagcaaAfuCfuaacasusu	1794
2373	gscsuuuUfGfUfAfAfUfuaacuggus{invAb}	1795	asAfscagUfuaauuaCfaAfaaagsusu	1796
2374	ususuguaAfuUfAfAfCfuggugcuus{invAb}	1797	asAfsagcaCfcaguuAfuUfacaasusu	1798
2375	gsusaauAfaCfUfGfGfugcuugas{invAb}	1799	usUfscaaaGfcaccagUfuAfaauacsusu	1800
2376	ususgaaaAfuCfUfUfUfuuuaggg{invAb}	1801	usCfscuuAfaaaaagAfuUfuucaasusu	1802
2377	asasaucUfCfAfAfCfCfaaaguuas{invAb}	1803	asAfsuaacUfuugguuGfaGfauuususu	1804
2378	uscsucaaCfCfAfAfGfuaugcucs{invAb}	1805	usGfsagcaUfaacuuUfGfUfugagasusu	1806
2379	csasaccaAfaGfUfUfAfugcucaucs{invAb}	1807	asGfsaugaGfcaaacUfuUfggugsusu	1808
2380	asasaguuAfuGfCfUfCfauccagacs{invAb}	1809	usGfsucugGfaugagcAfuAfacuuususu	1810
2381	asgsuuuGfCfUfCfAfUfccagacaas{invAb}	1811	asUfsugucUfggauGfCfuaaacsusu	1812
2382	gsusuaauUfUfAfGfCfacaacucas{invAb}	1813	asUfsgaguUfugugcUfAfaFuuaacsusu	1814
2383	gsasuagCfCfGfUfUfUfugcuuaas{invAb}	1815	usUfsuuagCfaaaacGfUfGfuaacsusu	1816
2384	usasgcacCfGfUfUfUfGfuaaaags{invAb}	1817	usCfsuuuUfGfcaaaaCfGfugcuasusu	1818
2385	asgscaccGfUfUfUfGfcaaaaagas{invAb}	1819	asUfscuuUfagcaaaAfcGfugcususu	1820
2386	gscsaccGfUfUfUfGfCfuaaaagaus{invAb}	1821	usAfsucuuUfuagcaaAfaCfggugcsusu	1822
2387	csasccguUfUfGfCfUfaaaagauas{invAb}	1823	asUfsaucUfuuaagcaAfaAfcggugsusu	1824
2388	ascscguUfUfGfCfUfAfaaagauacs{invAb}	1825	usGfsuauCfuuuagcAfaAfacggususu	1826
2389	csasuucUfCfUfUfGfUfuuccaacs{invAb}	1827	usGfsuugAfaaacaUfGfagaugsusu	1828
2390	asusucucAfuUfGfUfUfuuccaacs{invAb}	1829	asUfsguugGfaaaacaAfuGfagaasusu	1830
2391	usgsuuuUfCfAfAfCfAfgugaggcs{invAb}	1831	asGfscacuUfcuguuGfGfuaaacsusu	1832
2392	ascsauaaGfGfUfUfAfafacaacuacs{invAb}	1833	asUfsaguuUfguuuUfCfUfuaugsusu	1834
2393	csasuagGfUfUfAfAfAfaaacuags{invAb}	1835	asCfsuaguUfuguuuUfCfuaugsusu	1836
2394	asusaaggUfUfAfAfCfAfaaacuaggs{invAb}	1837	asCfscuagUfuuguuuUfAfcuuaasusu	1838
2395	usasagguUfaAfAfCfAfaacuaggus{invAb}	1839	asAfscuaGfuuuuuUfaAfcuuaasusu	1840
2396	gsusuaaaCfaAfAfCfUfaggugcuus{invAb}	1841	asAfsagcaCfcuaguuUfGfuaaacsusu	1842
2397	ususaaacAfaAfCfUfAfgugcuugs{invAb}	1843	asCfsaagCfaccuagUfuGfuuaasusu	1844
2398	asasuuaUfUfAfCfAfGfuuuacucus{invAb}	1845	usAfsagauAfaacugUfAfaaaususu	1846
2399	csusguaaCfUfGfAfAfaugcagcs{invAb}	1847	asGfscagCfuuucaUfGfuaacagsusu	1848
2400	asascaugAfaAfUfGfCfaucccuus{invAb}	1849	asAfsagggCfaugcuUfuCfauguususu	1850
2401	asasaugaGfaAfUfGfUfccuaagugs{invAb}	1851	usCfsacuuAfggacauUfCfcauuususu	1852
2402	asgsaaugUfCfUfAfAfgugauucas{invAb}	1853	asUfsgaauCfaccuagGfaCfaucucususu	1854
2403	gsgsaaaGfUfUfAfGfGfaacuguuas{invAb}	1855	usUfsaacaGfuucuaCfCfuuuacsusu	1856
2404	ususucacAfaAfGfUfCfauaggaggus{invAb}	1857	usAfsccuUfauagcuUfuGfugaasusu	1858
2405	asgscacuCfCfUfGfUfaauaugags{invAb}	1859	asCfsucaUfuuaacuUfGfAfgugcususu	1860
2406	usgsuaauAfuGfAfGfUfgcucugugs{invAb}	1861	usCfsacagAfgcacucAfuAfuuaacsusu	1862
2407	usasugagUfGfUfCfUfugagagugs{invAb}	1863	asCfsaucUfCfagagCfaCfuaasusu	1864
2408	gsusuuaUfaGfAfAfAfgguuguugs{invAb}	1865	asCfsaacaCfcauuUfAfaaaacsusu	1866
2409	ususuuuAfgAfAfAfuugguugcs{invAb}	1867	asGfsaacAfcauuUfCfAfaaaasusu	1868
2410	usasuguUfGfAfUfAfGfuucuuuacs{invAb}	1869	asUfsuaaaGfaacuUfCfAfaaasusu	1870
2411	asusaguuCfUfUfAfAfggagacaas{invAb}	1871	usUfsugucUfccuuUfAfaaasusu	1872
2412	ususcuuUfaGfGfAfGfacaacgs{invAb}	1873	asCfsguuUfgucuccUfAfaaasusu	1874

2413	ususaaggAfgAfCfAfAfaacgguaas{invAb}	1875	asUfsuaccGfuuuuguCfuCfcuaasusu	1876
2414	asgsacaaAfaCfGfUfaaugaacas{invAb}	1877	asUfsguucAfuuaaccgUfuUfugucususu	1878
2415	gsusugaaUfaGfAfUfGfuguauuucs{invAb}	1879	asGfsaaauAfcacauCfuUfucaacsusu	1880
2416	usasauguAfgGfUfGfAfucggagcus{invAb}	1881	asAfgscucCfgaucacCfuAfcuaasusu	1882
2417	usgsaucgGfGfCfUfCfuuuccuuus{invAb}	1883	asAfsaaggAfaagagCfcCfgaucasusu	1884
2418	gsasgcucUfuUfCfCfUfuugauagas{invAb}	1885	asUfscuauCfaaaggaAfaGfagcucsusu	1886
2419	usgsuagcAfaGfAfGfGfuguauuuaas{invAb}	1887	asUfsaauaAfcaccucUfuGfcuacacusu	1888
2420	gsusuacgAfaAfAfAfAfcuaugguus{invAb}	1889	asAfsaccaUfaguuuuUfuCfguaacusu	1890
2421	ascsuauGfUfGfUfGfuccgagugs{invAb}	1891	asCfsacucGfgacacaAfcCfauagususu	1892
2422	asusauuuAfgAfAfAfGfcaaagucs{invAb}	1893	usGfsacuuUfggcuuUfuAfaauasusu	1894
2423	gsusuucCfaAfCfAfGfugauggcus{invAb}	1895	asAfsaccaUfcacuguUfgGfaaaacsusu	1896
2424	usasuugaCfuAfUfCfUfGfcugcucas{invAb}	1897	asUfsgagcAfgcagauAfgUfcauacusu	1898
2425	asuscaaaGfCfCfCfAfuacauugcs{invAb}	1899	asGfscuuGfuaugguGfcUfuugaususu	1900
2426	asasagcaCfCfAfUfAfCfauugcuucs{invAb}	1901	usGfsaagcAfauguauGfgUfgcuuusu	1902
2427	ascscuugAfuCfCfAfUfaagcuuggs{invAb}	1903	asCfscaagCfuuauggAfuCfaaggusu	1904
2428	cscsauaaGfCfUfUfGfGfggcuucus{invAb}	1905	asAfsaagCfccccaaGfCfuauggsusu	1906
2429	ususcuaCfGfCfGfAfaggcucgas{invAb}	1907	asUfscgagCfcuucguCfGfugaasusu	1908
2430	uscscuacGfCfGfAfAfggcucgaus{invAb}	1909	asAfsucgaGfccuucgUfcGfuaugasusu	1910
2431	ascsgagcAfaGfGfCfUfGfugaas{invAb}	1911	asUfsuucUfcgagccUfuCfugcucusu	1912
2432	gsasugaaAfcAfCfCfAfauggacgs{invAb}	1913	asCfsguccAfcuugguGfuUfucaacsusu	1914
2433	gsasaacaCfCfAfGfAfUfggacggaas{invAb}	1915	usUfsuccgUfccaucUfgUfguuucsusu	1916
2434	asusagagCfuUfUfGfCfuccaugggs{invAb}	1917	asCfscuauGfgagcaaAfgCfucuaasusu	1918
2435	uscscuagGfGfCfAfUfauguugaas{invAb}	1919	asUfsucaCfuauaugCfcCfauggasusu	1920
2436	asusgggcAfuAfUfAfGfugaauuuaas{invAb}	1921	asUfsaauuCfaacuauAfuGfccaasusu	1922
2437	asusauagUfuGfAfAfUfuacuucgas{invAb}	1923	asUfscgaaGfuaauucAfaCfuauasusu	1924
2438	asusuucUfgGfAfUfUfacaugaas{invAb}	1925	asUfsucaUfguaucCfcAfgaaasusu	1926
2439	csusgugaGfUfGfUfUfcaucagugs{invAb}	1927	asCfsacugAfugaacaUfcUfcacagsusu	1928
2440	gsasaacuUfaCfAfAfUfgcacuuuuaas{invAb}	1929	asUfsaaagUfgcauugUfaAfguuucsusu	1930
2441	csusuacaAfuGfCfAfCfuuaagcgcs{invAb}	1931	usGfscgcuAfaagugAfuUfguaagsusu	1932
2442	ususcacUfgCfAfCfUfuuaagcgcas{invAb}	1933	asUfsgcgUfaaagugCfaUfugaasusu	1934
2443	ascsaagCfaCfUfUfUfagcgagcs{invAb}	1935	usAfcugcGfcuaaagUfgCfauugusu	1936
2444	usgscacuUfuAfGfCfGfcaguaaggs{invAb}	1937	asCfscuuaCfugcgcuAfaAfgugcasusu	1938
2445	gscscuuUfaGfCfGfCfaguaaggs{invAb}	1939	asCfscuuAfcugcgCfaAfaugcgsusu	1940
2446	ususuagcGfCfGfUfAfaaggcuugs{invAb}	1941	asCfsaagCfcuuacuGfcGfcuaasusu	1942
2447	ususcagCfaGfUfAfAfggcuuggs{invAb}	1943	asCfscaagCfcuuacUfgCfguacusu	1944
2448	csgscaguAfaGfGfGfCfuuggcaucs{invAb}	1945	asGfsaugcCfaagcccUfuAfcugcgsusu	1946
2449	ascscagCfaUfUfGfCfcaaacuas{invAb}	1947	asUfsaguuUfgggcaaUfgCfugggusu	1948
2450	asusugccCfaAfAfCfUfauuuugacs{invAb}	1949	usGfsucaAfaauaguUfuGfggcaasusu	1950
2451	usugcccAfaAfCfUfAfuuuugacas{invAb}	1951	asUfsgucaAfaauaguUfuGfggcaasusu	1952
2452	usgsuagAfuAfGfUfUfuuuaaggs{invAb}	1953	usCfscuuaAfaagacuAfuCfuacacusu	1954
2453	usasggugAfuCfGfGfAfgcucuuc{invAb}	1955	asGfsaaagAfgcuccgAfuCfaccuasusu	1956
2454	asgsgugaUfcGfGfAfgfcucuuc{invAb}	1957	asGfsgaaaGfaguccGfaUfcaccusu	1958

2455	usasuaguUfgAfAfUfUfacuucgacs{invAb}	1959	usGfsucgaAfguaauuCfaAfcuauasusu	1960
2456	usgsaaauAfcUfUfCfGfacagcagcs{invAb}	1961	usGfscugcUfgucgaaGfuAfaucasusu	1962
2457	asasuuaCfUfGfAfCfagcagcaas{invAb}	1963	asUfsugcuGfcugucgAfaGfaauususu	1964
2458	ususcgacAfgCfAfGfCfaauucuugs{invAb}	1965	asCfsaagaAfuugcugCfuGfucgaasusu	1966
2459	uscsuuccUfgGfAfAfGfgcacacgus{invAb}	1967	asAfschgUfgccuucCfaGfgaagasusu	1968
2460	ususugucAfgUfUfGfUfgguagauas{invAb}	1969	asUfsaucuAfccacaaCfuGfacaasusu	1970
2461	gsusccacAfcAfCfAfUfuguggcuus{invAb}	1971	asAfsagccAfcaauguGfuGfuggacsusu	1972
2462	csuscgugAfuUfUfUfGfaccuggggs{invAb}	1973	asCfscccaGfgucaaaAfuCfagcagsusu	1974
2463	gsusugaaGfgCfUfUfUfugcucauas{invAb}	1975	asUfsaugaGfcaaaagCfcUfucaacsusu	1976
2464	usasuuuaGfaAfCfCfUfuccuguus{invAb}	1977	asAfsacagGfaagggUfcUfaauasusu	1978
2465	asusuuaGfaCfCfCfUfuccuguuus{invAb}	1979	asAfsaacaGfgaaggUfuCfuauasusu	1980
2466	ususcugUfuUfUfAfUfugucguacs{invAb}	1981	asGfsuacaGfacauaaAfaCfaggaasusu	1982
2467	csasgguAfaGfCfUfGfuuuuugs{invAb}	1983	usCfsaagAfaacagcUfgUfaccugsusu	1984
2468	gsgsaaauCfCfCfAfaccaaauas{invAb}	1985	asUfsauuuGfguuggaGfgAfuuuacsusu	1986
2469	gsusuucCfuAfAfCfUfugauuagcs{invAb}	1987	asGfscuaaUfcauguAfgGfaaaacsusu	1988
2470	ususcuaAfcUfUfGfAfuuagcuugs{invAb}	1989	usCfsaagUfaaucaaGfuUfaggaasusu	1990
2471	cscsuaacUfuGfAfUfUfagcuugags{invAb}	1991	asCfsucaaGfcuaucAfaGfuuaggsusu	1992
2472	ususgaauAfgCfUfUfGfagcugacas{invAb}	1993	asUfsgucaGfcucaagCfuAfaucuasusu	1994
2473	gscsuuucUfgUfAfCfUfgcacacags{invAb}	1995	usCfsugugUfgcaguaCfaGfaagcsusu	1996
2474	gscsacacAfgAfUfUfUfugucugcs{invAb}	1997	usGfscaguAfcacaaCfuGfugugcsusu	1998
2475	csgsugcaCfaAfCfCfUfguccaguas{invAb}	1999	asUfsacugGfacagguUfgUfgcacgsusu	2000
2476	csasguauAfuGfCfAfUfguggugcs{invAb}	2001	asGfscacCfacaugcAfuAfuacugsusu	2002
2477	ascscaugAfcUfUfUfUfaaaaauus{invAb}	2003	asAfsauuuGfuuaaaaGfuCfauggususu	2004
2478	ascsauagUfgGfUfAfAfaauuuas{invAb}	2005	asAfsuaauUfauuuacCfaCfaugususu	2006
2479	csasuaguGfgUfAfAfAfaauuuags{invAb}	2007	usCfsauaaUfuauuuCfcAfcuagcsusu	2008
2480	gsuscuguUfcAfUfAfAfuugguaggs{invAb}	2009	asCfscuacCfaauuauGfaAfcagacsusu	2010
2481	asusuuuCfAfGfAfUfgaguguuas{invAb}	2011	asUfsaacaCfucaucuGfgAfaaaususu	2012
2482	gsgsgaugCfuGfAfUfUfgauuuuacs{invAb}	2013	usGfsaaauAfucaaucAfgCfaucacsusu	2014
2483	ususgaauUfuUfCfAfCfauguuags{invAb}	2015	usCfsauacAfaugugaAfaUfaucuasusu	2016
2484	uscsucaaGfuUfCfUfGfcauuuaas{invAb}	2017	usUfsuuaaAfuagcagaAfcUfugagasusu	2018
2485	ususcuaUfuUfAfCfUfgacuagggs{invAb}	2019	asCfscuaGfucaguaAfaAfuggaasusu	2020
2486	uscscuuUfuAfCfUfGfacuagggs{invAb}	2021	usAfsccuAfgucaguAfaAfauggasusu	2022
2487	asasguuuAfuCfCfAfGfuaggcaus{invAb}	2023	asAfsugccAfuacuggAfuAfaacuususu	2024
2488	ususuaucCfaGfUfAfUfggcauucus{invAb}	2025	asAfsgaauGfccauacUfgGfaaaaasusu	2026
2489	ascscagcAfgAfUfUfGfcauccugas{invAb}	2027	usUfscaggUfagcaauCfuCfcugususu	2028
2490	csasguuuAfuCfAfCfCfuuccuacac{invAb}	2029	asUfsguaaGfaaggugAfuAfaacugsusu	2030
2491	csusuacaGfaGfAfCfUfccuugggcs{invAb}	2031	asGfscccaAfggagucUfcUfguaagsusu	2032
2492	asasagagAfgUfGfUfCfuguuuuags{invAb}	2033	usCfsuaaaAfcagacaCfuCfucuuususu	2034
2493	csgsacaaAfaAfCfUfUfcaagaauas{invAb}	2035	asUfsauucUfagaaguUfuUfugucgsusu	2036
2494	asusauauUfcUfGfAfGfuuuuugs{invAb}	2037	asCfscacaAfaacucaGfaAfaauasusu	2038
2495	ususugugGfuGfCfUfGfuagguaacs{invAb}	2039	asGfsuacCfuacagcAfcCfacaasusu	2040
2496	usgsugguGfcUfGfUfAfgguaacgus{invAb}	2041	asAfsccuuAfcuacaGfcAfcacacacusu	2042

2497	gsusgcugUfaGfGfUfAfacguguggs{invAb}	2043	asCfscacaCfguuaccUfaCfagcacsusu	2044
2498	usgscagaUfaAfCfAfCfuuggggggs{invAb}	2045	usCfsccccCfaaguguUfaUfcugcasusu	2046
2499	gsasacagCfcCfCfAfAfugauccugs{invAb}	2047	asCfsaggaUfcauuggGfgCfuguucsusu	2048
2500	asasugauCfcUfGfGfCfuuuuucacs{invAb}	2049	asGfsugaaAfaagccaGfgAfucuuususu	2050
2501	csgsuaucAfgAfAfUfAfcauggaugs{invAb}	2051	usCfsauccAfuguauuUfGfauacgsusu	2052
2502	ascsaugaCfaGfGfAfCfcauucguus{invAb}	2053	asAfsacgaUfagguccUfgUfcaugususu	2054
2503	usgsacagGfaCfCfUfAfucguugags{invAb}	2055	asCfsucaaCfgauaggUfcCfugucasusu	2056
2504	asgsgaccUfaUfCfGfUfugagguuus{invAb}	2057	asAfsaaccUfcaacgaUfaGfguccususu	2058
2505	uscsuaagAfcUfUfAfCfuauugggcus{invAb}	2059	asAfsgccAFuaguaaGfuCfuuaugasusu	2060
2506	asasgacuUfaCfUfAfUfgggcuguas{invAb}	2061	usUfsacagCfcgauagUfaAfgucuuususu	2062
2507	asgsacuuAfcUfAfUfGfggcuguaas{invAb}	2063	usUfsuacaGfcccauaGfuAfagucususu	2064
2508	gsascuuaCfuAfUfGfGfgcuguaaas{invAb}	2065	asUfsuuacAfgcccauAfgUfaagucsusu	2066
2509	usasuuuuAfgAfAfAfCfcugagacus{invAb}	2067	asAfsugucuCfagguuuCfuAfaaaususu	2068
2510	csasuuaGfaAfGfAfGfauucuugas{invAb}	2069	asUfscaagAfaucucuUfuCfaaaugsusu	2070
2511	asasagagAfuUfCfUfUfgaccuuuus{invAb}	2071	asAfsuaagGfucaagaAfuCfucuuususu	2072
2512	asasgagaUfuCfUfUfgaccuuuuus{invAb}	2073	asAfsauaaGfgucaagAfaUfcucuususu	2074
2513	csusugauGfgAfAfGfGfuuuuaacs{invAb}	2075	asGfsuuuaAfuaccuuCfcAfucaagsusu	2076
2514	ususgaugGfaAfGfGfUfauuuaacus{invAb}	2077	usAfsguuuAfauaccuUfcCfaucaasusu	2078
2515	usasuuuaAfcUfAfUfUfugccuguus{invAb}	2079	asAfsacagGfcaauaGfuUfuaauasusu	2080
2516	gsusguauUfgCfAfAfGfaaacacags{invAb}	2081	usCfsugugUfuucuuGfaAfuaacacsusu	2082
2517	asgsaaaaAfuCfUfCfAfaccaagus{invAb}	2083	asAfsuuuGfguugagAfuUfuuuucusu	2084
2518	gsasuaacAfcUfUfGfGfggggaccus{invAb}	2085	asAfsggucCfccccaaGfuGfuuaucusu	2086
2519	usgsaguuUfaUfUfAfAfagauugacs{invAb}	2087	usGfsucaaUfcuuuaaUfaAfacucasusu	2088
2520	asasagauUfgAfCfAfUfuuaaguas{invAb}	2089	asUfsacuuAfaaauguCfaAfucuuususu	2090
2521	asasgauUGfaCfAfUfUfuuaaguacs{invAb}	2091	usGfsuacuUfaaaaugUfcAfaucuuususu	2092
2522	usasauuuGfuUfGfGfUfauuuuacs{invAb}	2093	asGfsauaaUfauaccaAfcAfaauuasusu	2094
2523	gsusucuuAfgAfUfCfCfcauuugas{invAb}	2095	asUfscaauAfugggauCfuAfugaacsusu	2096
2524	asgscauuGfcCfCfAfAfacuauuuus{invAb}	2097	asAfsaaauAfguuuggGfcAfaugcususu	2098
2525	asasagccAfaAfGfUfCfagaaaccgs{invAb}	2099	asCfsgguUfcugacuUfuGfgcuususu	2100
2526	{sGalNAc3}gcggaUfgUfUfUfuuaauucas{invAb}	2373	usUfsgauaUfaaaauaCfaUfuccgsusu	2374
2527	{sGalNAc3}cagcgaGfaUfUfGfCfuaccugaas{invAb}	2375	asUfsucagGfuagcaaUfcUfcgcugsusu	2376
2528	{sGalNAc3}acgaauUfuGfCfCfGfcuucuguus{invAb}	2377	asAfsacagAfagcggaAfaAfuucgususu	2378
2529	{sGalNAc3}accucaGfcCfUfCfUfauucgcaas{invAb}	2379	asUfsugcgAfauagagGfcUfgaggususu	2380
2530	{sGalNAc3}aucaaaAfgCfCfGfUfaacaaags{invAb}	2381	asCfsuuugUfuaacggCfuUfuugaususu	2382
2531	{sGalNAc3}uagcuuAfaUfUfUfuuaugggas{invAb}	2383	asUfscckaUfuaaaaaUfgUfagcuasusu	2384
2532	{sGalNAc3}uucagaAfgAfUfGfUfaguuagcs{invAb}	2385	usGfscauuAfcuacauCfuUfcugaasusu	2386
2533	{sGalNAc3}agcgguGfuUfAfCfCfagcuauacs{invAb}	2387	asGfsuuaGfcugguaAfcAfacgcususu	2388
2534	{sGalNAc3}guguuaUfuAfGfAfAfuguuacgas{invAb}	2389	usUfscguaAfcuuucuAfaUfaacacsusu	2390
2535	{sGalNAc3}uccuaaCfuUfGfAfUfagcuugas{invAb}	2391	asUfscaagCfuauucaAfgUfuaggasusu	2392
2536	{sGalNAc3}cauauaGfuUfGfAfAfuuacuucgs{invAb}	2393	usCfsgaagUfaauucaAfcUfaauugsusu	2394
2537	{sGalNAc3}gggcuuAfuAfGfUfUfgaauuacus{invAb}	2395	asAfsguuaUfucaacuAfuAfugcccsusu	2396
2538	{sGalNAc3}ugucuuCfcCfAfGfAfcaucuugas{invAb}	2397	asUfscaagAfugucugGfgAfugacasusu	2398

2539	{sGalNac3}uacgaaAfaAfAfCfUfaugguugus{invAb}	2399	asAfscaacCfauaguuUfuUfucguasusu	2400
2540	{sGalNac3}cugccuUfgCfCfAfGfacauuuuas{invAb}	2401	asUfsaaaaUfgucuggCfaAfggcagsusu	2402
2541	{sGalNac3}uuuuguCfaGfUfUfGfugguagaus{invAb}	2403	usAfsucuaCfcacaacUfgAfcaaaasusu	2404
2542	{sGalNac3}agaauGfUfCfGfAfaaaacuas{invAb}	2405	asUfsaguuUfuuuuGfUfaCfaauucususu	2406
2543	{sGalNac3}uguaauAfuGfAfGfUfgcucugugs{invAb}	2407	usCfsacagAfgcacucAfuAfuuacasusu	2408
2544	{sGalNac3}cacuuGfUfGfAfCfAfuggaugs{invAb}	2409	asUfsucauCfcaugucAfcAfaagugsusu	2410
2545	{sGalNac3}auuuggGfaAfUfUfAfcacuuugus{invAb}	2411	asAfscaaaGfuguaauUfcCfcaaaususu	2412
2546	{sGalNac3}auagcuGfaGfUfCfCfugaaguus{invAb}	2413	asAfsaacuUfcaggacUfcAfgcuaususu	2414
2547	{sGalNac3}cugaccCfuUfGfGfUfacaauagas{invAb}	2415	asUfscuauUfguaccaAfgGfgucagsusu	2416
2548	{sGalNac3}uaaucGfUfGfAfUfuggaaugas{invAb}	2417	usUfsauuuCfcaaucaGfuCfgaauasusu	2418
2549	{sGalNac3}aacugaUfaGfCfUfGfaguccugas{invAb}	2419	usUfscaggAfcucagcUfaUfcaguususu	2420
2550	{sGalNac3}cagcacAfuGfAfUfUfugggaauus{invAb}	2421	usAfsauucCfcaaaucAfuGfugcugsusu	2422
2551	{sGalNac3}acaugaUfuUfGfGfGfaauuacacs{invAb}	2423	asGfsuguaAfuucccaAfaUfcaugususu	2424
2552	{sGalNac3}cagaauAfcAfGfUfGfuuggucgas{invAb}	2425	asUfscgacCfaacacuGfuAfuucugsusu	2426
2553	{sGalNac3}cccagaCfaUfCfUfUfgauauacs{invAb}	2427	asGfsuauuAfucaagaUfgUfcugggsusu	2428
2554	{sGalNac3}ucuugaUfaAfUfAfCfcuguuggas{invAb}	2429	usUfsccaaCfagguauUfaUfcaagasusu	2430
2555	{sGalNac3}uguuauUfaGfAfAfUfuguuacgaas{invAb}	2431	usUfsucguAfacaauucUfaAfuacacusu	2432
2556	{sGalNac3}uguuacGfaAfAfAfAfacuauuggus{invAb}	2433	asAfsccauAfguuuuUfcGfuacacacusu	2434
2557	{sGalNac3}uuacgaAfaAfAfAfCfauugguugs{invAb}	2435	asCfsaaccAfuaguuUfuUfcguaasusu	2436
2558	{sGalNac3}aggaauAfuUfUfAfGfaagccaas{invAb}	2437	usUfsuggcUfuucuaaAfuAfuuccususu	2438
2559	{sGalNac3}acgaagGfaGfGfUfUfgauugcaas{invAb}	2439	usUfsugcaAfucaaccUfcCfuucgususu	2440
2560	{sGalNac3}uguuuUfcAfAfCfAfgugauggcs{invAb}	2441	asGfscgauCfacuguuGfgAfaaacacusu	2442
2561	{sGalNac3}cauagGfuUfAfAfAfaaacuagcs{invAb}	2443	asCfsuaguUfuguuuAfcCfuuaugsusu	2444
2562	{sGalNac3}ggacggAfaAfGfAfUfguucucuas{invAb}	2445	asUfsagagAfacaucUfuCfeguccsusu	2446
2563	{sGalNac3}ggaaauGfuGfUfAfGfaacuguuas{invAb}	2447	usUfsaacaGfuucuaCfcAfuuuccsusu	2448
2564	{sGalNac3}auaguuGfaAfUfUfAfcuucgacas{invAb}	2449	asUfsgucgAfaguuauUfcAfacuauususu	2450
2565	{sGalNac3}ucuucGfaCfUfCfAfacuucuaacs{invAb}	2451	usGfsuagaAfguugagUfuCfgaagasusu	2452
2566	{sGalNac3}cuucgaAfcUfCfAfAfcuucucacac{invAb}	2453	asUfsguagAfaguugaGfuUfcgaagsusu	2454
2567	{sGalNac3}uuccugUfuUfUfAfUfgucuguaacs{invAb}	2455	asGfsuacaGfacauaaAfaCfaggaasusu	2456
2568	{sGalNac3}cagguaCfaGfCfUfGfuuuuuggs{invAb}	2457	usCfscaagAfaacagcUfgUfaccugsusu	2458
2569	{sGalNac3}ccuaacUfuGfAfUfUfagcuugags{invAb}	2459	asCfsucaaGfcaaaucAfaGfuuaagsusu	2460
2570	{sGalNac3}cgugcaCfaAfCfCfUfguccaguas{invAb}	2461	asUfsacugGfacagguUfgUfgcacgsusu	2462
2571	{sGalNac3}caguauAfuGfCfAfUfuggugggcs{invAb}	2463	asGfscacCfacaugcAfuAfuacugsusu	2464
2572	{sGalNac3}accaugAfcUfUfUfUfaacaaauus{invAb}	2465	asAfsauuuGfuuaaaaGfuCfauggususu	2466
2573	{sGalNac3}acauagUfgGfUfAfAfauaaauuas{invAb}	2467	asAfsuauUfauuuacCfaCfuaugususu	2468
2574	{sGalNac3}cauaguGfgUfAfAfAfuaauuauus{invAb}	2469	usCfsauaaUfuauuuCfcAfcuaugsusu	2470
2575	{sGalNac3}auuuuuCfAfGfAfUfgaguguuas{invAb}	2471	asUfsaacaCfucaucGfgAfaaaususu	2472
2576	{sGalNac3}gggaugCfuGfAfUfUfgauuuuacs{invAb}	2473	usGfsaaauAfucaaucAfgCfaucccsusu	2474
2577	{sGalNac3}ucucuaGfuUfCfUfGfcauuuaas{invAb}	2475	usUfsuuuaAfugcagaAfcUfugagasusu	2476
2578	{sGalNac3}uuccauUfuUfAfCfUfgacuaggs{invAb}	2477	asCfscuaGfucaguaAfaAfuggaasusu	2478
2579	{sGalNac3}caguuuAfuCfAfCfCfuucuuacac{invAb}	2479	asUfsguaaGfaaggugAfuAfaacugsusu	2480
2580	{sGalNac3}cgacaaAfaAfCfUfUfucuaaauas{invAb}	2481	asUfsauucUfagaaguUfuUfugucgsusu	2482

SUBSTITUTE SHEET (RULE 26)

2623	{sGalNAc3}uuuuCfcAfGfAfUfgaguguuas{invAb}	2567	asUfsaacaCfucaucuGfgAfaaasusu	2568
2624	{sGalNAc3}uuuuccAfgAfUfGfAfguguuas{invAb}	2569	asUfsaacaCfucaucuGfgAfaaasusu	2570
2625	{sGalNAc3}uuuuuccAfgAfUfGfAfguguuas{invAb}	2571	asUfsaacaCfucaucuGfgAfaaaasusu	2572
2626	{sGalNAc3}accaugAfcUfUfUfUfaacaaauus{invAb}	2573	asAfsauuuguuaaAfaGfuCfauggususu	2574
2627	{sGalNAc3}caugAfcUfUfUfUfaacaaauus{invAb}	2575	asAfsauuuGfuuaaaaGfuCfaugsusu	2576
2628	{sGalNAc3}caugacUfuUfUfAfAfaaaauus{invAb}	2577	asAfsauuuGfuuaaaaGfuCfaugsusu	2578
2629	{sGalNAc3}accaugacUfuUfUfAfAfaaaauus{invAb}	2579	asAfsauuuGfuuaaaaGfuCfauggususu	2580
2630	{sGalNAc3}uagcuaCfaUfUfUfUfaaugggas{invAb}	2581	asUfscaccauuaaaAfaUfgUfagcuasusu	2582
2631	{sGalNAc3}gcuaCfaUfUfUfUfaaugggas{invAb}	2583	asUfscaccaUfuaaaaUfgUfagcsusu	2584
2632	{sGalNAc3}gcuacaUfuUfUfUfAfaugggas{invAb}	2585	asUfscaccaUfuaaaaUfgUfagcsusu	2586
2633	{sGalNAc3}uagcuacaUfuUfUfUfAfaugggas{invAb}	2587	asUfscaccaUfuaaaaUfgUfagcuasusu	2588
2634	{sGalNAc3}ucucaaGfuUfCfUfGfcauuuaas{invAb}	2589	usUfsuuaaAugcaGfaAfcUfugagasusu	2590
2635	{sGalNAc3}ucaaGfuUfCfUfGfcauuuaas{invAb}	2591	usUfsuuaaAfugcagaAfcUfugasusu	2592
2636	{sGalNAc3}ucaaguUfcUfGfCfAfuuuuaas{invAb}	2593	usUfsuuaaAfugcagaAfcUfugasusu	2594
2637	{sGalNAc3}ucucaaguUfcUfGfCfAfuuuuaas{invAb}	2595	usUfsuuaaAfugcagaAfcUfugagasusu	2596
2638	{sGalNAc3}aacugaUfaGfCfUfGfaguccugas{invAb}	2597	usUfscaggacucaGfcUfaUfcaguususu	2598
2639	{sGalNAc3}cugaUfaGfCfUfGfaguccugas{invAb}	2599	usUfscaggAfcucagcUfaUfcagsusu	2600
2640	{sGalNAc3}cugauaGfcUfGfAfGfuccugas{invAb}	2601	usUfscaggAfcucagcUfaUfcagsusu	2602
2641	{sGalNAc3}aacugauaGfcUfGfAfGfuccugas{invAb}	2603	usUfscaggAfcucagcUfaUfcaguususu	2604
2642	{sGalNAc3}ucuugauaAfuAfcCfUfuguuggas{invAb}	2605	usUfscacaaCfagguauUfaUfcaagasusu	2606
2643	{sGalNAc3}guguuaauAfgAfAfUfGfuuacgas{invAb}	2607	usUfscguaAfcuauuUfaUfaacacsusu	2608
2644	{sGalNAc3}uauaguUfaUfUfAfCfuucgacs{invAb}	2609	usGfsucgaAfguaauUfaAfcuauasusu	2610
2645	{sGalNAc3}cacuuuguGfaCfAfUfGfugaugs{invAb}	2611	asUfsucauCfcaugucAfcAfaagugsusu	2612
2646	{sGalNAc3}ugucauccCfaGfAfCfAfucuuugas{invAb}	2613	asUfscaagAfugucugGfgAfugacasusu	2614
2647	{sGalNAc3}ucuugaUfaAfUfAfCfcuguuggas{invAb}	2615	usUfscacaaCfagguauUfaUfcaagasusu	2616
2648	{sGalNAc3}guguuaUfuAfGfAfAfuguuacgas{invAb}	2617	usUfscguaaacaauUfaUfaacacsusu	2618
2649	{sGalNAc3}uauaguUfgAfAfUfUfacuucgacs{invAb}	2619	usGfsucgaaguuUfaUfaAfcuauasusu	2620
2650	{sGalNAc3}cacuuuGfuGfAfCfAfuggaugaas{invAb}	2621	asUfsucaucaugUfcAfcAfaagugsusu	2622
2651	{sGalNAc3}ugucauUfcCfAfGfAfcaucuugas{invAb}	2623	asUfscaagaugucUfgGfgAfugacasusu	2624
2652	{sGalNAc3}uugauaAfuAfcCfUfuguuggas{invAb}	2625	usUfscacaaCfagguauUfaUfcaasusu	2626
2653	{sGalNAc3}guuaauAfgAfAfUfGfuuacgas{invAb}	2627	usUfscguaAfcuauuUfaUfaacsusu	2628
2654	{sGalNAc3}uaguugAfaUfUfAfCfuucgacs{invAb}	2629	usGfsucgaAfguaauUfaAfcuauasusu	2630
2655	{sGalNAc3}cuuuguGfaCfAfUfGfugaugs{invAb}	2631	asUfsucauCfcaugucAfcAfaagsusu	2632
2656	{sGalNAc3}ucauccCfaGfAfCfAfucuuugas{invAb}	2633	asUfscaagAfugucugGfgAfugasusu	2634
2657	{sGalNAc3}uugaUfaAfUfAfCfcuguuggas{invAb}	2635	usUfscacaaCfagguauUfaUfcaasusu	2636
2658	{sGalNAc3}guuaUfuAfGfAfAfuguuacgas{invAb}	2637	usUfscguaAfcuauuUfaUfaacsusu	2638
2659	{sGalNAc3}uaguUfgAfAfUfUfacuucgacs{invAb}	2639	usGfsucgaAfguaauUfaAfcuauasusu	2640
2660	{sGalNAc3}cuuuGfuGfAfCfAfuggaugaas{invAb}	2641	asUfsucauCfcaugucAfcAfaagsusu	2642
2661	{sGalNAc3}ucauUfcCfAfGfAfcaucuugas{invAb}	2643	asUfscaagAfugucugGfgAfugasusu	2644
2662	{sGalNAc3}guuuauCfaCfCfUfUfcuuacas{invAb}	2723	asUfsguaaGfaaggugAfuAfaacsusu	2724
2663	{sGalNAc3}guuuAfuCfAfCfCfuucuuacas{invAb}	2725	asUfsguaaGfaaggugAfuAfaacsusu	2726
2664	{sGalNAc3}caguuuauCfaCfCfUfUfcuuacas{invAb}	2727	asUfsguaaGfaaggugAfuAfaacugsusu	2728

2665	{sGalNAc3}caguuuAfuCfAfCfCfuuccuacac{invAb}	2729	asUfsguaagaaggUfgAfuAfaacugsusu	2730
2666	{sGalNAc3}caguuuauCfAfCfUfUfcuuacac{invAb}	2731	asUfsguaaGfaaggUfgAfuuaacugsusu	2732
2667	{sGalNAc3}caguuuAfuCfAfCfCfuuccuacac{invAb}	2733	asUfsguaagaaggUfgAfuAfaacugsusu	2734
2668	{sGalNAc3}guuuAfuCfAfCfCfuuccuacac{invAb}	2735	asUfsguaaGfaaggugAfuAfaacsusu	2736
2669	{sGalNAc3}caguuuAfuCfAfCfCfuuccuacac{invAb}	2737	asUfsguaaGfaaggUfgAfuAfaacugsusu	2738
2670	{sGalNAc3}caguuuauCfAfCfCfuuccuacac{invAb}	2739	asUfsguaaGfaaggugAfuAfaacugsusu	2740
2671	{sGalNAc3}guguuuuAfgAfAfUfGfuucacac{invAb}	2741	usUfscguaAfcuuCfuAfaaacacsusu	2742
2672	{sGalNAc3}guguuaUfuAfgAfauguuacac{invAb}	2743	usUfscguaacauuCfuAfaUfaacacsusu	2744
2673	{sGalNAc3}guuaUfuAfgAfAfuguuacac{invAb}	2745	usUfscguaAfcuuuAfaUfaacsusu	2746
2674	{sGalNAc3}guguuaUfuAfgAfAfuguuacac{invAb}	2747	usUfscguaAfcuuCfuAfaUfaacacsusu	2748
2675	{sGalNAc3}guguuuuAfgAfAfuguuacac{invAb}	2749	usUfscguaAfcuuuAfaUfaacacsusu	2750
2676	{sGalNAc3}uauaguugAfaUfUfAfCfuucgac{invAb}	2751	usGfsucgaAfguaaUfuCfaacuauasusu	2752
2677	{sGalNAc3}uauaguUfgAfaUfuacuucgac{invAb}	2753	usGfsucgaaguaaUfuCfaAfcuauasusu	2754
2678	{sGalNAc3}uaguUfgAfAfUfUfacuucgac{invAb}	2755	usGfsucgaAfguaauuAfaAfcuauasusu	2756
2679	{sGalNAc3}uauaguUfgAfAfUfUfacuucgac{invAb}	2757	usGfsucgaAfguaaUfuCfaAfcuauasusu	2758
2680	{sGalNAc3}uauaguugAfaUfUfUfacuucgac{invAb}	2759	usGfsucgaAfguaauuAfaAfcuauasusu	2760
2681	{sGalNAc3}ugucauccCfaGfAfCfAfucucac{invAb}	2761	asUfscaagAfugucUfgGfgaugacac{invAb}	2762
2682	{sGalNAc3}ugucauUfCfAfGfAfucucac{invAb}	2763	asUfscaagugucUfgGfgAfugacac{invAb}	2764
2683	{sGalNAc3}ucauUfCfAfGfAfcaucucac{invAb}	2765	asUfscaagAfugucUfgGfgAfugacac{invAb}	2766
2684	{sGalNAc3}ugucauUfCfAfGfAfcaucucac{invAb}	2767	asUfscaagAfugucUfgGfgAfugacac{invAb}	2768
2685	{sGalNAc3}ugucauccCfAfGfAfcaucucac{invAb}	2769	asUfscaagAfugucUfgGfgAfugacac{invAb}	2770
2686	{sGalNAc3}aacuguaGfCfUfGfAfGfuccac{invAb}	2771	usUfscaggAfcuaGfCfUfGfagucac{invAb}	2772
2687	{sGalNAc3}uagcuacUfuUfUfUfAfauggac{invAb}	2773	asUfscagaUfuuaaAfaUfguagucac{invAb}	2774
2688	{sGalNAc3}acaugauUfgGfGfAfAfuacac{invAb}	2775	asGfsuguaAfuuccCfaAfaucagucac{invAb}	2776
2689	{sGalNAc3}auuuuuccAfgAfUfGfAfgugucac{invAb}	2777	asUfsaacaCfucaUfuGfgaaaaacac{invAb}	2778
2690	{sGalNAc3}aacugaUfaGfCfUfgaguccac{invAb}	2779	usUfscaggacuaGfCfUfGfagucac{invAb}	2780
2691	{sGalNAc3}uagcuacUfuUfUfUfAfauggac{invAb}	2781	asUfscagaUfuuaaAfaUfguagucac{invAb}	2782
2692	{sGalNAc3}acaugaUfuUfgGfgaauuacac{invAb}	2783	asGfsuguaauuccCfaAfaucagucac{invAb}	2784
2693	{sGalNAc3}auuuuuCfAfGfAfugagucac{invAb}	2785	asUfsaacacuaCfuGfgAfaaaacac{invAb}	2786
2694	{sGalNAc3}cugaUfaGfCfUfgaguccac{invAb}	2787	usUfscaggAfcuacGfCfUfGfagucac{invAb}	2788
2695	{sGalNAc3}gcuaCfaUfUfUfUfAfauggac{invAb}	2789	asUfscagaUfuuaaAfaUfguagucac{invAb}	2790
2696	{sGalNAc3}augaUfuUfgGfGfAfaauuacac{invAb}	2791	asGfsuguaAfuuccCfaAfaucagucac{invAb}	2792
2697	{sGalNAc3}uuuuCfAfGfAfUfgagucac{invAb}	2793	asUfsaacaCfucauGfgAfaaaacac{invAb}	2794
2698	{sGalNAc3}aacugaUfaGfCfUfgaguccac{invAb}	2795	usUfscaggAfcuaGfCfUfGfagucac{invAb}	2796
2699	{sGalNAc3}uagcuacUfuUfUfUfAfauggac{invAb}	2797	asUfscagaUfuuaaAfaUfguagucac{invAb}	2798
2700	{sGalNAc3}acaugaUfuUfgGfGfAfaauuacac{invAb}	2799	asGfsuguaAfuuccCfaAfaucagucac{invAb}	2800

EXAMPLE 2: Efficacy of select GPAM siRNA molecules in RNA FISH assay

[0168] A panel of fully chemically modified siRNA from Example 1 were prepared and tested for potency and selectivity of mRNA knockdown in vitro. Each siRNA duplex consisted of two strands, the sense or 'passenger' strand and the antisense or 'guide' strand.

[0169] RNA FISH (fluorescence in situ hybridization) assay was carried out to measure GPAM mRNA knockdown by test siRNAs. HepG2 cells (ATCC HB-8065) were cultured in Eagle's Minimum Essential Medium (EMEM) (ATCC® 30-2003™) supplemented with 10% fetal bovine serum (FBS, Sigma) and 1% penicillin-streptomycin (P-S, Corning). siRNAs were transfected into cells by reverse transfection using Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific). 1 µL of test siRNAs (in 10 data points dosed with 1:3 dilution starting at 500 nM final concentration) or phosphate-buffered saline (PBS) vehicle and 4 µL of plain EMEM without supplements were added to PDL-coated CellCarrier-384 Ultra assay plates (PerkinElmer) by a Bravo automated liquid handling platform (Agilent). 5 µL of Lipofectamine RNAiMAX (Thermo Fisher Scientific), pre-diluted in plain EMEM without supplements (0.06 µL of RNAiMAX in 5 µL EMEM), was then dispensed into the assay plates by a Multidrop Combi reagent dispenser (Thermo Fisher Scientific). After 20-minute incubation of the siRNA/RNAiMAX mixture at room temperature (RT), 30 µL of HepG2 cells (2000 cells per well) in EMEM supplemented with 10% FBS and 1% P-S were added to the transfection complex using a Multidrop Combi reagent dispenser. The assay plates were incubated at RT for 20 mins prior to being placed in an incubator. Cells were incubated for 72 hrs at 37 °C and 5% CO₂.

[0170] RNA FISH assay was performed 72 hours after siRNA transfection using the manufacturer's assay reagents and protocol (QuantiGene® ViewRNA HC Screening Assay from Thermo Fisher Scientific) on an in-house assembled automated FISH assay platform. In brief, cells were fixed in 4% formaldehyde (Thermo Fisher Scientific) for 15 mins at RT, permeabilized with detergent for 3 mins at RT and then treated with protease solution for 10 mins at RT. Target-specific probes (Thermo Fisher Scientific, VA6-3170392-VC (GPAM) and VA1-10148-VC (PPIB) or vehicle (target probe diluent without target probes as negative control) were incubated for 3 hours, whereas preamplifiers, amplifiers, and label probes were incubated for 1 hour each. All hybridization steps were carried out at 40 °C in a Cytomat 2 C-LIN automated incubator (Thermo Fisher Scientific).

[0171] After hybridization reactions, cells were stained for 30 mins with Hoechst and CellMask Blue (Thermo Fisher Scientific) and then imaged on an Opera Phenix high-content screening system (PerkinElmer). The images were analyzed using a Columbus image data storage and analysis system (PerkinElmer) to obtain the mean spot count per cell. The mean spot count per cell was normalized using the high (PBS with target probes) and low (PBS without target probes) control wells. The high and low controls have normalized values of 100 and 0, respectively. The normalized values against the test siRNA concentrations were fitted to a 4-parameter sigmoidal model using Genedata Screener data analysis software (Genedata, Basel, Switzerland) to obtain IC50 values and maximum activity.

[0172] The results of the assay are shown in Table 3. GPAM knockdown provides a percentage of knockdown compared to control samples. Negative values indicate a decrease in GPAM levels.

Table 3. RNA FISH Assay with Human/Cyno GPAM-Spanning siRNA

Duplex No.	IC50 (nM)	GPAM knockdown (%)
2001		-18.1
2002	14.70	-65.0
2003	19.30	-56.7
2004	14.00	-56.4
2005	35.60	-66.7
2006	10.94	-86.0
2007	7.32	-84.5
2008	20.30	-64.1
2009	15.40	-70.9
2010	4.87	-90.6
2011	7.84	-85.4
2012	9.94	-73.5
2013	8.85	-74.4
2014	5.80	-70.9
2015	5.18	-82.0
2016	5.27	-72.3
2017	2.00	-62.2
2018	0.61	-71.5
2019	4.48	-74.8
2020	1.78	-70.6

Duplex No.	IC50 (nM)	GPAM knockdown (%)
2021	2.55	-75.4
2022	1.43	-68.6
2023		-17.6
2024	2.45	-84.1
2025	1.84	-89.7
2026	6.65	-85.6
2027	1.70	-88.5
2028	6.58	-86.2
2029	2.71	-57.9
2030	4.26	-75.4
2031	7.42	-82.5
2032	1.33	-94.2
2033	8.79	-53.7
2034		5.9
2035	5.10	-73.6
2036	2.42	-89.1
2037	3.29	-73.7
2038	26.40	-65.5
2039	5.64	-66.4
2040	2.81	-84.4

WO 2023/069754

PCT/US2022/047491

Duplex No.	IC50 (nM)	GPAM knockdown (%)
2041	8.27	-66.0
2042	2.62	-57.4
2043		-65.7
2044		5.9
2045	1.68	-82.0
2046	1.51	-66.2
2047	4.21	-64.4
2048	25.60	-44.6
2049	22.20	-78.8
2050	2.67	-84.5
2051	0.58	-78.2
2052		-36.3
2053		-28.8
2054	127.00	-48.6
2055	4.92	-69.5
2056	2.43	-51.1
2057	150.00	-56.3
2058	22.80	-69.1
2059	34.90	-57.7
2060	0.26	-74.5
2061	18.60	-65.7
2062	2.00	-86.3
2063	0.52	-73.3
2064	0.28	-57.0
2065		-34.5
2066	32.50	-79.6
2067	2.60	-58.2
2068	11.40	-73.6
2069	22.40	-66.8
2070	6.58	-62.6
2071	12.70	-69.8
2072	1.91	-84.8
2073	0.93	-55.8
2074	7.52	-76.9
2075		-11.0
2076		-25.1
2077	1.35	-85.1
2078	2.97	-85.0
2079	55.20	-66.0
2080		-31.4

Duplex No.	IC50 (nM)	GPAM knockdown (%)
2081		-58.9
2082		-47.9
2083	58.10	-65.7
2084	64.90	-62.9
2085	3.55	-69.6
2086	2.43	-85.5
2087	45.20	-72.9
2088	0.54	-77.4
2089	76.90	-74.5
2090	5.37	-56.5
2091		-49.0
2092	114.00	-56.0
2093		-40.9
2094		-50.9
2095		-0.4
2096		-38.9
2097	0.99	-69.8
2098	2.33	-77.2
2099	6.31	-73.1
2100	16.00	-89.4
2101	4.08	-78.8
2102	3.08	-85.5
2103	1.46	-86.9
2104	58.30	-40.0
2105		-57.1
2106		-23.7
2107	5.10	-74.1
2108	15.90	-70.3
2109	0.92	-69.5
2110	2.26	-53.0
2111	133.00	-59.9
2112	1.77	-54.6
2113	35.00	-68.7
2114		-46.2
2115	2.75	-62.9
2116	2.34	-52.9
2117		-42.4
2118	0.23	-52.1
2119	34.30	-69.2
2120	4.32	-72.7

WO 2023/069754

PCT/US2022/047491

Duplex No.	IC50 (nM)	GPAM knockdown (%)
2121	57.80	-64.5
2122	3.13	-75.2
2123	11.30	-77.7
2124		-14.4
2125	9.25	-45.8
2126	1.84	-83.1
2127	1.51	-92.6
2128	2.41	-84.2
2129	7.48	-78.2
2130	12.70	-60.4
2131	25.40	-77.8
2132	5.98	-77.7
2133	4.44	-70.9
2134	2.97	-59.6
2135	1.50	-84.4
2136	2.13	-65.3
2137	1.48	-76.2
2138	67.80	-67.5
2139		-59.4
2140	12.90	-55.8
2141	2.10	-89.6
2142	12.00	-68.9
2143	1.64	-86.6
2144	4.98	-81.9
2145	2.96	-79.5
2146	4.71	-63.1
2147	2.35	-86.3
2148	1.89	-80.6
2149	5.57	-78.0
2150	1.28	-82.4
2151	1.82	-70.8
2152	1.35	-87.1
2153	2.00	-84.8
2154	3.03	-64.8
2155	7.37	-61.1
2156	2.48	-73.7
2157	2.35	-86.5
2158	1.06	-90.2
2159	8.59	-86.2
2160	2.10	-81.6

Duplex No.	IC50 (nM)	GPAM knockdown (%)
2161	3.25	-79.5
2162	7.23	-71.8
2163	2.05	-73.7
2164	4.76	-87.3
2165	9.73	-86.5
2166	2.34	-82.5
2167	18.70	-63.6
2168	1.81	-80.3
2169	1.64	-91.9
2170	3.93	-78.3
2171	3.39	-87.4
2172	4.91	-87.1
2173	1.47	-79.6
2174	1.41	-79.1
2175	2.09	-86.0
2176	2.55	-81.4
2177	17.00	-46.9
2178	1.03	-87.1
2179	1.99	-86.2
2180	3.44	-81.1
2181	2.28	-84.9
2182	1.23	-73.7
2183	3.26	-78.9
2184	1.30	-92.4
2185	1.99	-58.3
2186	2.64	-81.9
2187	3.41	-85.1
2188	2.84	-89.1
2189	2.24	-89.9
2190	2.12	-80.8
2191	2.36	-72.5
2192	7.50	-67.3
2193	1.62	-87.1
2194	1.55	-81.6
2195	1.77	-80.1
2196	2.38	-61.1
2197	1.70	-82.0
2198	11.20	-61.8
2199		2.8
2200	15.40	-73.4

WO 2023/069754

PCT/US2022/047491

Duplex No.	IC50 (nM)	GPAM knockdown (%)
2201	1.52	-89.1
2202	75.60	-56.0
2203	13.10	-66.9
2204	1.82	-89.2
2205	33.40	-59.3
2206	16.63	-88.6
2207	13.50	-67.0
2208	1.39	-66.7
2209	0.49	-72.2
2210		-67.4
2211	2.02	-70.6
2212	19.33	-85.6
2213		-71.4
2214	21.33	-79.0
2215	17.25	-77.3
2216	3.12	-84.6
2217	13.40	-62.1
2218		-18.3
2219	1.81	-60.2
2220		-8.1
2221		-68.6
2222	6.64	-67.0
2223	1.68	-91.1
2224	43.80	-64.6
2225	18.80	-79.3
2226	71.70	-77.4
2227	2.10	-63.4
2228	99.60	-61.9
2229		-50.6
2230	16.60	-60.2
2231	7.80	-55.6
2232	3.33	-87.7
2233	4.11	-78.0
2234	2.75	-87.4
2235	2.35	-88.5
2236	7.40	-85.4
2237	2.28	-86.1
2238	12.40	-67.0
2239		5.2
2240	8.38	-53.5

Duplex No.	IC50 (nM)	GPAM knockdown (%)
2241		-32.3
2242		-48.6
2243		6.3
2244		-19.3
2245	1.46	-89.0
2246	5.15	-67.7
2247	8.42	-82.1
2248	5.96	-79.4
2249	88.50	-50.6
2250	3.39	-86.8
2251	3.20	-93.0
2252	7.15	-79.1
2253		-52.2
2254	8.31	-84.8
2255	33.50	-59.3
2256	64.70	-53.8
2257	16.68	-84.2
2258	69.10	-66.1
2259		-38.1
2260		-44.7
2261	3.81	-79.1
2262		-16.5
2263	5.39	-89.6
2264	63.20	-60.2
2265		-38.0
2266		-23.8
2267		-23.4
2268	6.41	-58.5
2269	2.80	-81.7
2270	1.49	-84.8
2271	4.71	-79.3
2272	94.40	-61.6
2273	0.77	-57.4
2274	15.50	-55.1
2275	3.09	-56.6
2276	35.00	-57.9
2277		-0.7
2278	9.41	-59.1
2279	5.49	-78.7
2280	85.40	-50.4

WO 2023/069754

PCT/US2022/047491

Duplex No.	IC50 (nM)	GPAM knockdown (%)
2281	2.33	-62.8
2282		-13.8
2283		-42.2
2284		-56.5
2285		-34.3
2286		-17.0
2287	97.80	-62.6
2288	7.98	-79.4
2289	4.21	-81.9
2290	3.67	-88.2
2291	5.42	-60.6
2292	4.29	-87.2
2293	3.45	-85.5
2294	1.80	-73.6
2295	6.23	-82.1
2296	3.71	-68.0
2297	14.83	-82.1
2298	7.21	-82.8
2299	15.00	-70.7
2300	10.73	-85.9
2301	14.60	-75.9
2302	12.99	-90.5
2303	5.99	-81.8
2304	15.00	-61.5
2305	5.72	-48.0
2306	3.01	-76.8
2307	4.95	-74.0
2308	7.07	-78.6
2309	5.38	-76.5
2310	5.57	-79.3
2311	41.70	-74.7
2312	23.90	-68.4
2313	13.00	-70.0
2314	168.00	-67.2
2315	18.00	-63.9
2316	29.10	-56.1
2317	54.90	-62.9
2318	13.20	-54.6
2319	10.10	-60.8
2320		-33.5

Duplex No.	IC50 (nM)	GPAM knockdown (%)
2321	15.90	-81.3
2322	9.02	-62.9
2323	2.17	-77.9
2324	2.17	-63.3
2325	4.10	-78.3
2326		-14.3
2327	3.14	-74.2
2328	1.58	-89.1
2329		10.0
2330		11.7
2331	35.10	-68.9
2332	4.18	-69.1
2333	21.10	-79.4
2334	3.49	-60.7
2335	12.20	-46.7
2336		15.2
2337		-21.6
2338	6.03	-76.4
2339	9.95	-46.6
2340	3.74	-82.1
2341	1.95	-67.4
2342		4.8
2343	2.30	-88.0
2344		5.0
2345	3.36	-87.7
2346	3.51	-79.6
2347		6.6
2348	4.22	-79.7
2349	5.54	-87.0
2350		7.9
2351	17.10	-60.7
2352	0.55	-77.1
2353	8.18	-66.2
2354	14.10	-67.5
2355		-70.3
2356	3.93	-58.3
2357	4.83	-61.7
2358		-70.3
2359	33.70	-60.1
2360		-12.9

WO 2023/069754

PCT/US2022/047491

Duplex No.	IC50 (nM)	GPAM knockdown (%)
2361		-6.3
2362	4.49	-53.8
2363	1.80	-64.1
2364	2.78	-65.8
2365	5.24	-74.5
2366		-55.4
2367		-27.2
2368	1.43	-68.4
2369	37.60	-67.6
2370	0.84	-67.9
2371		-46.9
2372	42.90	-71.3
2373		-31.7
2374	0.54	-47.7
2375	0.57	-59.8
2376		-39.8
2377	2.32	-77.7
2378		-52.1
2379	1.53	-86.3
2380		2.6
2381		-43.1
2382	2.88	-78.3
2383		-37.9
2384		-12.8
2385	14.00	-44.9
2386	98.50	-69.8
2387	25.80	-68.4
2388	1.27	-57.5
2389		6.0
2390		-20.9
2391	3.32	-84.8
2392	9.88	-78.2
2393	1.65	-85.2
2394	4.51	-84.9
2395	3.36	-76.7
2396	3.09	-32.7
2397	4.04	-80.0
2398	3.49	-72.5
2399	7.00	-85.2
2400	4.89	-75.7

Duplex No.	IC50 (nM)	GPAM knockdown (%)
2401	3.33	-51.1
2402	2.76	-81.9
2403	2.11	-84.5
2404	9.06	-64.1
2405	5.22	-35.2
2406	3.07	-94.6
2407	35.40	-55.1
2408	6.99	-73.7
2409	8.04	-72.0
2410	4.60	-82.9
2411	1.69	-78.5
2412	1.97	-78.0
2413	2.20	-81.6
2414	2.41	-72.5
2415	6.32	-78.9
2416		-40.7
2417	1.22	-64.6
2418	1.32	-66.5
2419	15.00	-59.5
2420		-60.5
2421	2.33	-87.1
2422	2.09	-88.8
2423	5.29	-84.1
2424	1.52	-94.0
2425	3.50	-84.5
2426	16.90	-63.1
2427	1.58	-89.3
2428	8.65	-84.4
2429	5.23	-86.1
2430	7.23	-78.8
2431	10.20	-83.2
2432	1.49	-52.4
2433	2.77	-77.1
2434	3.36	-80.5
2435	3.57	-85.5
2436	6.18	-86.4
2437	4.40	-85.6
2438	6.92	-74.4
2439	2.49	-73.9
2440	2.91	-80.0

WO 2023/069754

PCT/US2022/047491

Duplex No.	IC50 (nM)	GPAM knockdown (%)
2441	3.87	-91.0
2442	5.58	-86.2
2443	30.00	-86.0
2444	4.64	-68.0
2445	6.08	-61.1
2446	1.93	-89.0
2447	2.48	-89.1
2448	10.40	-63.5
2449		-42.2
2450	3.44	-85.1
2451	6.83	-71.5
2452	1.90	-68.5
2453	5.22	-78.2
2454	4.29	-89.7
2455	2.57	-91.9
2456	3.24	-91.7
2457	1.69	-93.2
2458	8.29	-83.7
2459	8.21	-77.8
2460	13.90	-86.9
2461	32.80	-57.6
2462	5.93	-82.8
2463	1.83	-83.1
2464	1.84	-87.0
2465	5.03	-90.3
2466	5.26	-86.5
2467	1.66	-91.2
2468	3.18	-79.5
2469	1.80	-87.9
2470	2.73	-73.1
2471	3.10	-87.5
2472	5.24	-73.7
2473	12.40	-79.9
2474	6.12	-76.6
2475	5.46	-91.2
2476	3.53	-89.6
2477	1.90	-85.1
2478	3.08	-85.6
2479	2.24	-88.4
2480	17.70	-78.0

Duplex No.	IC50 (nM)	GPAM knockdown (%)
2481	0.76	-90.3
2482	3.70	-88.0
2483	1.68	-79.3
2484	4.35	-86.1
2485	23.00	-72.7
2486	5.35	-65.5
2487	7.05	-71.2
2488	4.50	-84.0
2489	5.13	-85.1
2490	1.47	-88.8
2491	2.23	-87.0
2492	4.94	-82.4
2493	4.66	-86.1
2494	4.13	-90.9
2495	2.80	-73.4
2496	14.00	-82.0
2497		-66.8
2498	22.60	-73.6
2499	6.17	-79.8
2500	3.62	-93.4
2501	3.28	-92.2
2502	1.54	-87.9
2503	3.00	-85.9
2504	0.81	-75.8
2505	1.15	-87.9
2506	0.56	-89.7
2507	0.97	-81.3
2508	1.33	-87.4
2509	0.70	-85.1
2510	5.94	-92.8
2511	5.52	-82.4
2512	5.34	-82.1
2513	6.76	-92.6
2514		-73.8
2515		-28.8
2516	3.24	-92.8
2517	3.18	-87.3
2518	9.68	-72.9
2519	1.36	-79.9
2520	1.24	-82.5

Duplex No.	IC50 (nM)	GPAM knockdown (%)
2521	1.39	-85.4
2522	2.50	-83.3
2523	3.37	-82.2

Duplex No.	IC50 (nM)	GPAM knockdown (%)
2524	4.14	-72.9
2525	3.34	-84.6

Example 3: Efficacy screening of select PNPLA3 siRNA molecules in AAV-based mouse models containing human PNPLA3 sequences

[0173] Adeno-associated adenovirus (AAV; serotype AAVDJ8; endotoxin-free, prepared internally by Amgen) diluted in phosphate buffered saline (Thermo Fisher Scientific, 14190-136) was administered at 1×10^{12} viral particles per animal into the tail vein of C57BL/6NcrI male or female mice (Charles River Laboratories Inc.) to drive expression of human GPAM sequences in the liver. Five AAV constructs were designed from the GPAM_XM_005269998.1 transcript for *in vivo* screening; one containing the full-length coding sequence for *GPAM*^{I43V}, and four enhanced green fluorescence protein (eGFP) reporter constructs containing stretches of the 5' untranslated region, coding region, and 3' untranslated region (nucleotides (nt) 1-1700, nt 1600-3300, nt 3200-4900, and nt 4800-6527 (AAV-A, AAV-B, AAV-C, and AAV-D). The eGFP-containing constructs also contained a benchmark siRNA target sequence to compare siRNA-mediated knockdown efficacy across AAVs and studies.

[0174] GalNAc-conjugated siRNAs shown in Table 4 were tested against *GPAM*^{I43V}, AAV-A, AAV-B, AAV-C, or AAV-D. Two weeks after AAV injection, mice (generally 10-12 weeks of age and an n=3-4 animals per group) were treated with a single dose of siRNA via subcutaneous injection, at 0.5, 1.0, or 3.0 milligrams per kilogram of animal, diluted in phosphate buffered saline (Thermo Fisher Scientific, 14190-136). After 28 days post-siRNA injection, animals were euthanized, and livers collected from the animals and snap-frozen in liquid nitrogen. A portion of the liver was processed for purified RNA using a QIAcube HT instrument (Qiagen, 9001793) and RNeasy 96 QIAcube HT kits (Qiagen, 74171) according to manufacturer's instructions. Samples were analyzed using a QIAxpert system (Qiagen, 9002340). RNA was treated with RQ1 RNase-Free DNase (Promega, M6101) and prepared for Real-Time qPCR using the TAQMANTM RNA-to-CTTM 1-Step kit (Applied Biosystems,

4392653). Real-Time qPCR was run on a QuantStudio Real-Time PCR machine. Results were based on gene expression of human *GPAM* (Invitrogen, Hs00326039), *GFP2* (IDT custom assay: Forward primer: TCATCTGCACCACTGGAAAG (Sense; SEQ ID NO: 2801), Reverse primer: CTGCTTCATATGGTCTGGGTATC (AntiSense; SEQ ID NO: 2802), Probe: 5'-6FAM CCAACACTGGTCACTACCCTCACC TAMRA-3' (Sense; SEQ ID NO: 2803), and/or bovine growth hormone polyadenylation (*BghpA*, which is included in each AAV construct; IDT custom assay: Forward: 5'-GCCAGCCATCTGTTGT-3' (SEQ ID NO: 2804), Reverse: 5'-GGAGTGGCACCTTCCA-3' (SEQ ID NO: 2805), Probe: 5'-6FAM-TCCCCCGTGCCTTCCTTGACC TAMRA-3' (SEQ ID NO: 2806), as normalized to mouse TATA-binding protein (*Tbp*) (IDT, Hex Mm.PT.39a.22214839), and presented as the relative percent knockdown of human *GPAM*, *GFP*, and/or *BghpA* mRNA expression, normalized to mouse *Tbp*, compared to vehicle-treated control animals. Negative results indicate knockdown. (nd=not determined).

Table 4. Day 28 GPAM knockdown assay

Duplex number	Dose administered (mg/kg)	GFP2 Avg KD	BghpA Avg KD	GPAM Avg KD
D-2548	1	-32.8	-38.3	
D-2549	1	-61.0	-56.5	
D-2546	1	-54.8	-56.7	
D-2550	1	-47.0	-43.1	
D-2551	1	-73.3	-67.0	
D-2545	1	-55.4	-50.4	
D-2544	1	-65.2	-57.2	
D-2614	1	-61.6	-50.7	
D-2615	1	-58.3	-53.9	
D-2529	1	53.6	42.2	
D-2591	1	31.3	38.5	
D-2592	1	-54.2	-51.5	
D-2531	1	-66.3	-62.2	
D-2567	1	-53.6	-48.8	
D-2568	1	-3.4	8.1	
D-2535	1	-52.9	-51.7	
D-2569	1	32.3	27.9	

D-2570	1	0.2	-2.5	
D-2571	1	-30.5	-23.3	
D-2572	1	-67.6	-64.2	
D-2584	1	-41.0	-33.9	
D-2573	1	-0.4	10.7	
D-2574	1	nd	-45.3	
D-2585	1	6.2	1.4	
D-2575	1	-72.7	-72.7	
D-2576	1	-36.9	-40.4	
D-2577	1	-65.7	-65.8	
D-2578	1	-49.4	-45.8	
D-2589	1	-71.4	-69.7	
D-2612	1	2.0	11.8	
D-2590	1	-20.2	-14.8	
D-2560	1	-2.6	-6.0	
D-2561	1	-12.3	1.6	
D-2563	1	-14.1	-10.2	
D-2543	1	-39.9	-31.8	
D-2601	1	-20.5	-30.3	
D-2602	1	-26.4	-11.4	
D-2603	1	-26.9	-19.9	
D-2604	1	-27.5	-25.0	
D-2605	1	-31.3	-8.0	
D-2606	1	18.3	46.1	
D-2582	1	-4.2	0.1	
D-2583	1	-13.9	-4.0	
D-2587	1	-43.0	-34.3	
D-2588	1	38.7	48.4	
D-2610	1	20.3	23.2	
D-2611	1	15.1	20.7	
D-2566	1	-56.9	-57.4	
D-2540	1	-40.4	-39.8	
D-2527	1	-58.1	-55.5	
D-2579	1	-54.3	-59.9	
D-2580	1	-37.3	-49.0	
D-2581	1	-54.5	-55.5	
D-2529	1	-46.5	-48.4	
D-2591	1	-62.7	-60.8	
D-2544	1			0.6
D-2547	1			-24.2

D-2552	1			-16.1
D-2613	1			-39.5
D-2614	1			-36.7
D-2615	1			-49.1
D-2616	1			-39.0
D-2617	1			-44.8
D-2530	1			-29.3
D-2593	1			-22.4
D-2594	1			-2.2
D-2528	1			-30.0
D-2595	1			-42.1
D-2596	1			-38.6
D-2597	1			-12.1
D-2562	1			-0.3
D-2598	1			-43.2
D-2599	1			3.7
D-2537	1			-16.2
D-2536	1			-8.8
D-2600	1			-21.6
D-2607	1			-62.3
D-2564	1			-48.6
D-2608	1			-20.9
D-2541	1			-41.7
D-2609	1			-36.4
D-2538	1			-60.5
D-2553	1			-56.5
D-2554	1			-52.8
D-2534	1			-61.8
D-2555	1			-37.6
D-2542	1			-47.9
D-2556	1			-42.9
D-2586	1			-36.4
D-2558	1			-42.3
D-2559	1			-20.0
D-2532	1			-22.9
D-2565	1			-24.8
D-2600	1			-21.6
D-2598	1			-43.2
D-2607	0.5	-6.6	-2.9	
D-2607	1	-36.7	-36.5	

D-2607	3	-30.7	-46.7	
D-2549	0.5	-38.5	-49.5	
D-2549	1	-38.8	-51.9	
D-2549	3	-34.6	-49.6	
D-2551	0.5	-52.8	-56.4	
D-2551	1	-40.1	-48.3	
D-2551	3	-49.9	-64.9	
D-2607	0.5		4.5	-1.2
D-2607	1		-37.9	-35.6
D-2607	3		-45.6	-46.7
D-2544	0.5		-35.7	-32.5
D-2544	1		5.9	7.6
D-2544	3		-29.1	-30.5
D-2554	0.5		-22.7	-22.2
D-2554	1		-40.3	-40.3
D-2554	3		-18.7	-16.3
D-2534	0.5		-41.4	-41.4
D-2534	1		13.8	2.1
D-2534	3		-63.3	-56.7
D-2538	0.5		-40.2	-27.0
D-2538	1		-31.2	-31.3
D-2538	3		-53.7	-54.1
D-2551	0.5	-33.0	-42.5	
D-2618	0.5	-5.0	-13.1	
D-2619	0.5	-47.4	-49.4	
D-2620	0.5	-47.5	-49.7	
D-2621	0.5	4.3	-8.3	
D-2549	0.5	-40.5	-43.1	
D-2638	0.5	-37.9	-32.4	
D-2639	0.5	-29.0	-35.2	
D-2640	0.5	-50.9	-56.0	
D-2641	0.5	-25.8	-28.7	
D-2531	0.5	-27.6	-26.4	
D-2630	0.5	-10.1	-8.1	
D-2631	0.5	-15.1	-14.2	
D-2632	0.5	-23.2	-26.2	
D-2633	0.5	-51.8	-51.7	
D-2575	0.5	-42.4	-48.8	
D-2622	0.5	-59.3	-59.7	
D-2623	0.5	-42.9	-44.7	

D-2624	0.5	-48.2	-52.1	
D-2625	0.5	-15.8	-24.2	
D-2572	0.5	-38.5	-36.5	
D-2626	0.5	-43.7	-41.4	
D-2627	0.5	-33.8	-33.3	
D-2628	0.5	-9.1	-12.2	
D-2629	0.5	-2.2	-2.5	
D-2577	0.5	-5.4	-12.6	
D-2634	0.5	2.1	13.2	
D-2635	0.5	2.8	5.2	
D-2636	0.5	-3.4	-13.0	
D-2637	0.5	1.3	0.1	
D-2557	0.5		-36.2	-40.0
D-2530	0.5		-27.0	-26.6
D-2533	0.5		-15.3	-11.4
D-2566	0.5		19.0	17.8
D-2540	0.5		-48.6	-48.5
D-2527	0.5		-30.0	-30.9
D-2579	0.5		-60.2	-62.0
D-2580	0.5		-14.9	-8.9
D-2581	0.5		-31.0	-35.7
D-2544	0.5		0.2	2.8
D-2645	0.5		-28.0	-32.4
D-2650	0.5		-21.8	-28.6
D-2655	0.5		-34.1	-36.8
D-2660	0.5		-16.8	-15.3
D-2607	0.5		-47.6	-43.5
D-2644	0.5		-55.7	-51.2
D-2649	0.5		-40.8	-45.0
D-2654	0.5		0.8	-6.1
D-2659	0.5		-28.8	-35.2
D-2538	0.5		-21.4	-16.7
D-2646	0.5		2.1	0.6
D-2651	0.5		-3.5	-6.7
D-2656	0.5		-37.7	-40.9
D-2661	0.5		-53.3	-53.3
D-2554	0.5		-16.9	-19.1
D-2642	0.5		-33.9	-28.4
D-2647	0.5		-32.8	-34.8
D-2652	0.5		-24.0	-22.6

D-2657	0.5		-42.9	-46.1
D-2534	0.5		-55.0	-50.6
D-2643	0.5		-51.6	-57.0
D-2648	0.5		-49.1	-46.5
D-2653	0.5		-41.2	-44.9
D-2658	0.5		-24.0	-21.6
D-2579	0.5			-21.2
D-2579	1			24.1
D-2662	0.5			-13.8
D-2663	0.5			-0.1
D-2664	0.5			-10.9
D-2665	0.5			8.6
D-2666	0.5			-8.0
D-2667	0.5			130.6
D-2668	0.5			47.5
D-2669	0.5			23.0
D-2670	0.5			-3.8
D-2534	0.5			-28.1
D-2534	1			-61.9
D-2671	0.5			10.8
D-2672	0.5			-42.1
D-2673	0.5			-2.6
D-2674	0.5			14.6
D-2675	0.5			1.9
D-2643	0.5			-13.4
D-2643	1			-20.0
D-2676	0.5			-24.0
D-2677	0.5			-47.1
D-2678	0.5			-37.8
D-2679	0.5			45.9
D-2680	0.5			2.8
D-2661	0.5			35.7
D-2661	1			31.7
D-2681	0.5			65.2
D-2682	0.5			-2.2
D-2683	0.5			-5.2
D-2684	0.5			4.1
D-2685	0.5			-45.6
D-2619	0.5	-28.7	-34.4	
D-2619	1	-18.9	-29.0	

D-2688	0.5	-32.7	-40.7	
D-2692	0.5	13.0	2.5	
D-2696	0.5	13.8	8.1	
D-2700	0.5	-34.8	-38.8	
D-2640	0.5	-44.6	-47.6	
D-2640	1	-59.7	-69.0	
D-2686	0.5	-19.1	-22.4	
D-2690	0.5	-11.6	-15.3	
D-2694	0.5	-37.1	-45.5	
D-2698	0.5	nd	nd	
D-2661	1	-3.4	-12.3	
D-2622	0.5	-43.4	-37.4	
D-2622	1	-64.7	-69.0	
D-2689	0.5	-53.8	-54.3	
D-2693	0.5	-53.2	-56.4	
D-2697	0.5	-64.9	-64.7	
D-2624	0.5	-62.8	-66.8	
D-2633	0.5	-57.2	-62.4	
D-2633	1	-69.8	-77.1	
D-2687	0.5	-53.9	-61.7	
D-2691	0.5	-16.9	-21.8	
D-2695	0.5	-33.6	-37.5	
D-2699	0.5	-44.2	-47.6	
D-2640	0.5	-58.9	-61.4	
D-2640	1	-65.9	-74.7	
D-2640	3	-86.0	-89.4	
D-2551	0.5	-42.3	-45.5	
D-2551	1	-60.6	-66.7	
D-2551	3	-79.9	-85.1	
D-2531	0.5	-29.0	-41.9	
D-2531	1	-52.1	-64.0	
D-2531	3	-76.8	-89.8	
D-2633	0.5	-5.9	-50.6	
D-2633	1	-55.5	-71.3	
D-2633	3	-82.9	-90.0	
D-2575	0.5	-17.6	-45.3	
D-2575	1	-55.5	-69.9	
D-2575	3	-79.8	-89.7	
D-2622	0.5	-17.7	-41.8	
D-2622	1	-39.3	-54.9	

D-2622	3	-73.8	-84.0	
D-2589	0.5	-33.1	-59.3	
D-2589	1	-65.0	-77.3	
D-2589	3	-81.4	-91.9	

[0175] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. However, the citation of a reference herein should not be construed as an acknowledgement that such reference is prior art to the present invention. To the extent that any of the definitions or terms provided in the references incorporated by reference differ from the terms and discussion provided herein, the present terms and definitions control.

[0176] The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The foregoing description and examples detail certain preferred embodiments of the invention and describe the best mode contemplated by the inventors. It will be appreciated, however, that no matter how detailed the foregoing may appear in text, the invention may be practiced in many ways and the invention should be construed in accordance with the appended claims and any equivalents thereof.

What is Claimed

1. An RNAi construct comprising a sense strand and an antisense strand, wherein the antisense strand comprises a region that is complementary to a glycerol-3-phosphate acyltransferase, mitochondrial (GPAM) mRNA sequence listed in Table 1, and wherein the RNAi construct inhibits the expression of GPAM.
2. The RNAi construct of claim 1, which comprises a region having at least 15 contiguous nucleotides differing by no more than 3 nucleotides from an antisense sequence listed in Table 2.
3. The RNAi construct of claim 1 or claim 2, wherein the antisense strand hybridizes to a GPAM mRNA sequence listed in Table 1.
4. The RNAi construct of any one of claims 1-3, wherein the sense strand comprises a sequence that is sufficiently complementary to the sequence of the antisense strand to form a duplex region of about 15 to about 30 base pairs in length.
5. The RNAi construct of claim 4, wherein the duplex region is about 17 to about 24 base pairs in length.
6. The RNAi construct of claim 4, wherein the duplex region is about 19 to about 21 base pairs in length.
7. The RNAi construct of claim 6, wherein the duplex region is 19 base pairs in length.
8. The RNAi construct of claim 6, wherein the duplex region is 20 base pairs in length.
9. The RNAi construct of claim 6, wherein the duplex region is 21 base pairs in length.
10. The RNAi construct of any one of claims 4-10, wherein the sense strand and the antisense strand are each about 15 to about 30 nucleotides in length.
11. The RNAi construct of claim 10, wherein the sense strand and the antisense strand are each about 19 to about 27 nucleotides in length.
12. The RNAi construct of claim 10, wherein the sense strand and the antisense strand are each about 21 to about 25 nucleotides in length.

13. The RNAi construct of claim 12, wherein the sense strand and the antisense strand are each about 21 to about 23 nucleotides in length.
14. The RNAi construct of any one of claims 1 to 13, which comprises at least one blunt end.
15. The RNAi construct of any one of claims 1 to 13, which comprises at least one nucleotide overhang of 1 to 4 unpaired nucleotides.
16. The RNAi construct of claim 15, wherein the nucleotide overhang has two unpaired nucleotides.
17. The RNAi construct of claim 15 or 16, wherein the RNAi construct comprises a nucleotide overhang at the 3' end of the sense strand, the 3' end of the antisense strand, or the 3' end of both the sense strand and the antisense strand.
18. The RNAi construct of any one of claims 15-17, wherein the nucleotide overhang comprises a 5'-UU-3' dinucleotide or a 5'-dTdT-3' dinucleotide.
19. The RNAi construct of any one of claims 1 to 18, wherein the RNAi construct comprises at least one modified nucleotide.
20. The RNAi construct of claim 19, wherein the modified nucleotide is a 2'-modified nucleotide.
21. The RNAi construct of claim 19, wherein the modified nucleotide is a 2'-fluoro modified nucleotide, a 2'-O-methyl modified nucleotide, a 2'-O-methoxyethyl modified nucleotide, a 2'-O-allyl modified nucleotide, a bicyclic nucleic acid (BNA), a glycol nucleic acid, an inverted base, or combinations thereof.
22. The RNAi construct of claim 21, wherein the modified nucleotide is a 2'-O-methyl modified nucleotide, a 2'-O-methoxyethyl modified nucleotide, a 2'-fluoro modified nucleotide, or combinations thereof.
23. The RNAi construct of claim 19, wherein all of the nucleotides in the sense and antisense strands are modified nucleotides.
24. The RNAi construct of claim 23, wherein the modified nucleotides are 2'-O-methylmodified nucleotides, 2'-fluoro modified nucleotides, or combinations thereof.
25. The RNAi construct of any one of claims 1 to 24, which comprises at least one phosphorothioate internucleotide linkage.

26. The RNAi construct of claim 25, wherein the RNAi construct comprises at least one phosphorothioate internucleotide linkages at the 3' end of the sense strand.
27. The RNAi construct of claim 25, wherein the RNAi construct comprises at least one phosphorothioate internucleotide linkages at both the 3' and 5' ends of the sense strand.
28. The RNAi construct of any one of claims 1-27, wherein the antisense strand comprises a sequence selected from the antisense sequences listed in Table 2.
29. The RNAi construct of claim 28, wherein the sense strand comprises a sequence selected from the sense sequences listed in Table 2.
30. The RNAi construct of any one of claims 1-29, wherein the RNAi construct is any one of the duplex compounds listed in Table 2.
31. The RNAi construct of any one of claims 1-30, wherein the RNAi construct reduces the expression level of GPAM in liver cells following incubation with the RNAi construct as compared to the GPAM expression level in liver cells that have been incubated with a control RNAi construct.
32. The RNAi construct of claim 31, wherein the liver cells are HepG2 cells.
33. The RNAi construct of any one of claims 1-32, wherein the RNAi construct inhibits at least 10% of GPAM expression at 5 nM in HepG2 cells *in vitro*.
34. The RNAi construct of any one of claims 1-33, wherein the RNAi construct inhibits GPAM expression in HepG2 cells with an IC₅₀ of less than about 1 nM.
35. The RNAi construct of any one of claims 1-34, further comprising a ligand that binds to one or more proteins expressed on the surface of liver cells.
36. A composition comprising the RNAi construct of any one of claims 1-35 and a pharmaceutically acceptable carrier, excipient, or diluent.
37. A method for reducing the expression of GPAM in a patient in need thereof comprising administering to the patient the RNAi construct of any one of claims 1-36.
38. A method for reducing the expression of GPAM in a patient in need thereof comprising administering to the patient the composition of claim 36.

39. The method of claim 37 or claim 38, wherein the expression level of GPAM in hepatocytes is reduced in the patient following administration of the RNAi construct as compared to the GPAM expression level in a patient not receiving the RNAi construct.
40. The method of any one of claims 37-39, wherein the patient suffers from nonalcoholic fatty liver disease (NAFLD).
41. The method of claim 40, wherein the patient suffers from non-alcoholic steatohepatitis (NASH).
42. An RNAi construct of any one of claims 1-35 or a composition of claim 36 for use in the treatment of NAFLD.